Loading…

Flash Player 9 (or above) is needed to view presentations.
We have detected that you do not have it on your computer. To install it, go here.

Like this document? Why not share!

Like this? Share it with your network

Share

Annual Report 2007/2008 Department of Oncology

on

  • 5,603 views

 

Statistics

Views

Total Views
5,603
Views on SlideShare
5,602
Embed Views
1

Actions

Likes
0
Downloads
18
Comments
0

1 Embed 1

http://ngoding.co 1

Accessibility

Categories

Upload Details

Uploaded via as Adobe PDF

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

Annual Report 2007/2008 Department of Oncology Document Transcript

  • 1. Annual Report 2007/2008 Department of Oncology August 2008 Chair: Gerald Batist, MD Prepared by: Gayle A. Shinder, PhD 1
  • 2. Department of Oncology Annual Report 2007/2008 Message from the Chair We were pleased to have been invited to write a paper describing the past, present and future of the McGill Department of Oncology. This paper, entitled The McGill University Department of Oncology: Structure depicts the shape of evolving knowledge, and co-authored by me and Dr. Gayle Shinder, was published in Current Oncology 15(3): 28-35, 2008. It describes the changes that we’ve all made in how we function, which reflects the rapid evolution of both cancer care and research to interdisciplinarity. A very strongly positive response has come from across Canada, and I believe that the leadership McGill held in first creating the Department persists in the innovations we’ve created since its inception. There were two new Department of Oncology faculty appointments in the 2007/2008 academic year: Dr. Thomas Jagoe joined as an Assistant Professor in November 2007 and began his tenure as the Director of the Cancer Nutrition-Rehabilitation Program, replacing Founding Director, Dr. Neil MacDonald, who continues to play an active role in the Program. Dr. François DeBlois joined Medical Physics as an Assistant Professor in May 2008. In addition, in May 2008 Dr. Golda Tradounsky, from Palliative Care, became a Faculty Lecturer. The academic year also saw the departures of Dr. Ala-Eddin Al Moustafa, who was involved in cancer genetics research, and Dr. Tarek Bismar who was an academic Pathologist at the Jewish General Hospital. Two faculty members were awarded tenure as of June 1, 2007: Dr. Robin Cohen (Palliative Care) who was also promoted to Associate Professor, and Dr. Frank Verhaegen (Medical Physics). Dr. Paul Allison, an Associate Member, was appointed the Dean of the Faculty of Dentistry. The 5 year term began on June 1st. There were also several administrative staff changes. Pamela Hodgson joined Palliative Care as a Research Assistant while Sara Marcil-Johnson became Palliative Care’s new Administrative and Student Affairs Coordinator, replacing Lucy Saunders who was in that position since August 2007 when she replaced Marie-José Martirene. Mary Jane MacDonald, the administrative coordinator for the Cancer Nutrition-Rehabilitation Program, retired in January 2008 and was replaced, in May, by Christine Sgherri. Kingsley Cheung, who was responsible for the Department of Oncology website maintenance left in April 2008 and was replaced, in May, by Jasper Palfree. A number of Department faculty members received awards and honours: Dr. Paul Allison received the 2007 Howard Katz Award for Excellence in Teaching; Dr. Gerald Batist received the Minda de Gunzburg Chair in Oncology, McGill University in 2007; Dr. Nicole Beauchemin was on the 2007 “Faculty Honour List for Educational Excellence”; Dr. Bernard Lapointe was the recipient of the 2007 Canadian Hospice Palliative Care Association Award of Excellence; Dr. Carmen Loiselle, with her colleague, Lynne McVey, received 2nd place prize at the Regional Order of Nurses Competition for Clinical Innovation/3M. in Montreal on May 26, 2008 for Technology and intensive care units: Health information and support are just as present. In addition, the photo she submitted for the Fonds de la recherche en santé du Québec (FRSQ) Scientific Photo Competition (November 2007) was one of 33 chosen to become part of 2
  • 3. Department of Oncology Annual Report 2007/2008 the FRSQ Image Bank. Dr. Neil MacDonald received the 2007 Statesman Award from the American Society of Clinical Oncology; Dr. Morag Park was inducted as a Fellow of the Royal Society of Canada; Dr. Ervin Podgorsak received a 2007 Fellowship from The American College of Medical Physics (ACMP) and in 2008 was the recipient of a Gold Medal from the Canadian Organization of Medical Physicists (COMP); Dr. Shafaat Rabbani received the 2008 Outstanding Achievement Award from the Society of American Asian Scientists in Cancer Research; Dr. Janusz Rak was awarded an Honorary Professorship at Masaryk University, Czech Republic (in progress 2008); In 2007 Dr. Marc Tischkowitz received the Fanconi Anemia Research Fund Discovery Award and also received the FRSQ Chercheur-bousier clinicien Junior 1 award; Dr. Anna Towers was given the 2007 Ethel Lilian Creller Award from the MUHC Research Institute; and Dr. Te Vuong received the Hebert S. Lang Oncology Surgery award as well as a CIHR Investigator Salary Award (2007). The Division of Cancer Epidemiology was pleased to announce awards given to two of its trainees: Andrea Spence, a PhD student, received a merit award for the best paper presented at the 60th Anniversary Celebration of the NCIC while Dr. Marie-Hélène Mayrand, was awarded a McGill Principal’s Dissertation Fellowship. In 2007, the Oncology Summer Scholarship Program awarded a summer research bursary to Vincent Lavallée for the project entitled “Comparing ectopic and endogenous replication in normal vs. tumor cells” under the guidance of Dr. Maria Zannis-Hadjopoulos. This year’s Department of Oncology Retreat was held on March 13-14, 2008 at the Château Vaudreuil. Talks ranged from basic research studies in tumour suppression, angiogenesis, and DNA replication to clinical studies on cancer nutrition and rehabilitation as well as radiation therapy. A highlight of the retreat was the “Being Mindful-How to Stay Awake on the Job” meditation presentation given by Dr. Thomas Hutchinson from the Department of Oncology’s McGill Programs in Whole Person Care. Through Dr. Hutchinson’s expert guidance, the attendees were able to try their hand at Mindfulness Meditation, a practice that many cancer patients use as a method of relaxation. The McGill Centre for Translational Research in Cancer/Montreal Centre for Experimental Therapeutics in Cancer held its Fifth Annual Meeting on December 3-4, 2007. On the first day presentations focused on prostate cancer, ovarian cancer, muscle wasting, vitamin D hybrid molecules and radiopharmaceutical chemistry. The second day was devoted to presentations from the CIHR Training Program trainees who presented on a variety of research areas. In Fall 2006 the inaugural edition of Palliative Care Research News reported on the research interests of the members of the Division of Palliative Care. The second edition of the Newsletter, which came out in Fall 2007, followed up with research findings from the studies conducted on nutritional interventions for anorexia-cachexia, prognostic indicators of cancer cachexia, exercise in patients with non-small cell lung cancer, 3
  • 4. Department of Oncology Annual Report 2007/2008 lymphedema research, pain management, quality of life and bereavement, and pediatric palliative care. The Visiting Professors in Oncology Program had another successful year with presentations covering areas such as acute myeloid leukemia, colorectal cancer, breast cancer, radiation oncology, psychosocial oncology and mind-body medicine. The Programme Québecois de lutte contre le cancer evaluations of the tumour site teams at the McGill teaching hospitals continued in 2007/2008. The Table d’oncologie of RUIS McGill continued to meet on a monthly basis, tackling a range of policy and service issues related to the RUIS. It’s been a very busy and productive year, with the expanding mandate in cancer care related to the RUIS structure added to our strong and growing academic programs. We continue to develop new interdisciplinary and interprofessional programs, such as the Nursing Oncology program and Geriatric Oncology this past year. Plans to team with Pathology and other Departments will evolve during the next year. Gerald Batist, MD 4
  • 5. Department of Oncology Annual Report 2007/2008 PAUL ALLISON 1. Research Grants (new and ongoing) Developing a team to address oral health disparities in Canada. PI: Drs. Paul J Allison and Christophe Bedos, Co-investigators: T.Barnett, C.Bell, J.Feine, R.Harrison, D. Matthews, M.McNally, B.Nicolau M.Raynault, J.Veronneau, C.Wyatt. Canadian Institutes of Health Research. $121,750. January 2008 – December 2008 À L'écoute Les Uns Des Autres – Implantation d'un programme visant à améliorer les compétences des professionnels de la santé buccodentaire pour entrer en relation et soigner les personnes en situation de pauvreté. PI: Dr. Christophe Bedos, Co- investigators: P.J. Allison, G. Arbour, A. Charbonneau, J. Coté S. Dupéré, C. Erdelyon, M-M. Jacob, I. Laurin, C. Loignon, L. Whitmore. Ministère de Développement économique, innovation et de l’Exportation; Réseau de recherche en santé buccodentaire et osseuse. $299,950. April 2008 – March 2011 Changing Demographics: The Oral Health of our Aging Population. PI: Drs Debora Matthews and Joanne Clovis. Co-investigators: P.J. Allison, M. Filiagi, S. Kirkland, H. Lawrence, M. McNally. Health Canada (Office of the Chief Dental Officer); Nova Scotia Health Research Foundation & CIHR, $280,701. February 2008 – January 2011 Réseau de recherche en santé bucco-dentaire et osseuse. PI: P.J.Allison, Co- investigators: C. Bedos, R. St.Arnaud, M.Rouabhia, J-P. Goulet, J. Henderson. Fonds de Recherche en Santé du Québec, $1,800,000. April 2007 – March 2011 The life course approach to studying the etiology of head and neck cancer: HeNCe life study. PI: B. Nicolau, Co-investigators: P.J.Allison, R. Burk, F. Coutlée, E. Franco, G. Humphris, J. O’Loughlin, A. Sacker, N. Schlecht. Canadian Institutes of Health Research, $476,000, October 2006 – September 2010 Personnes en situation de pauvreté : Une étude de leur trajectoire dans le système de soins buccodentaires au Québec PI: C.P. Bedos, Co-investigators: P.J.Allison, J-M Brodeur, B. Nicolau, L. Richard, Canadian Institutes of Health Research, $211,437. April 2006 – March 2009 A randomised controlled trial of the effectiveness of a coping strategies intervention for people with head and neck cancer. Principal Investigator: P.J.Allison, Co- investigators: L.J.Edgar, J.S.Feine, E.L.Franco, B.F.Nicolau, R.D.Rajan. Canadian Institutes of Health Research, $471,139. April 2005 – March 2009 2. Education and Research Training Master’s Students Hawazin Elani, January 2007 – present (Supervisor) 5
  • 6. Department of Oncology Annual Report 2007/2008 PhD Students Larissa Vilela, January 2005 – present (Supervisor) Reem Alansari, January 2006 – present (Co-supervisor) Nora Makinsi, September 2007 – present (Supervisor) Violet D’Souza, September 2007 – present (Supervisor) Postdoctoral Fellows Christine Loignon, May 2006 – present (Co-supervisor) Katia Muller, September 2006 – present (Supervisor) Saul Paiva, March 2007 – February 2008 (Supervisor) 3. Scientific Reviews Editorial boards Journal of Dental Research Oral Oncology Journal reviewer Community Dental Health Journal of Dental Research Quality of Life Research Social Science and Medicine Oral Oncology Preventive Medicine Community Dentistry & Oral Epidemiology Canadian Medical Association Journal Journal of the Canadian Dental Association Health & Quality of Life Outcomes Grant reviewer NCIC operating grant review panel K – Supportive Care, Palliative Care and Psychosocial Issues (Oct 2005 – present day) NIH-NIDCR special grants panel 4. Conference Organization Member, Local Organising Committee: “International Association for Dental Research” annual scientific meeting, Toronto, July 2008 5. External Committees and Boards Director: Réseau de recherche en santé bucco-dentaire et osseuse (Network for Oral and 6
  • 7. Department of Oncology Annual Report 2007/2008 Bone Health Research), FRSQ Committee member: Conseil d’administration, Fondation de l’Ordre des dentistes du Québec Committee member: Advisory Board, CIHR Clinician Scientist Training Program in Oral Health Research 6. Invited Presentations P.J.Allison & J.Veronneau : Intervention pour prevenir la carie de la petite enfance : resultats d’un projet de recherche. Presented to the 9e Colloque de santé dentaire publique du Québec, Montréal, June 2007 P.J.Allison : Recommendations et initiatives issues des actes du colloque « Pour un meilleur acces aux soins dentaires pour les personnes defavorisees au Quebec » place de la sante dentaire publique. Presented to the 9e Colloque de santé dentaire publique du Québec, Montréal, June 2007 P.J.Allison : L’acces aux soins dentaires au Quebec. Presented at the « Colloque Acces sante » organised by the Insitut quebecopis de la deficiance intellectuelle, Saint Georges, Quebec, November 2007 P.J.Allison : Comment utiliser la science en pratique clinique? Presented to the 28e Journées Scientifiques du CNEOC (Collège Nationale des Enseignants Odontologie Conservatrice), Clermont Ferrand, France, May 2008. 7. Hospital and University Activities Faculty of Education University Tenure Committee DAWN ANDERSON 1. Summary of New and Ongoing Research Ongoing project on the potential benefit of cytotechnician screening in thyroid biopsy evaluation. Co-Investigator at St. Mary’s for a new study on the effect of pre-operative dietary changes on pain following breast cancer surgery (Dr. Yoram Shir PI) 2. Education and Training Postgraduate Surgical Education Coordinator for St. Mary’s Hospital- supervising, advising and evaluating the surgical residents, family medicine residents and surgical oncology fellows who rotate through the surgical service at SMH, as well as mentoring ICM students to review case reports and supervising residents and students who choose electives at SMH 7
  • 8. Department of Oncology Annual Report 2007/2008 Formal small group teaching to ICM students. 3. Presentations On-site cytotechnician screening improves efficient management of thyroid nodules D. Anderson, M. Prevost. Ville Marie Medical Center, Montreal, Canada 4. Continuing Education Activities Attended ECCO 14 the European Cancer Conference in Barcelona, September 2007. Attended the meetings of the Société d’Oncologie de Montréal Attended a CHUM-organized day-long update on Melanoma, May 2008,. 5. University and Hospital Activities Surgical Grand Rounds at SMH including advising the Chief resident on appropriate topics. Recording secretary for the St. Mary’s Interdisciplinary Thyroid Rounds, where patients are presented pre and/or post operatively to a team made up from surgery, endocrinology, pathology, medical oncology and nuclear medicine. Lower GI Tumor Board at the Montreal General Hospital. St. Mary’s weekly Tumor Board. Ville Marie Breast Cancer weekly Clinico-Pathology Rounds . Member of the General Surgery Residency Committee. Member of the Surgical Oncology Residency Training Committee MARK BASIK 1. Summary of New and Ongoing Research Basic research 1. Mechanisms of resistance to herceptin 2. Stromal-tumor cell interactions in breast cancer 3. Genomics of breast cancer: new amplicon discovery 4. Discovery of novel tumor suppressor genes in breast cancer 5. Serum proteomics 6. The role of the CXCR4/SDF-1 axis in breast cancer 8
  • 9. Department of Oncology Annual Report 2007/2008 Clinical Research 1. Adjuvant and neoadjuvant trials in breast cancer (participating in NSABP and other clinical trials) 2. Research Grants (new and ongoing) Ongoing DARPP32 in resistance to trastuzumab in breast cancer, PI : M. Basik, co-applicant : W. Miller. Cancer Research Society $ 60000/year 2006-8 The Discovery of Novel Tumor Suppressor Genes in Breast Cancer. PI: M. Basik; co- applicants: P. Tonin, S.Mader, C.Rancourt. Quebec Breast Cancer Foundation $ 138 000/year 2004-2008 Multi-investigator grant (total amount $1 500 000 total) Targeting Carcinoma-associated fibroblasts in breast cancer, PI: M. Basik. Weekend to End Breast Cancer, $50000 (2007-8) New Predictive markers for therapy in breast cancer, PIs: M. Basik, M Park, Terry Fox Research Institute $ 163000 1 year (2008-9) 3. Education and Research Training Saima Hassan: PhD student, Dept Experimental Surgery, McGill University 07/2004- present; Role of stromal cell derived factor-1 in breast cancer metastasis Abdel Hosein : PhD student, Dept Pharmacology, McGill University, 06/2004-present : targeting tumor stroma for cancer therapeutics. Aline Mamo : Postdoctoral fellow, Dept Oncology, McGill University, 05/2005-present, Discovery of novel tumor suppressor genes in breast cancer Adriana Aguilar: Postdoctoral fellow, Dept Oncology, McGill University, 03/2005- present, Discovery and validation of novel markers predictive of response to cancer therapy using protein microarrays. Sophie Hamel : MSc Student, Dept Experimental Medicine, McGill University, 01/2006- present : Mechanisms of resistance to herceptin. Marie-France Savard; Undergraduate student, dept Biochemistry, Universite de Montreal, 06/2007-08/2007: Genomic changes in breast cancer PhD Committees Patrick Fok, PhD defense committee, Supervisor : Josephine Nalbantoglu, Dept of Experimental Medicine, McGill University, May 2008. “The identification of protein- protein interactors of the Coxsackievirus and adenovirus receptor (CAR) and Their impact on cell migration” 9
  • 10. Department of Oncology Annual Report 2007/2008 Osama Hussein, PhD Committee : Breast cancer metastases to bone, Supervisor; Svetlana Komarova, faculty of Dentistry, McGill University May 2008 4. Scientific Reviews Journal Reviews Cancer Research International Journal of Cancer Mutation Research Grant Reviews CIHR operating grant Invited member of Evaluating Committee CIHR Team Grants, Fall 2007 5. External Committees and Boards Member of strategy committee for position paper for Genome Canada on treatment optimization (2007) Invited researcher to meeting about State of Genomics in Quebec organized by Genome Quebec, Montreal, August 24, 2007. 6. Invited Presentations Cancers Héréditaires: sein et côlon”. Led workshop seminar at the Annual Congress of the Association Québécoise de Chirurgie. La Malbaie, Qc, May 31, 2007. “Screening for Breast Cancer”, Thursday Evening Learning Series, McGill University Faculty of Medicine, January 24,2008. “The Genomic Landscape of Cancer”, presentation at the Annual Retreat of the Department of Oncology of McGill University, March 14, 2008. “Reverse-phase Protein microarrays: validation and discovery”, invited speaker at the Genome Quebec conference “Rendez-Vous Proteomique 2008”, McGill University, April 10, 2008. “Tumor banking in cancer research”, Invited speaker at the First International Conference on “Translational Research in Oncology”, Forli, Italy, May 14, 2008. 7. Continuing Education Activities attended or lectured Discovering and validating novel targets and markers in breast and colon cancer », Seminar in the course. Genomic Medicine » given to 4th year Medical students, McGill University. 2007/03 Lecture to Oncology Fellows, “Surgical Principles of Melanoma”, McGill University. 2008/04 Lecture on Breast Disease to 3rd year Surgical Clerks, Jewish General Hospital. 2008/05 10
  • 11. Department of Oncology Annual Report 2007/2008 Lecture to Surgery Residents, “High Risk Breast Cancer Patients”, Dept surgery, McGill University. 2008/05 8. Hospital and University Activities Medical Director, Inter-disciplinary breast cancer team, Segal Cancer Center (obtained level IV accreditation from Ministry of Health, Québec) GERALD BATIST 1. Summary of New and Ongoing Research The Quebec - Clinical Research Organization in Cancer (Q-CROC) is a Quebec oncology research consortium that is also active in oncology care. Q-CROC operates as a network, bringing together basic and clinician researchers, oncologists, surgeons and pathologists, amongst others. It was created by Dr Gerald Batist (Director of the Segal Cancer Centre) and Dr Luc Bélanger (Director of the Centre de Recherche Clinique et Évaluative en Oncologie). It is Q-CROC's firm intention to establish a province-wide translational and clinical research infrastructure in oncology in Quebec. By working together toward a common goal, members of Q-CROC will bring about major changes and improvements, for the ultimate well-being of patients. 2. Research Grants (new and ongoing) Canadian Institutes of Health Research, partnership with FRSQ, Montreal Centre for Experimental Therapeutics in Cancer, Strategic Training Program , G. Batist - P.I., Co- Invs. W. Miller, M. Alaoui-Jamali, J. Galipeau, C. Rancourt, et al. 6yrs., average operating $262,500 (Total : $1,455,000+ $120,000FRSQ). 2002-2009 Canadian Institutes of Health Research,Regulation of glutathione and related enzymes: dissection of the Nrf-2 master regulator and generation of novel potential chemopreventive molecules. $100,655/yr. 04/2006-03/2009 The Cancer Research Society, research grant, Cullin3 regulates the proliferation of breast cancer cells, a potential novel target for therapeutic intervention, Co-PI/ Weimin Miao, 2yrs - $60,000 per annum ($120,000) 09/2006-08/2008 Canadian Institutes of Health Research, GD2 gangliosides and Small Cell Lung Cancer, one year(Aug.1/06 to July 31/07). Partners: Mimetogen Pharmaceuticals Inc. $250,000(non-renewable) 08/2006-2007 Canadian Institutes of Health Research, EphB2, a novel target for gamma-secretase inhibitors (GSIs) in cancer therapy, P.I.- G. Batist,Co-PI: M. Kandouz, $150,000 per annum ($450,000). 07/2007-2010 FQRNT, Team grant, Title of Grant: Plateforme pour les interventions médicales ciblées par des dispositifs propulsés par gradients générés par un système d'imagerie par 11
  • 12. Department of Oncology Annual Report 2007/2008 resonance magnétique; $60,000/per annum (renewable for 3rd yr), PI-Martel Sylvain. 04/2007-2008 National Institutes of Health(NIH), Title of project: MRI-Based Tumor Trgeting Enhancement with Magnetotactic Bacterial Carriers, PI- Martel Sylvain, Co-PIs - Batist G, Beaudoin G, Aloyz R. Amount:$405,000, 09/2008-2010. 3. Education and Training Andrew Bier, Ph.D. Student 2001- Mustapha Kandouz, Ph.D. Student, 2001- Khadijia Haidara, Ph.D. Student, 2003- 4. Scientific Reviews Editorial Boards Associate Editor, J. Cellular Pharmacology, Springer-Verlag Editorial Board, Journal of Liposome Research, Marcel Dekker Editorial Board, Molecular Cancer Therapeutics, AACR Member, Montreal Gazette "Board of Contributors" Ad hoc Reviews Cancer Research Journal of Biological Chemistry Biochemical Pharmacology Journal of Clinical Oncology Cancer Chemotherapy and Pharmacology 5. External Committees and Boards Membre, FRSQ comité évaluatif, Centre de recherche, CHUM Scientific Advisory Committee, Israel Cancer Research Fund Investigational New Drug Committee, National Cancer Institute of Canada Member, Scientific Advisory Board, Les Laboratoires Aeterna (Aeterna Zentaris). Member, Scientific Advisory Board, Thallion Pharmaceuticals Inc(Ecopia) Member, Scientific Advisory Board, Immunotec Inc., 6. Invited Presentations Queen’s University Cancer Research Inst. Annual Retreat, Invited speaker, title: “Chemoprevention and chemotherapy resistance: the importance of context”. 7. Hospital and University Activities MUHC Cancer Care Mission Retreat (Dr. Jeremy Sturgeon), Mont-Tremblant 12
  • 13. Department of Oncology Annual Report 2007/2008 Title: MUHC within the McGill University Dept of Oncology and the McGill RUIS: how best can we work together? NICOLE BEAUCHEMIN 1. Summary of New and Ongoing Research 1) Modifiers of colon cancer. Dr. Philippe Gros, Dept. of Biochemistry, McGill University. 2) Evaluation of colon cancer pathology in transgenic and knockout mice. Dr. Victoria Marcus, MUHC pathologist, McGill University. 3) Investigation into the insulin resistance phenotype of Ceacam1-/- mice. Dr. Emile Lévy, Centre de Recherche, Hôpital Ste-Justine, Montréal. 4) Investigations into the altered fat metabolism in Ceacam1-/- mice. Dr. Roland Savard. Dept. of Biologie, UQAM, Montréal. 5) Immunology and infections with MHV of Ceacam1-/- mice. Dr. Lucie Lamontagne. Dept. of Biologie, UQAM, Montréal. 6) The role of the tyrosine phosphatase SHP-1 in metabolism. Dr. André Marette, Centre de Recherche du CHUL. Ste-Foy Qué. 7) Phenotypes of an endothelial-specific transgenic mouse model for CEACAM1, Dr. Christoph Wagener, Dept. of Clinical Biochemistry, Univ. of Hamburg, Hamburg, Germany. 8) The role of CEACAM1 in endothelial progenitor cells. Dr. Suleyman Ergun, Essen University, Germany. 9) Mice Resistant to mouse hepatitis viral infections. Dr. Kathryn V. Holmes, Dept. of Microbiology, Univ. of Colorado, Denver, CO. 10) Analyses of brain-tropism of MHV in Ceacam1-/- targeted mice. Dr. Susan Weiss, Department of Microbiology, Univ. of Pennsylvania School of Medicine, Philadelphia, USA. 11) Development of a Humanized CEACAM1-targeted mouse. Dr. Scott Gray- Owen, Dept. of Microbiology, Univ. of Toronto, Toronto, Canada. 12) The functions of CEACAM1 in platelets. Dr. Denise Jackson. Austin Research Institute. Melbourne Australia. 13) The role of CEACAM1 in dendritic cells. Drs. Robert Kammerer and Wolfgang Zimmerman. Klinikum der Universität München. Munich Germany. 14) The role of CEACAM1 in insulin receptor signaling. Dr. Sonia M. Najjar. Medical College of Ohio. Toledo Ohio. 15) The role of CEACAM1 in graft versus host disease. Dr. Marcel R.M. van den Brink. Memorial Sloan-Kettering Cancer Center. New York. N.Y. 16) The role of CEACAM1 in immune responses of M cells. Drs. H. Kiyono and O. Igarashi. Institute of Medical Science, The University of Tokyo. Tokyo, Japan. 17) The role of CEACAM1 in lung tissue. Dr. Bob Scholte, Cell Biology Dept. Eramus University Medical Centre, Rotterdam, The Netherlands. 18) The role of CEACAM1 in T lymphocytes. Dr. Richard Blumberg, Harvard University. 13
  • 14. Department of Oncology Annual Report 2007/2008 2. Research grants (new and on-going) CEACAM1 signaling in epithelial cell adhesion and motility Canadian Institutes for Health Research PI: Nicole Beauchemin $128,664./yr, 2003-2007 Involvement of mouse biliary glycoproteins (CEACAM1) in tumor development and metastasis, PI: Nicole Beauchemin, Cancer Research Society Inc. $60,000./yr 2005-2007 CEACAM1 in colon cancer progression, PI: Nicole Beauchemin, National Cancer Institute of Canada, $113,050./yr 2005-2008 Genetic control to susceptibility of carcinogen-induced colon cancer (PI: Philippe Gros, co-PI: Nicole Beauchemin) Miriam and Saul Goldberg Innovative Research $ 15,000./yr 2007-2008 Metabolic functions of the PTPase SHP-1 in insulin target tissues (co-PI with: André Marette & Kathryn Siminovitch) Canadian Institutes for Health Research $136,515./yr 2007-2012 Genetic control to susceptibility of carcinogen-induced colon cancer (PI: Philippe Gros, co-PI: Nicole Beauchemin) National Cancer Institute of Canada $123,000./yr 2007-2010 CEACAM1 as a regulator of normal and tumor angiogenesis. PI: Nicole Beauchemin Canadian Institutes for Health Research $141,480./yr 2007-2011 Involvement of mouse biliary glycoproteins (CEACAM1) in tumor development and metastasis. PI: Nicole Beauchemin Cancer Research Society Inc. $60,000./yr 2007- 2009 (declined) CEACAM1 in colon cancer progression PI: Nicole Beauchemin Canadian Institutes for Health Research $177,253./yr 2008-2012 Coordinator for the McGill Cancer Centre, the Segal Cancer Centre and the MUHC CIHR Training Grant Letter of Intent. Full grant to be submitted on Nov. 1, 08. $325,000/yr for 6 years. 3. Education and Research Training Undergraduate Students Sarah Leblanc Winter 2007 (Biochemistry) Denitza Roudeva Autumn 2007 (Biochemnistry) Justin Drager Autumn-Winter 07-08 (Biochemistry) Samantha Benlolo Summer 2008 (Biochemistry) Graduate Students Nelly Leung Ph.D. (2008) (Biochemistry) Anne-Marie Charbonneau-Allard M.Sc. (2007) (Biochemistry) 14
  • 15. Department of Oncology Annual Report 2007/2008 Sarah LeBlanc M.Sc. (2009) Post-Doctoral Fellows Anne-Laure Nouvion 2006-2010 Ph.D. Institute de Chimie-Biologie, Lyon Azadeh Arabzadeh 2008-2012 Ph.D. University of Ottawa Graduate students on whose supervisory committees I currently serve. 1. RAC Nelly Leung, Dept. of Biochemistry 2001- 2. RAC Melanie Chagnon, Dept. of Biochemistry 2003- 3. RAC Patrick Fok, Montreal Neurological Institute, 2004-2006 4. RAC Valérie Hudon, Dept. of Biochemistry, 2004- 5. RAC Ghada Kurban, Dept. Biochemistry, 2004- 6. RAC for Charles Meunier, Dept. of Biochemistry, 2006- 7. RAC Malika Oubaha, IRCM, student of J.P. Gratton, 2006- 8. RAC Kataryna Jesien, Dept. of Medicine, IRCM, 2007- 9. GAC Shun Li, Royal Victoria Hospital, student of Dr. P. Brodt, 2007- 10. GAC and RAC for Sami Bouahia, Dept. of Biochemistry, May 2007- 11. GAC and RAC for David Grote, Dept. of Biochemistry, April 2007- 12. GAC for Alana Nguyen, Dept. of Biochemistry, April 2007- 13. GAC for Karen Doody, Dept. of Biochemistry, September 07- 14. GAC & RAC Patricia McDonald, Dept. of Experimental Medicine, May 2008- 15. Ph.D. Oral Defense for Pierre-Luc Tremblay, Laval University, November 2007. 16. Ph.D. Oral Defense for Nelly Leung, Dept. of Biochemistry, December 2007. 4. Scientific Reviews Journal Reviews Nature Reviews Immunology Oncogene X 4 Molecular Cell Biol. Experimental Medicine and Biology Colon Cancer Metastasis J. Biol. Chem. Grant Reviews Canadian Institutes for Health Research NSERC 5. Conference Organization Organizer of the McGill Cancer Centre seminar series 2005-2008 Co-organizer of the Angiogenesis-Metastasis Research Group 2006-present: meeting once/month of 20 research groups from the Montreal region interested in these topics. 15
  • 16. Department of Oncology Annual Report 2007/2008 6. External Committees and Boards Panel Member Canadian Institutes for Health Research, Palliative Care committee 2 days/year National Cancer Institute of Canada, Panel J 2 days/year 7. Invited Presentations and Workshops CEACAM1 as a regular of normal and tumor angiogenesis. Angiogenesis and Metastasis Research Group. January 2007. CEACAM1: entre l’adhésion cellulaire, le cancer du côlon et l’angiogénèse. Invited talk at the Centre de Recherches de l’Hotel Dieu, Québec, Qc, May 25 2007. La tyrosine phosphatase SHP-1 régule négativement l’homéostasie du glucose. Invited talk at the Symposium de physiopathologie de l’intestin. Sherbrooke June 2007. Intestinal Tumor Progression Is Promoted by Decreased Apoptosis and Dysregulated Wnt Signaling in Ceacam1-/- Mice. Invited talk at the 17th CEA International Workshop. Los Angeles California, Sept. 2007. CEACAM1, a cell adhesion molecule that functions as an inhibitor of tumor progression and a modulator of neo-angiogenesis. Invited talk at the Sunnybrook Health Sciences Centre. Toronto, December 2007. CEACAM1, a cell adhesion molecule that functions as an inhibitor of tumor progression and a modulator of neo-angiogenesis. Invited talk at the McGill Cancer Centre. Montreal, March 2008. Colon Cancer Susceptibility Gene Loci. Canadian Cancer Society, May 2008. 8. University Committees Member of an Ad Hoc Faculty Postgraduate Promotions Review committee, Faculty of Medicine, since November 2003-2008. Member of the Dept. of Oncology Promotions Committee, 2 meetings per year since 2006-. Member of the Faculty of Medicine Admissions committee, 2 weeks/year of interviews of potential Medicine students, 2007-present. Member of MUHC Lutte Contre le Cancer (Colorectal) team (2006-…). Presentation at McGill University Grantsmanship meeting (2007-…). 16
  • 17. Department of Oncology Annual Report 2007/2008 Member of McGill University’s Harassment and Sexual Harassment Committee (2007). This was a 6- month involvement for one of the worse cases to happen at McGill University. It required 3 months of non-stop work on my own, with the help of the University lawyers. Member of McGill University’s committee on Policy on the Care and Use of Animals in Scientific Research and Teaching (2007-08). 9. Involvement in the community Member of the Institutional Review Board at the Ville-Marie Breast Clinic. Meetings once/month for evaluation of clinical trial protocols. (2004-…). Actively involved in speaking engagements to volunteers of the Canadian Cancer Society. Oct. 4, 2007: interview for TeleQuebec, Une pillule, une petite granule. Oct. 11, 2007: 45 min talk for employees of Canadian Public Security for Canadian Cancer Society. Oct. 23, 2007: one hour radio interview for Radio-Centre Ville on breast cancer. Nov. 6, 2007: meeting with large donors for the Canadian Cancer Society. Nov. 8, 2007: invited speaker for Canadian Cancer Society donors of the Mauricie region. Jan. 15, 2008: meeting with donors of Canadian Cancer Society at Cossette Communications. May 6, 2008: meeting with large donors for the Canadian Cancer Society. MARTIN BLACK and MICHAEL HIER 1. Summary of New and Ongoing Research 1) A phase 3 randomized trial of chemotherapy with or without panitumumab in patients with metastatic and/or recurrent squamous cell carcinoma of the head and neck (McG0723) 2) A phase 2,randomized trial of chemoradiation with or without panitumumabin subjects with unresected ,locally advanced squamous cell carcinoma of the head and neck (McG0735) 3) Can Post-parathyroidectomy Hypocalcemia Be Attributed to Research Abnormal 17
  • 18. Department of Oncology Annual Report 2007/2008 Synthesis of Parathyroid Hormone? Richardson K, Payne RJ, Hier MP, Black MJ, Tamilia M 4) Defining Success Following Parathyroidectomy for Primary Hyperparathyroidism Rotstein D, Payne RJ, Hier MP, Black MJ, Tamilia M 5) Radiation Therapy Oncology Group, RTOG 0514 Establishment Of A Head And Neck Cancer Tissue/Specimen Repository 6) Radiation Therapy Oncology Group, RTOG 0522 A Randomized Phase Iii Trial Of Concurrent Accelerated Radiation And Cisplatin Versus Concurrent Accelerated Radiation, Cisplatin, And Cetuximab (C225) [Followed By Surgery For Selected Patients] For Stage Iii And Iv Head And Neck Carcinomas 7) Radiation Therapy Oncology Group, RTOG 0615 A Phase Ii Study Of Concurrent Chemoradiotherapy Using Three-Dimensional Conformal Radiotherapy (3d-Crt) Or Intensity-Modulated Radiation Therapy (Imrt) + Bevacizumab (Bv) For Locally Or Regionally Advanced Nasopharyngeal Cancer NCI-supplied agent: Bevacizumab (NSC 704865; IND 79211) 8) Phase Ii Study Of Peri-Operative Brachytherapy ± Intenisty Modulated Radiotherapy (Imrt) With Or Without Chemotherapy For Carcinoma Of The Oral Tongue Investigators: Dr. Boris Bahoric Radiation Oncologist, Dr. Michael Hier ENT Surgeon, Dr. Martin Black ENT Surgeon. 2. Research Grants (new and ongoing) The life course approach to the aetiology of squamous cell carcinoma in the upper aerodigestive tract. P.J.Allison, EL Franco, R Fuhrer, G Humphris. Collaborators: M.Black, M.Hier. Canadian Institutes of Health Research. $434,063. Oct 2004 - Sept 2007 A randomized controlled trial of the effectiveness of a coping strategies intervention for people with head and neck cancer. P.J.Allison, LJ Edgar, JS Feine, EL Franco. Collaborators: M.Black, M.Hier. Canadian Institutes of Health Research. $471,139. April 2005 – March 2009 3. Education and Research Training Dr Limor Kalmovitch. H&N fellow from Isreal finishing Sept/08 4. Scientific Reviews (M. Hier and M Black) Editorial Board Can. Journal of Otolaryngology Reviewer Head and Neck Surgery 18
  • 19. Department of Oncology Annual Report 2007/2008 5. External Committees and Boards M. Hier “Head and Neck Plenary Session”, Chairman, 61st Annual Meeting of the Canadian Society of Otolaryngology/Head and Neck Surgery. Montreal, Quebec, May 14, 2007 M Black Retired as Surgeon in chief …JGH in 2007…15years 6. Invited Presentations M. Black Community Mini-Med presentation – “Update in Head and Neck Surgery” YMHA, Montreal. 2007 “Thyroid Cancer Update”, Jewish General Hospital in conjunction with Hope & Cope, 2007 M Hier Non-Melanoma Skin Cancer, Chair: M. Hier Panel: J. Chaplin, J. Harris, N. Jha, C. Keeling, C. Moore, M. Taylor, H. Seikaly, M. Sapijaszko, J. Yoo. Presented at the Canadian Society of Otolaryngology – Head and Neck. Surgery, 62nd Annual Meeting, June 1 -4, 2008, Jasper, Alberta. 7. Hospital and University Activities Many many committees at university and the hospitals PHILIP BRANTON 1. Summary of New and Ongoing Research Our studies continue on 2 projects. In the first we are examining the degradation of proteins by the adenovirus E4orf6-E1B55K complex and studies focus on identifying the target proteins, especially those involved in mRNA transport. In the second we continue work on the adenovirus E4orf4 protein that kills cancer cells specifically. We are working on the mechanism of action, especially on the inhibition of PP2A by E4orf4. 2. Research Grants (new and ongoing) Major Grants Mechanism of oncogenic transformation by human adenovirus, Canadian Institutes of Health Research (CIHR), $204,000/yr, 1998-2009 Mechanism of action of the adenovirus death protein E4orf4 and their targets, National Cancer Institute of Canada (NCIC), $150,000/yr, 2004-2009 19
  • 20. Department of Oncology Annual Report 2007/2008 3. Education and Research Training PhD Students Melissa Mui Chi Ying (Theresa) Cheng Postdoctoral Fellows Paola Blanchette Suiyang Li 4. Scientific Reviews Journal Reviews MCB J Virology Oncogene 5. Conference Organization DNA Tumor Virus Meeting, Madison, WI 2008 6. External Committees and Boards Scientific Director, CIHR Institute of Cancer Research (until July 31, 2008) 7. Hospital and University Activities Advisor for the Terry Fox Research Institute MARTIN CHASEN 1. Summary of New and Ongoing Research Principal Investigator, The Value Of The Egg (Electrogastrogram) In Patients With The Anorexia/Cachexia Syndrome (Ethical approval, October 2005) Co-Investigator, NCIC Sociobehavioural Cancer Research Network-Clinical Trials Group. Cancer Pain Classification Project: Pilot and Feasibility Phase Co-Investigator, Phase II Study of Neoadjuvant Taxotere, Cisplatin, and 5-Fluorouracil in Patients With Gastric or Gastroesophageal Junction Adenocarcinoma Co-Investigator, A Double-Blind, Randomized, Placebo Controlled Clinical Trial to Evaluate the Efficacy of Orexigenic Therapy with delta-9-Tetrahydrocannabinol (THC) in Advanced Cancer Patients with Chemosensory Abnormalities A Phase 2, Open-Label, Multi-Center Study with AVRll8 in Anorectic Patients with Recurrent or Advanced Malignancies Principal Investigator 20
  • 21. Department of Oncology Annual Report 2007/2008 Utility of #D Ultrasound for assessing cachexia through measurement of muscle volume changes Gut Brain Axis Phenotype –Cachexia Assessment Trial (GUBRA-CAT) 2. Reasearch Grants (new and ongoing) NCIC Sociobehavioural Cancer Research Network: Cancer Pain Classification Project: Pilot and Feasibility Phase ($45,000) Expanding the Role of Pre-operative Rehabilitation: The Impact of a Multidisciplinary Program of Improving Nutritional Reserve and Exercise Capacity on Post-operative Complications after Major Thoracic Cancer Surgery ($20,000) – Co-investigator—Research Institute of the McGill University Health Centre (awarded) Sept 2007-Sept 2008 Evaluation of a 12-week comprehensive exercise program following adjuvant therapy for breast cancer ($10,000)—Co-investigator—Research Institute of the McGill University Health Centre (awarded) Towards an understanding of cancer cachexia—Linking molecular mechanisms with novel treatment options ($2,000,000)—Co-investigator—Terry Fox Research Institute TFRI (Montreal) (awarded) 3. Education and Training Undergraduate: Medical students ICM (Introduction to Clinical Medicine): Introduction to Oncology Feb-June 2007 1-3 students, 1-2 days/week—clinic tutorial/ward rounds Feb-June 2008 1-3 students, 1-3 days/week—clinic tutorial/ward rounds Courses/lectures (undergraduate) Oct. 2007 Lecture (1 hr.) entitled, “Spirituality”, McGill University School of Physical and Occupational Therapy, Course # POTH 446: Current Topics in Rehabilitation: Cancer Rehabilitation Jan 2008 ICM--Introduction to Clinical Medicine Class 2010: Professional Skills (Course # IMED 301) Jan 2008 Introduction to Clinical Sciences (ICS) Evidence Based Medicine Universal Precautions (Course # INDS 301) May 2008 Group leader (ranked highest by students), “Spirituality, Religious Adherence and Medicine”, (Course # INDS 120, “Physicianship I”- 1st year medical and dental students) Electives (R2, R3 & R4 medical students) 30/07-26/08 2007 Michael Palumbo (McGill) 20/08-12/10 2007 Shermaine Ye Yun Pan (visiting) 23/03-06/06 2007 Soumaya El Fahmy (visiting) 19/11-16/12 2007 Andries Petrus Dippenaar (visiting) 21
  • 22. Department of Oncology Annual Report 2007/2008 10/03-06/04 2008 Matthias Haas (visiting) Oncology Residents 09/07-18/11 2007 Ashley Davidson 13/02-30/06 2008 Giovanna Speranza Lectures (post-graduate) Jan 25, 2008 Lecture (2 hr.) entitled, “Chemotherapy for Oesophagus Cancer”, Faculty of Medicine, Medical Oncology Feb 26, 2008 Lecture (1hr.) entitled, “Chemotherapy for patients with head and neck cancer”, for ENT residents, Royal Victoria Hospital May 21, 2008 Lecture (1hr) entitled, “Cancer Rehabilitation”, for surgical residents, Royal Victoria Hospital May 21, 2008 Lecture (1hr) entitled, “Spiritual Care of the Terminally Ill”, for surgical residents, Royal Victoria Hospital 4. Scientific Reviews Editorial Boards Editorial Manager/Peer Review, Journal of Cancer Survivorship: Research and Practice Section editor of section Cancer Rehabilitation and Survivorship in Current Oncology Journal Reviews Supportive Care in Cancer Journal of the National Cancer Institute Annals of Oncology 5. External Committees and Boards Member, Palliative Care Working Group, European Society of Medical Oncology Member, Board of Directors of the Canadian Society of Palliative Care Physicians Member, Eyes on the Prize.org Medical Advisory Panel Member, ESMO Palliative Care Working Group for the European Society of Medical Oncologists, Budapest, Hungary Foundation Board Member Miriam Home, Montreal Member, Advisory Board Abbott North American Ensure Health Care Professionals 6. Invited Presentations Television interview, “Healthy Living”, Radio-Canada (Télé journal), Montreal. Sept. 28, 2007 Hôpital Charles Lemoyne, Montreal, “Cancer – Nutrition Rehabilitation: It Really Works!” Oct. 26, 2007 22
  • 23. Department of Oncology Annual Report 2007/2008 Editorial co-author, “Optimism Matters in the Treatment of Cancer: Montreal Patients do not have to Navigate this often Terrifying Journey Alone,” the Montreal Gazette, Montreal Nov. 4, 2007 Organizer, Inaugural Steven and Lillian Vineberg Lecture: Dr. Stephen Sagar, “Complimentary Therapies—New Horizons in Cancer Care”, Gelber Centre, Montreal Nov. 5, 2007 Department of Radiation, Montreal General Hospital, Montreal, “Cancer – Nutrition - Rehabilitation: It Really Works!” Nov. 12, 2007 Department of Continuing Medical Education, Faculty of Medicine, McGill University, “Cancer Rehabilitation”, as part of the Thursday Evening Learning Series, By Special Request, Fall 2007 Session. Dec 13, 2007 McGill Oncology Research Retreat, “Cancer Nutrition and Rehabilitation: Current Status”, Montreal. March 13, 2008 Invited faculty/speaker, Cancer Education Committee for the 2008 ASCO Annual Meeting, Education Session entitled, “The Path to Self-Healing. Delivering Bad News: An Opportunity for Healing the Patient and Physician.” Chicago, Illinois May 30-June 3, 2008 7. Continuing Education Activities attended or lectured The 5th Annual Advanced Learning in Palliative Medicine, Ottawa, Canada (May 8-10, 2008) 8. Hospital and University Activities Member, Upper GI Site-Specificity Committee, McGill University Health Centre Member, Palliative Care Site-Specificity Committee, McGill University Health Centre Member of Institutional Review Board of the Faculty of Medicine, McGill University Supervisor, Clinical Teaching McGill medical students and R3-R4 elective students (McGill University and visiting students), Medical Oncology, Royal Victoria Hospital, MUHC Faculty-observer, McGill Internal Medicine Residency Training Program using the McGill Simulation Centre (Jan 11 & April 5, 2007) Examiner, McGill Internal Medicine Residency Training Program Royal Victoria Hospital, R1 & R2 Oral Examinations 23
  • 24. Department of Oncology Annual Report 2007/2008 Small group facilitator, Professionalism Seminar, McGill University, Postgraduate Core Competencies Program for R2s in all disciplines Small group facilitator (15 first-year students from McGill Faculty of Medicine), Inter- professional Cultural Competence Seminar as part of the Joint Inter-professional Curriculum Committee from the McGill Educational Initiative on Inter-professional Collaboration (Funded by Health Canada) Faculty-observer, McGill Internal Medicine Residency Training Program using the McGill Simulation Centre (Jan 17, 2008: Academic half day) Small group facilitator (students within the Faculty of Medicine Schools of PT, OT, Nursing, Medicine, Dentistry and Communication Sciences and Disorders ), Cultural Awareness Workshop, Developing Cultural Competence: Raising Awareness & Building Knowledge for Effective Health Care Practice, The McGill Educational Initiative on Interprofessional Collaboration: Partnerships for Patient and Family-Centred Practice Co-attending, Royal Victoria Hospital 10 Medicine Clinical Teaching Unit Rounds. ROBIN COHEN 1. Research Grants (new and ongoing) Strategic Training Program in Palliative Care Cancer Research. Robin Cohen (PI). Canadian Institutes of Health Research/National Cancer Institute of Canada - #STI- 63286. $1,800,000 04/2003 – 03/2009 GRISIM: Groupe de recherche interuniversitaire en soins infirmiers de Montréal. Investigator. (P.I.s: Celeste Johnston and Nicole Richard) FRSQ/Newton Foundation/MSSS $2,000,000 04/2004 – 03/2008 Family caregiving in palliative and end-of-life care: A new emerging team. Co-principal investigator with K.I. Stajduhar, University of Victoria. Canadian Institutes of Health Research- #129692 $1,361,361 2004 – 2009 A national cancer pain research network to improve the classification, assessment, and management of difficult cancer pain problems. Co-investigator. (P.I.s: N.A. Hagen, University of Calgary, R.L. Fainsinger, University of Alberta, P.M. Brasher, Alberta Cancer Board) Canadian Institutes of Health Research- # 129697 $1,363,586 2004 – 2009 Quality of life in cancer patients admitted to an acute palliative care unit and their caregivers: a prospective study of self-report and proxy-for-patient ratings Co- Investigator. (P.I.: Jennifer Jones) National Cancer Institute of Canada – CCS Research 24
  • 25. Department of Oncology Annual Report 2007/2008 Grant for New Investigators $55,371 (2005 – 2006); $56,956 (2006 – 2007); $62,614 (2007 – 2008) Measuring the quality of end-of-life care provided in inpatient health care settings (Co- investigator) (P.I. Kelli Stajduhar) Michael Smith Foundation for Health Research HSPRSN Research Operating Grant $99,796 05/2006 – 04/2008 An evaluation of Canada’s compassionate care benefit from a family caregiver’s perspective (P.I. A Williams, co-investigators: Stajduhar K, Crooks V, Allan D, Cohen SR , Brazil K.) Canadian Institutes of Health Research (CIHR) $169,729 09/2006 – 08/2009 Safety in home care: Perspectives from clients, family members, caregivers, and providers. (P.I: Lang A, co-investigators: Cohen SR, Easty AC, Lachance JA, Germain D, Stajduhar KI, Williams AM) Canadian Institutes of Health Research (CIHR) $53, 237 04/2007-03/2010 An anthropology of bereavement: a sociocultural analysis of parental grief and mourning. (P.I.: Macdonald, ME, co-investigators: Mitchell L, Stephenson PH, Cadell SA) (collaborator: Cohen SR) Social Sciences and Humanities Research Council (SSHRC) $75,000. 04/2007-03/2010 2. Education and Research Training Ph D Students Anita Mehta: Family caregivers of palliative care patients at home: The pain management process Marianne Olivier- d’Avignon: Development of a needs profile for siblings of terminally ill children Lisa Chan: The experience of end-of life-care on an end-stage medical in-patient unit Shuling Chen: Spirituality & Palliative Care in Chinese Canadians Réjeanne Dupuis: Nursing leadership in palliative care Christopher MacKinnon: Spirituality and ethnicity in palliative care Postdoctoral Students Mary Rykov, Ph.D. The impact of music therapy on patients and families on palliative care units Melissa Henry, Ph.D. Meaning Making Intervention for women with newly diagnosed advanced ovarian cancer 25
  • 26. Department of Oncology Annual Report 2007/2008 Dawn Allan Ph.D Dr. Javad Shahidi (Iran): Quality of life of people with advanced cancer and their family carers Traugott Roser Ph.D.: Spirituality in palliative care Nadine Bernier Ph.D.: Projet sur les facteurs facilitant et contraignants la prestation de services aux proches de maladies en fin de vie Winter 2007, NUR2 705 Instructor: Robin Cohen A required course for the interdisciplinary Psychosocial Oncology Option in the Faculty of Graduate Studies and Research, Palliative Care in Cancer 3. Scientific Reviews Editorial Boards Journal of Palliative Care American Journal of Hospice and Palliative Care Ad Hoc Reviews Journal of Pain and Symptom Management Journal of Palliative Care Palliative Medicine Psycho-oncology Quality of Life Research Grant Reviews Panel Member: National Cancer Institute of Canada, Clinical Fellowships , July 1-2006- June 30-2008. 4. Congress and Workshop Organization 17th International Congress on Care of the Terminally Ill, Montreal, September 22-26, 2008, Executive and Organizing Committee Oct 2006- Sept 2008 • Determining Congress content and schedule • Sole Organizer of Research Program. • Chair of Research Abstract Review Committee. • Chair all Research Fora European Association for Palliative Care 5th Research Forum, Trondheim, Norway, May 28-31, 2008. Scientific Committee, March 2007 – May 2008 5. External Committees Director, Quebec Research Satellite Centre of the National Cancer 26
  • 27. Department of Oncology Annual Report 2007/2008 Institute of Canada Sociobehavioural Cancer Research Network Director, Palliative Care Research Team of the National Cancer Institute of Canada Sociobehavioural Cancer Research Network Founding Member, Quebec Pain Research Initiative 6. Invited Presentations and Workshops (National and International) Cohen SR, Fyles G, Viola R, Lachance J, Leis A, Brown KS, Porterfield P. Predicting carer experience in the first six months of bereavement. 9th World Congress of Psycho- Oncology, London, England, September 16-20, 2007. 7. Hospital and University Activities Hospital Wellness Centre, Jewish General Hospital, Research Advisory Board, Member. McGill Founding Member, McGill Pain Centre McGill Department of Oncology Clinical Trials Operations, Supportive Care Section, Member ANNA DEROSSIS 1. Research Training Mc Gill Undergraduate Breast Surgery Elective Director/Supervisor (undergraduate students) Surgical Oncology Fellowship Site Coordinator (SMBD JGH) 2. External Committees and Boards Medical Council of Canada Examiner 3. Invited Presentations Derossis AM. International Society of Surgery, International Surgery Week 2007, Montreal, Quebec. Panel: “Is Breast Cancer the same Disease in Asia as in the West?; Breast Cancer in Canada”. August 2007. 4. Continuing Education Activities Attended International Society of Surgery Meeting (Montreal) August 2007 Searching the literature for evidenced-based teaching and learning (McGill) November 2007 27
  • 28. Department of Oncology Annual Report 2007/2008 Association of Surgical Education Meeting (Toronto) April 2008 American Society of Breast Surgeons Meeting (New York) May 2008 Lectured Faculty Development, Faculty of Medicine, McGill University, “Life as a Physician Series”, Derossis AM, November 2007. Faculty Development, Faculty of Medicine, McGill University, “Designing Successful Workshops” (Workshop Leader), Derossis, AM., December 2007. Department of Surgery, McGill University, “Breast Cancer in Canada: Changes in Presentation and Management”, Derossis AM, Surgical Grand Rounds, March 2008. 5. Hospital and University Activities SMBD - Jewish General Hospital, Department of Surgery, Surgical Education Director McGill University, Faculty of Medicine, Faculty Development Committee Member LINDA EDGAR 1. Research Grants (new and ongoing) PI. Working with The Wellness Community of America and the BC Cancer Agency , Hope & Cope is a partner in researching cultural differences and generic composition of patient education for cancer treatment and survivorship. $10,000.00 2008 -2009 Co-Investigator with Paul Allison, PI, A randomized controlled trial of the effectiveness of a coping strategies intervention for people with head and neck cancer. CIHR. $480,000.00. 2005-2009 PI. In house funding. Evaluating the Wellness Center for its impact on psychological factors and goal attainment. Hope and Cope Research Fund. 2005- 2. Education and Training Inhouse Examiner for PhD thesis, School of Nursing, McGill. Adjunct Professor, Brock University, Ontario – Lead Professor for 4th year Bac. Nursing Program Course on Applied Nursing Research. Developed web site on coping with cancer. www.Copingwellwithcancer.com Developed and taught The Cancer Coach Program now in use by CCAC. 28
  • 29. Department of Oncology Annual Report 2007/2008 Training volunteers to act as research assistants, and to facilitate coping workshops at the JGH Hope & Cope Wellness Centre. 3. Scientific Reviews Journal reviewer for International Journal of Nursing Studies 4. External Committees and Boards Director of Support, Colorectal Cancer Association of Canada. Consulting and training Functions. 10 hours/week Presented at Advocacy Training for the Canadian Colorectal Cancer Association 1day Consultant and Presenter, for Staff at McNally House, a newly built hospice, Grimsby, Ontario.7 days. Consulted with Cancer Care Ontario on developing Care pathways for specific cancer sites. MICHAEL EVANS 1. Education and Research Training McGill University Graduate Courses 563-613B Health Physics 563-603 B Laboratory In Radiation Therapy Dawson CEGEP Laboratory In Radiation Oncology M.Sc. Thesis: A Dosimetric Analysis Of The Varian Enhanced Dynamic Wedge Factor For Symmetric And Asymmetric Configurations. Richard Benson, 2008 Medical Physics Resident Supervision Eric Reynard, M. Sc. 2007 – Present Gabriella Stroian, Ph.D. 2007 – Present Krum Asiev, M. Sc. 2007 – Present Ismail Dahlawi, M. Sc. 2008 - Present 2. External Committees and Boards Canadian College Of Physicists In Medicine (Ccpm), Board Member And Chief Examiner C.C.P.M., Fellowship Examination (Oral) Committee C.C.P.M., Membership Examination (Oral) Committee 29
  • 30. Department of Oncology Annual Report 2007/2008 Canadian Organization Of Medical Physics: Radiation And Technical Standards Advisory Committee: Canadian Medical Association Conjoint Committee On Accreditation Site Visit : Mcmaster University / Mohawk Institute, Hamilton Ontario, 2008 3. Invited Presentations M.D.C. Evans, An Overview Of Brachytherapy At Mcgill University. Workshop On The Role Of Hdr Brachytherapy In Multi-Modality Treatment Of Rectal Carcinoma. Montreal, October 19 – 21, 2007. 4. Hospital and University Activities Hospital Committees McGill University Health Center: Radiation Safety Committee McGill University Health Center: Radiation Oncology Qa Committee McGill University Health Center: Med. Physics Qa Committee McGill University Health Center: Med. Physics Radiation Safety Committee SERGIO FARIA 1. New and Ongoing Research With Dr. Te Vuong reviewing the MUHC experience in Rectal cancer and Anal Canal cancer. Reviewing with our fellow in GU tumors (Nicholas Rene) changes in Testosterone levels after hypofractionation 2. Education and Training Dr Wael El-Sheshtawy Dr Nicholas Rene 3. Scientific Reviews Journal Reviews International Journal of Radiation Oncology Biology and Physics Radiotherapy & Oncology 4. Conference Organization Workshop - 6 MV vs 18 MV and Heterogeneity correction in Lung Cancer. Does it matter? CARO –ACRO meeting 2007, October 13, 2007, Toronto, Ontario 5. External Committees and Boards NCIC- National Cancer Institute of Canada: Member, Lung Disease Site Committee RTOG – Radiotherapy Oncology Group: Member, Lung Disease Site Committee 30
  • 31. Department of Oncology Annual Report 2007/2008 6. Invited Presentations Terapia hypofracionada: o futuro da radioterapia? Oral presentation at the Curso avançado de Uro Oncologia November 30, 2007-12-09. Campinas, Sao Paulo, Brazil Como conduzir a recidiva bioquímica pós radioterapia? Oral presentation at the Curso avançado de Uro Oncologia November 30, 2007-12-09. Campinas, Sao Paulo, Brazil Hypofractionation in prostate cancer. Oral presentation at the 1st ALATRO – Asociacion Latinoamericana de Terapia Radiante Oncologica, Mesa de Cancer de Prostata 4 – 7 December, 2007-12-09 Montevideo, Uruguay Nodule pulmonaire inopérable. Vaut-il la peine de l’irradier ? Comment? Soiree de Pneumoligie de la Rive Sud 15 Janvier 2008 Brossard, Quebec, Canada The challenge of scoring late radiation induced lung toxicity. Radiation Oncology Research Retreat, on May 30, 2008, Montreal,Quebec, Canada 7. Hospital and University Activities McGill University: Member, Lung Cancer Committee Member, Genito-Urinary Tumor Board, Montreal General Hospital, Montreal Member, Lung Cancer Tumor Board, Montreal General Hospital, Montreal Member, Lung Cancer Tumor Board, Jewish General Hospital, Montreal WILLIAM FOULKES 1. Summary of New and Ongoing Research 1) Finding out PALB2 cause breast cancer 2) Investigation of an Inuit family with a recessive cancer syndrome 3) Investigation of a new aneuploidy-related cancer syndrome 4) Variation in the breast cancer transcriptome 5) Cyclin E and breast cancer 6) Basal breast cancer and BRCA1 2. Research Grants (new and ongoing) Systematic Characterization of Dasatinib Sensitivity and Resistance in Breast Cancer Cells: Rationale for Patient Selection and Treatment Design. Susan G Komen BrCa Foundation 31
  • 32. Department of Oncology Annual Report 2007/2008 Exploring the pathogenic and therapeutic implications of aberrant splicing in breast cancer. U.S. Army Medical Research and Materiel Command Toward the biological treatment of BRCA1-related breast cancer: EGF, EGFR and tyrosine kinase inhibitors. Canadian Breast Cancer Research Alliance The 3D telomeric signature(s) of DCIS. Susan G Komen BrCa Foundation BRCA1, CDC4, Cyclin E, and Chromosomal Instability in Breast Cancer. Canadian Breast Cancer Research Alliance Risk factor analysis of hereditary breast and ovarian cancer. Canadian Breast Cancer Research Alliance The Genetic of Prostate Cancer: The ICPCG Study. National Institutes of Health (NIH) 3. Education and Training Graduate Students Name: Tayma Khalil (Raquel Aloyz: co-supervisor) Department: Human Genetics Years: 2005-2007 Degree: MSc Topic: CDC4 in hereditary breast cancer Name: Lili Li Department: Human Genetics Years: 2007- Degree: PhD Postdoctoral Fellows Ahmet Yilmaz, 2006-2008 Martin Couillard, 2008-2010 Supervision of McGill University Genetic Counselling M.Sc. students 2005-2007 Jennifer MacLean Marilyn Richard Nassim Taherian Teresa Tiberg 2006-2008 Danna Loder Karine Bedard Rachel Vanneste Stephanie Neuert 32
  • 33. Department of Oncology Annual Report 2007/2008 McGill University Medical Genetics Elective 2006-2007 Marta McCrum Aspasia Karalis Cristina Stanculescu 2007-2008 Nga Man Lau Royal College Resident Trainees Nicholas Ah Mew 2002-7 Philippe Campeau 2003-8 Maha Al-Awadi 2004-9 Khalid Al-Thihli 2004-9 Mouna Ben Amor 2004-9 Ahmed Alfares 2006-11 Daniela D'Agostino 2006-11 Sébastien Lévesque 2007-10 (entering at RIII level) Asparia Karalis 2007-12 Graduate And Undergraduate Courses 516-614B Environmental Carcinogenesis Department: Medicine (Div. Experimental Medicine) Format: Lecture Title: Cancer Genetics/Prevention Role: Lecturer Level: MSc Program Time: One 2 hour session Years: 1996-1999, 2003, 2005 516-0635D Experimental and Clinical Oncology Department: Medicine Format: Lecture Title: Cancer Genetics Role: Lecturer Level: MSc program Time: 1.5 hour seminar Years: 2002- 521-690B Inherited Cancer Syndrome Department: Department of Human Genetics Format: Lecture Title: Cancer Genetics Role: Lecturer Level: MSc program Time: Four 2 hour sessions Years: 2003, 2005, 2007 33
  • 34. Department of Oncology Annual Report 2007/2008 Medical Genetics Unit 8 small group teaching in medical genetics Format: Lecture Role: Lecturer Level: Medical Students Time: One 2 hour lecture and 4 small group sessions, 3 hours each Years: 1977- 4. Scientific Reviews Journal Reviews Journal of Medical Genetics International Journal of Cancer British Journal of Cancer Breast Cancer Research Nature Genetics Lancet Journal of the National Cancer Institute Cancer Research Clinical Cancer Research European Journal of Cancer American Journal of Human Genetics Lancet Oncology Human Mutation Oncogene Gastroenterology Prostate Journal of Clinical Pathology Oncology Research Molecular and Cellular Probes Canadian Journal of Oncology Grant Reviews Canadian Institute for Health Research, Genetics Panel 5. Conference Organization Second International Symposium on Hereditary Breast and Ovarian Cancer, Montreal Oct 17-19, 2007. (www.odon.ca/brca/). Co-sponsored by the Program in Cancer Genetics and the Hereditary Breast and Ovarian Cancer Foundation (www.hboc.ca). Role: Scientific Director of Conference. 6. External Committees and Boards International Committees Member, Steering Committee, International Prostate Cancer Genetics Collaborative Group (representing Eastern Canada) 34
  • 35. Department of Oncology Annual Report 2007/2008 Scientific Advisory Committee, Breast Cancer Family Registry (NIH) Member, Advisory Board, Conseil d’Évaluation des technologies de la santé du Québec, 7. Invited Presentations International BRCA1 and sporadic basal-like breast cancers: similarities and differences. Triple Negative Breast Cancer Conference, San Antonio, TX, USA. December 11th 2007 How should we study special populations-Ashkenazim, Minorities? BCFR Scientific Conference, San Antonio, TX, USA. December 12th 2007 From the bedside to the bench and back again: short stories that end up as novels, Breakthrough Breast Cancer Research Centre Seminar. London, UK. March 13th 2008 National New developments in breast cancer genetics. Winnipeg, Manitoba. May 10, 2007 Samuel Lunenfeld Research Institute Seminar. Toronto, Ontario. November 8th, 2007 Prevention/risk factors: Non-modifiable factors and hereditary breast cancer (Chair) CBCRA Reasons for Hope Fifth Scientific Conference. Vancouver, British Columbia. April 25-27, 2008 Local/Provincial Hereditary breast cancers - Guidelines for treatment options to women at high risk: what id the evidence behind? 42nd World Congress of the International Society of Surgery, International Surgical Week. Palais des Congrès. Montreal, Quebec. August 28th, 2007 Is breast cancer the same disease in Asia as in the west? – Analysis and summary. 42nd World Congress of the International Society of Surgery, International Surgical Week Palais des Congrès. Montreal, Quebec. August 30th, 2007 Les aspects génétiques du cancer du sein. Découvrir de nouveaux sommets, 28ième Congrès Annuel de la société québécoise de biologie clinique. Mont-Tremblant, Qc. October 11th, 2007 BRCA1/2 mutations: helping you and your loved ones deal with the hand you are dealt BRCA: New Frontiers in Research and Practice, Second International Symposium on the Hereditary Breast and Ovarian Cancer Susceptibility Genes. Hotel Delta, Montreal, Qc October 17th, 2007 From the bedside to the bench and back again: translating cancer genetics. 1st Annual Canadian Human Genetics Conference. Manoir St-Sauveur, St-Sauveur, Qc. April 10th, 2008 35
  • 36. Department of Oncology Annual Report 2007/2008 Improving breast cancer mortality: have genetic markers helped? The 2008 CLIMOA Annual Scientific Meeting. Sofitel Montreal, Montreal, Qc. May 12th, 2008 Institutional DNA repair and cancer susceptibility. Radiation Science Seminar. Montreal General Hospital. January 5th, 2007 Genetics of pheochromocytoma and other paragangliomas. MUHC Cancer Genetics Services. MUHC January 12, 2007 The role of medical genetic services in the management of pediatric cancer patients and their families. Joint meeting of the Departments of Medical Genetics and Pediatric Hematology/Oncology, Montreal Children’s Hospital. January 17th, 2008 It is a short walk from the clinic to the laboratory, but sometimes you get lost on the way. MUHC Urology seminar. MUHC, April 1st, 2008 8. Hospital and University Activities Member, Curriculum Committee, Department of Human Genetics Member, Fellowship Committee, Department of Human Genetics Member, Standing Committee, Department of Human Genetics Member, Management Committee, Department of Oncology EDUARDO FRANCO 1. Research Grants (new and ongoing) In brief, my research program covers the molecular epidemiology and prevention of cervical cancer and human papillomavirus-associated diseases, upper aero-digestive tract cancers, and childhood tumours; studies of epidemiologic methods for evaluating efficacy of cancer screening strategies; the impact of measurement error in epidemiology; and studies of societal and clinical influences on the survival of cancer patients. The titles of funded research projects are listed below: As PI Biomarkers of cervical cancer risk (E Franco, F Coutlée, G Matlashewski, M. Pollak, M Roger) Canadian Institutes of Health Research (CIHR grant #MOP-42532, $418,119, 2000-04; renewed 2005-08, $313,587). Antioxidant nutrients among a Brazilian population (A Giuliano, E Franco [co-Pis], J Marshall, D Roe, L Villa, N Craft) National Institutes of Health (NCI Grant # 36
  • 37. Department of Oncology Annual Report 2007/2008 RO1CA81310, approx. $1.3 million [US$ 870,000], 2000-03; renewed 2004-07, approx. $1.2 million). Efficacy trial of HPV versus Pap testing for screening cervical cancer precursors (E Franco, F Coutlée, S Ratnam, S Walter, E Duarte, I Rodrigues, R Rajan, M Steben). Canadian Institutes of Health Research (CIHR grant #MCT-54063, $1,071,837, 2002- 08). PAP Cytology Screening Failure: Influences of the Patient, Physician, and Laboratory (E Franco, E Duarte-Franco, F Coutlée, A Ferenczy, P Ghadirian, M Dawes, M Deschamps, P Drouin). Canadian Institutes of Health Research (grants # IHS-61108, $48,545, 2002- 03 and MOP-64454 $312,945, 2003-08). HPV infection and transmission among couples through heterosexual activity (the HITCH cohort) (E Franco, F Coutlée, J Hanley, P Tellier). Canadian Institutes of Health Research (grant# 68893, $546,544, 2004-09). CIHR Team in HPV infection and associated diseases (E Franco, F Coutlée [co-PIs], M Roger, G Matlashewski, P Brassard, Z Rosberger, A Al-Moustafa, J Archambault, P Davies, B Duval, R Rajan). Canadian Institutes of Health Research (grant #83320, $2,546,941, 2007-13). As Co-investigator Characterization of the human papillomavirus infection among a population of Inuit women in Québec. (P Brassard, E Franco, F Coutlée, M Roger). Canadian Institutes of Health Research (CIHR grant #MOP57749, $496,752, 2002-08). Development and validation of new statistical methods for modeling intermediate events in CIHR training program in applied Oral Health Research (J Feine, P Allison, E Franco, W Fraser, M Frenette, D Grenier, A Kolta, G Lavigne, J Lund, M Mckee). Canadian Institutes of Health Research (grant #QTA-68723, $1.76M, July 2004 –June 2010). Molecular analysis of HPV infection in precancerous and cancerous lesions of the uterine cervix (F Coutlée, E Franco, G Matlashewski). Canadian Institutes of Health Research (grant# MOP-67155, $289,371, 2004-07). The psychosocial impact of Pap versus HPV testing on Canadian women screened for cervical cancer (Z Rosberger, P DiDio, E Duarte, E Franco, B Knauper, MH Mayrand). Canadian Institutes of Health Research (grant# pending, $160,000, 2005-08). A randomized controlled trial of the effectiveness of a coping strategies intervention for people with head and neck cancer (P Allison, LJ Edgar, J Feine, E Franco, B Nicolau, R Rajan). Canadian Institutes of Health Research (grant #MCT-75475, $471,139, April 2005 – March 2009). 37
  • 38. Department of Oncology Annual Report 2007/2008 A randomised controlled evaluation of HPV testing for cervical cancer screening (A Coldman, P Davies, R Martin, J Matsic, D Van Niekerk, G Ogilvie, T Ehlen, G Stuart, E Franco, S Peacock, M Krajden), Canadian Institutes of Health Research (grant #TBA, $6,268,935, 2006-13). The life course approach to studying the etiology of head and neck cancer: HeNCe life study (B Nicolau, P Allison, R Burk, F Coutlée, E Franco, G Humphris, J O’Loughlin, A Sacker, N Schlecht), Canadian Institutes of Health Research (grant # MOP-81172, $478,236, 2006-10). Industry support (non-peer-reviewed unrestricted grants) (amounts in Canadian dollars) Support for the Canadian Cervical Cancer Screening Trial (Merck-Frosst Co., $75,000, 2004-08). Support for the HPV infection and transmission among couples through heterosexual activity (the HITCH cohort) (Merck-Frosst Co., $472,072, 2006-09) 2. Education and Research Training H Trottier. Epidemiology of cervical cancer. Postdoctoral fellow, Department of Oncology, McGill University, Montreal, 2004-08. M-H Mayrand. Efficacy trial of HPV testing in cervical cancer screening. Ongoing PhD research, Department of Epidemiology & Biostatistics, McGill University, Montreal, 2002-07 (FRSQ and NCIC scholarships). A Spence. Determinants of cervical cancer screening failure. Ongoing PhD research, Department of Epidemiology & Biostatistics, McGill University, Montreal, 2001-09. T Dang-Tan. Childhood cancer surveillance. Ongoing PhD research, Department of Epidemiology & Biostatistics, McGill University, Montreal, 2002-08 (CIHR scholarship). S Lau. Natural history of ASCUS cervical cytological abnormalities. Ongoing MSc research (part-time student), Department of Epidemiology & Biostatistics, McGill University, Montreal, 2002-07. A. Burchell. Behavioural determinants of HPV transmissibility. Ongoing PhD research, Department of Epidemiology & Biostatistics, McGill University, Montreal, 2003-08 (Tomlinson and NCIC scholarships). A De Pokomandy. Anal intraepithelial neoplasia in HIV-infected men. Ongoing MSc research, Department of Epidemiology & Biostatistics, McGill University, Montreal, 2005-08. 3. Scientific Reviews Editorial Boards Cancer Detection and Prevention Cancer Epidemiology, Biomarkers and Prevention Epidemiology 38
  • 39. Department of Oncology Annual Report 2007/2008 Oral Diseases Public Library of Science (PLoS) – Medicine Salud Pública de México HPV Today (Scientific Committee Member) Manuscript Reviews American Journal of Epidemiology American Journal of Obstetrics & Gynecology American Journal of Tropical Medicine & Hygiene British Medical Journal Cancer Causes and Control Cancer Detection and Prevention Cancer Epidemiology, Biomarkers and Prevention Cancer Research Epidemiology European Journal of Obstetrics & Gynecology and Reproductive Biology International Journal of Cancer Journal of Adolescent Health Journal of Medical Virology Journal of Infectious Diseases Lancet Oral Oncology Preventive Medicine Public Library of Science-Medicine Regulatory Toxicology and Pharmacology Scandinavian Journal of Infectious Diseases Sexually Transmitted Diseases Grant reviews (internal) National Institutes of Health, Epidemiology of Cancer [EPIC] panel, Bethesda, USA: Member (2008) (3 written critiques). Scottish Government Health Department, Edinburgh, Scotland (2008) (1 written critique) Cancer Research UK, London, England (2008) (5 written critiques) Fundação para a Ciência e a Tecnologia, Lisbon, Portugal (2008) (3 written critiques) Faculty evaluations University of California at Los Angeles, Department of Epidemiology, Los Angeles, USA (evaluation of Dr Haroutune Armenian promotion to professor-in-residence), September 2007. University of Washington, Department of Epidemiology, Seattle, USA (evaluation of Dr Steve Hawes’ promotion to Associate Professor), September 2007. 39
  • 40. Department of Oncology Annual Report 2007/2008 University of Washington, Department of Pathology, Seattle, USA (evaluation of Dr Long-Fu Xi’s promotion to Associate Professor), September 2007. Johns Hopkins University, Departments of Epidemiology and Infectious Diseases, Baltimore, USA (evaluation of Dr Patti Gravitt’s promotion to Associate Professor), December 2007. Fred Hutchinson Cancer Research Center, Division of Public Health Sciences, Seattle, USA (Evaluation of Dr. Stephen Schwartz’s 5-year report and plan, December 2007). Fred Hutchinson Cancer Research Center, Division of Public Health Sciences, Seattle, USA (Evaluation of Dr. Margaret Madeleine’s promotion to Assistant Member), April 2008. University of Washington, Department of Epidemiology, Seattle, USA (evaluation of Dr Rachel Winer’s recruitment dossier to Assistant Professor), May 2008. Other scientific review work Judge for prize of best paper in the journal Salud Publica de Mexico (annual). Judge for Rothman prize, given to best article published in the journal Epidemiology (annual). Oregon Evidence-based Practice Center, Agency for Health Care Research and Quality, Rockville, USA. Screening for Cervical Cancer: A Systematic Evidence Review for the US Preventive Services Task Force (2008) 5. Conference Organization Member, International Scientific Committee, 24th International Papillomavirus Conference and Clinical Workshop, Beijing, China (November 2007). Member, Candidacy Planning Committee (subsequently, Local Organizing Committee), World Cancer Congress of the Union Internationale Contre le Cancer, Montreal, Canada (winning bid for 2012). Member, Local Organizing Committee, International Papillomavirus Conference, Montreal, Canada (July 2010). Member, 60th Anniversary Cancer Research Conference Program Committee, National Cancer Institute of Canada, Toronto (November 2007). Member, Program Committee, EUROGIN 2007 Congress, European Research Organization on Genital Infection and Neoplasia, Monte-Carlo, Monaco (October 2007). 40
  • 41. Department of Oncology Annual Report 2007/2008 Member, Scientific Committee, XVIII IEA World Congress of Epidemiology, Porto Alegre, Brazil (September 2008). Member, Program Committee, EUROGIN 2008 Congress, European Research Organization on Genital Infection and Neoplasia, Nice, France (November 2008). Organizer and Instructor, Satellite Workshop “Reading, writing, and publishing in Epidemiological and Clinical Research”, 7th Scientific Meeting, IEA-Eastern Mediterranean Region, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia (November 29, 2007). Co-Organizer and Lecturer, Satellite Course “Epidemiologic Research and New Directions” in conjunction with the XVIII IEA World Congress of Epidemiology, Porto Alegre, Brazil (September 20-21, 2008). 6. External Committees and Boards National National Cancer Institute of Canada, Toronto: Member, Awards-in-Excellence Committee (2005-08). National Cancer Institute of Canada, Toronto: Member, Governance and Nominating Committee (2007-). Canadian Institutes of Health Research, Ottawa, Canada: Member (2007-08), Michael Smith Prize in Health Research Committee. Canadian Institutes of Health Research, Ottawa, Canada: Member (2008), Meetings, Planning and Dissemination Grant Program. Clinical Medicine and Basic Biology Working Group, National Cancer Institute of Canada’s Prevention Initiative, Toronto, Canada (2006-08) Member, National Infectious Agents Committee, Primary Prevention Action Group, Canadian Partnership Against Cancer, Vancouver, Canada (2007-). Co-Chair, HPV Prevention Network, International Centre for Infectious Diseases, Winnipeg, Canada (2007-). Member, Environment Cancer Fund Advisory Board, Cancer Research Society, Toronto, Canada (2006-) International National Institutes of Health, Epidemiology & Disease Control-2 Study Section (renamed Epidemiology of Cancer [EPIC] panel in 2003), Bethesda, USA: Member (2002-07). 41
  • 42. Department of Oncology Annual Report 2007/2008 Steering Committee Member, HPV-040 Vaccination Study, National Public Health Institute, Helsinki, Finland (2007-11) Member, External Advisory Committee, Cancer Control and Population Sciences, University of Puerto Rico Comprehensive Cancer Center, San Juan, USA (2007-). Member, Expert committee on burden of HPV-related disease and health economics, Sabin Institute, Washington, USA (2007-). Member, Steering Committee, HPV Vaccine Global Forum and Communities of Practice, Department of Reproductive Health and Research, World Health Organization, Geneva, Switzerland (2007-). Member, Nominating Committee, International Epidemiological Association (2005-) Chair, World Congress Advisory Committee, International Epidemiological Association (2005-) 7. Invited Presentations National “New paradigms in primary and secondary cervical cancer prevention” Keynote plenary lecture, 63rd Annual Clinical Meeting, Society of Obstetricians and Gynaecologists of Canada, Ottawa, Canada (June 22, 2007). “Cervical cancer screening in the era of HPV vaccination” Keynote plenary lecture, 63rd Annual Clinical Meeting, Society of Obstetricians and Gynaecologists of Canada, Ottawa, Canada (June 22, 2007). “Expected impact of vaccination on screening practices: Theoretical concerns and research opportunities” Lecture at the HPV Master Class of the Canadian Association for Immunization Research and Evaluation, Ottawa, Canada (September 22, 2007). “HPV testing in cervical cancer screening” Grand Rounds Seminar at McMaster University, Hamilton, Canada (September 28, 2007). “New Primary and Secondary Prevention Strategies for Cervical Cancer Prevention” Lecture to the Alberta Cancer Board Provincial/Regional Medical Laboratory Meeting, Banff, Canada (October 17, 2007). “What’s the fuss about infectious diseases? Infections and cancer” Café Scientifique, Canadian Institutes of Health Research, Montreal, Canada (January 22, 2008). “Arguments for and against HPV vaccination: Separating sensible from silly” Seminar to the Merck HPV Club, Toronto, Canada (February 4, 2008). 42
  • 43. Department of Oncology Annual Report 2007/2008 “Research at McGill’s Division of Cancer Epidemiology” Seminar at the Faculty Retreat of the Department of Oncology, McGill University, Montreal, Canada (March 13, 2008). International “Presente, futuro y recomendaciones de la aplicación de la vacuna 16-18 para VPH” Plenary Lecture, VI International and XI National Conference of the Mexican Association of Colposcopy and Pathology, Acapulco, Mexico (July 20, 2007). “Las vacunas y los cambios en las politicas de salud: Sinergismo en las estrategias preventivas” Plenary Lecture, VI International and XI National Conference of the Mexican Association of Colposcopy and Pathology, Acapulco, Mexico (July 20, 2007). “La vacuna VPH 16/18: de la investigación a la realidad” Keynote plenary lecture, 3rd Regional Congress of the Pediatric College of Puebla, Puebla, Mexico (July 20, 2007). “Avances en vacunas en la prevención del HPV” Symposium lecture, Congreso Internacional, Hospital Aleman, Buenos Aires, Argentina (August 9, 2007). “Epidemiology of Cervical Cancer in Latin American Countries” Lecture at the Latin American HPV Master Class and Clinical Workshop, São Paulo, Brazil (August 16, 2007). “Expected impact of HPV vaccination on Screening for cervical cancer” Lecture at the Latin American HPV Master Class and Clinical Workshop, São Paulo, Brazil (August 16, 2007). “Rastreamento. Uma nova geracao livre do cancer? Symposium lecture, XII Congresso Paulista de Obstetrícia e Ginecologia, São Paulo, Brazil (August 17, 2007). “Diagnóstico: Citologia e métodos moleculares” Symposium lecture, XII Congresso Paulista de Obstetrícia e Ginecologia, São Paulo, Brazil (August 18, 2007). “Expected impact of HPV vaccination on current screening practice” Lecture at the Middle East and North Africa HPV Master Class and Clinical Workshop, Cairo, Egypt (September 6, 2007). Co-Moderator and Speaker “Impact of Mandatory and/or Universal Immunization for HPV on the Epidemiology of Cervical Cancer” Policy Workshop, Annual Meeting of the American College of Epidemiology, Fort Lauderdale, USA (September 17, 2007). “The burden of HPV-related diseases” Plenary lecture, EUROGIN 2007 Conference on New Strategies of Cervical Cancer Prevention: The Reality of Hpv Vaccines, Monte- Carlo, Monaco (October 4, 2007). 43
  • 44. Department of Oncology Annual Report 2007/2008 “What new proofs are needed to foster universal implementation of HPV vaccines?” Plenary lecture, EUROGIN 2007 Conference on New Strategies of Cervical Cancer Prevention: The Reality of Hpv Vaccines, Monte-Carlo, Monaco (October 5, 2007). “HPV testing as a more logical screening approach following vaccination” Plenary lecture, EUROGIN 2007 Conference on New Strategies of Cervical Cancer Prevention: The Reality of Hpv Vaccines, Monte-Carlo, Monaco (October 6, 2007). Rapporteur “Screening approach for vaccinated population” Plenary session, EUROGIN 2007 Conference on New Strategies of Cervical Cancer Prevention: The Reality of Hpv Vaccines, Monte-Carlo, Monaco (October 6, 2007). Chair, Scientific Session 12: Epidemiology. EUROGIN 2007 Conference on New Strategies of Cervical Cancer Prevention: The Reality of Hpv Vaccines, Monte-Carlo, Monaco (October 6, 2007). “The value of HPV testing in cervical cancer screening” Plenary session, Symposium on HPV and Cervical Cancer, Hong Kong, China (November 1, 2007). “Epidemiology of HPV infection” Lecture, Fogarty Symposium, 24th International Papillomavirus Conference and Clinical Workshop, Beijing, China (November 5, 2007). Co-Chair, Scientific Session: Epidemiology I, 24th International Papillomavirus Conference and Clinical Workshop, Beijing, China (November 6, 2007). “Impacto de la vacuna VPH en el cribado del cancer de cervix” Keynote lecture, XIX Congreso Annual, Asociación Española de Patología Cervical y Colposcopia, Oviedo, Spain (November 17, 2007). “Cancer Epidemiology at a Crossroads: Time for Reappraisal” Keynote lecture, 7th Scientific Meeting of the International Epidemiological Association, Eastern Mediterranean Region, Riyadh, Saudi Arabia (November 28, 2007). “Perspectivas en tamización de cáncer de cuello uterino” Keynote lecture, Programa Evento Socialización y Recomendaciones Tamización de Cancer de Cuello Uterino, Ministerio de la Protección Social, Instituto Nacional de Cancerología, Bogota, Colombia (December 17, 2007: via teleconference; travel cancelled due to snow storm). “HPV DNA testing: a more logical cervical cancer screening strategy for the era of HPV vaccination?” Plenary lecture, 1st Scientific Meeting of the Hellenic HPV Society, Thessaloniki, Greece (January 26, 2008). “Confidence in implementing universal HPV vaccination: What additional proofs are needed?” Plenary lecture, 1st Scientific Meeting of the Hellenic HPV Society, Thessaloniki, Greece (January 26, 2008). 44
  • 45. Department of Oncology Annual Report 2007/2008 “Epidemiologic issues in implementing HPV vaccination” Lecture at the Sub-Saharan Africa HPV Master Class and Clinical Workshop, Johannesburg, South Africa (February 26, 2008). “Cervical Cancer Prevention in Latin America: Gaps in Knowledge and Research Priorities” Plenary lecture, Congreso Internacional de Colposcopia en la Practica Medica, Mexico City, Mexico (April 4, 2008). “Scientific Merit of Arguments Against HPV Vaccination: An Epidemiologic Perspective” Plenary lecture, Congreso Internacional de Colposcopia en la Practica Medica, Mexico City, Mexico (April 4, 2008). “Human papillomaviruses and neoplasia: New prevention strategies” Session lecture, American Association for Cancer Research Annual Meeting 2008, San Diego, USA (April 12, 2008). “Molecular epidemiology of HPV infection and cervical cancer” Seminar at the Division of Epidemiology, School of Public Health, University of California, Berkeley, USA (April 15, 2008). 8. Hospital and University Activities University Member, Management Committee, Department of Oncology (2001-) Member, Committee on Multidisciplinary Oncology Residency/Fellowship Curriculum Chair, Faculty Promotion Sub-committees, Department of Oncology (2003-present). Chair, Student Funding Committee, Department of Epidemiology and Biostatistics Member, Comprehensive PhD Exam Committee, Department of Epidemiology and Biostatistics Member, Search Committee, Director of Surgical Oncology, Department of Oncology CAROLYN FREEMAN 1. Summary of New and Ongoing Research Clinical research in paediatric tumours especially brain tumours. Use of radio-sensitising and biological agents in pediatric brain tumours. Development of new radiotherapy treatment techniques. 45
  • 46. Department of Oncology Annual Report 2007/2008 Evaluation of new radiotherapy technologies. 2. Research Grants (new and ongoing) Radiotherapy co-PI of grant from National Institute of Health (USA) for clinical pediatric oncology research studies (per case funding). 1980 - present National Childhood Cancer Foundation (NCCF): ~ $20,000.00/yr. Co-Chair CNS Strategy Committee, Children’s Oncology Group. 2001 - 2008 National Cancer Institute of Canada $61,960/yr. (With Seuntjens, J. (PI), Verhaegen, F., Shenouda, G. and Podgorsak, E.) Monte Carlo-based modulated electron beam inverse treatment planning and delivery. 2005-2008 Canadian Medical Protective Association $31,000. (Role PI, with Parker, W., Gingras, C., Podgorsak, E., Daly, M., and Shenouda, G.) Development of a comprehensive system for classifying, recording and analysing radiation events. 2007-2008 3. Scientific Reviews Editorial Boards Associate Editor, Perez: Principles and Practice of Radiation Oncology 5th edition, 2007 Associate Editor, International Journal of Radiation Oncology, Biology and Physics Member, Editorial Board, Pediatric Blood and Cancer Section Editor (Radiation Oncology), Current Oncology Ad Hoc Reviews Ad hoc reviewer, Societé française de lutte contre le cancer (translational research) 4. Conference Organization Member of Scientific Committee, Second International Congress on Pediatric Radiation Oncology, Barcelona, Spain. 2007 Judge of Resident Poster Award session, Annual Meeting of the Canadian Association of Radiation Oncologists, Toronto, October 2007 Moderator of poster session, Annual Meeting of the Canadian Association of Radiation Oncologists, Toronto, October 2007 Co-organiser and co-moderator of session on adult-type tumours seen in paediatric oncology practice, Annual Meeting of SIOP, Mumbai, November 2007 Abstract reviewer. SIOP 2008 Berlin Chair of Scientific and Local Organizing Committees, Third International Congress on 46
  • 47. Department of Oncology Annual Report 2007/2008 Pediatric Radiation Oncology, Montréal. 5. External Committees and Boards Chair, Radiotherapy Advisory Committee, Radiotherapy Technology Training Program, Dawson College Chair, Medical Advisory Board, Sarah Cook Fund Co-Chair, Brain Tumor Strategy Committee, Children’s Oncology Group Member, Brain Tumour Core Committee, Pediatric Oncology Group, now the Children’s Oncology Group Member, Board of Directors, Quality Assurance Review Centre, Rhode Island (NIH funded) Member, Data Monitoring and Safety Committee, SIOP PNET - 4 Member, Data Monitoring and Safety Committee, UKCCSG Study on Low Grade Gliomas Member, Manpower Committee, Canadian Association of Radiation Oncologists Membre, Comité de direction, Direction de la lutte contre le cancer, MSSS Membre, Groupe conseil de lutte contre le cancer, MSSS Membre, Comité d’évaluation de la mise en oeuvre des équipes interdisciplinaires de lutte contre le cancer, MSSS Member of Board of Directors, Pediatric Radiation Oncology Society Member of Board of Directors, Canadian Radiation Oncology Foundation 6. Invited Presentations Guest lecture. “Children’s Oncology Group CNS studies.” Meeting of the International Pediatric Radiation Oncology Society. Barcelona, June 2007. Educational course. “Medulloblastoma.” Annual meeting of the International Society of Paediatric Oncology. Mumbai, October 2007. 7. Continuing Education Activities lectured “Radiotherapy in the treatment of sarcomas.” Oncology Level 2 course. McGill University Health Centre. January 2008. 8. Hospital and University Activities Co-chair, McGill Télé-oncologie committee 47
  • 48. Department of Oncology Annual Report 2007/2008 Co-Chair, Tumor Board, Montreal Children’s Hospital Ad hoc member Promotions Review Committee Member, Tumor Board, Montreal Children's Hospital Member, Radiation Safety Committee, Montreal General Hospital/McGill University Health Centre Member, Medical/Clinical Advisory Committee, Montreal General Hospital/McGill University Health Centre Member, Oncology Quality Improvement Committee, McGill University Health Centre Member, Medical Advisory Committee, Cedars Cancer Institute Member, Board of Directors MUHC Research Institute BRUNO GAGNON 1. Research Grants (new and ongoing) Co-Investigator (PI: P. Gagnon). Étude de faisabilité pour le traitement du delirium hyperactif chez les patients atteints de cancer avancé par l’haloperidol à dose différentielle. Funded by CIHR through NET Grant ($1.3million): Developing, evaluating, and implementing new interventions in palliative care. CIHR. 2007-2009 Co-Investigator (CO-PIs: J. Pelletier, N. MacDonald). Towards an understanding of cancer cachexia –Linking molecular mechanisms with novel treatment options. Terry Fox Research Institute (Montreal). 2007-present Chair. A Phase II study of methadone as a first line agent in the treatment on neuropathic pain. National Cancer Institute of Canada (NCIC) $120,000. 2007-present Principle Investigator. Patterns of care during the last six months of life of patients dying of cancer. CIHR: Operating Grant $411,610. 2004-present Principle Investigator. Les différents profiles de soins reçus par les patients mourant du cancer durant les six derniers mois de vie : une étude basée sur des banques de données administratives. Fonds de la recherche en santé du Québec (FRSQ) $30,000. 2004-2008 Principle Investigator. Characterizing cognitive failure, physical retardation and hypo- active delirium in advanced cancer patients: A Pilot Project. CIHR: Palliative and End of Life Care: A Pilot Project $80,160. 2004-2007 48
  • 49. Department of Oncology Annual Report 2007/2008 2. Education and Training Undergraduate Teaching ICM-B (Introduction to Clinical Medicine) a day rotation to CNR clinic – for 1st and 2nd year students. 2008-present Research Trainees Mentored Dominique Elie, Dept. Pharmacie, U Laval. Primary supervisor P. Gagnon. May 2008 – present. 3. Scientific Reviews Editorial and Advisory Boards Member, Editorial Committee of Medicina Paliativa Member, Advisory Board of Medicina Paliativa Ass. Editor, Palliative Care, Pain Research & Management Ad hoc Reviews The Open Clinical Cancer Journal European Journal of Cancer Journal of Pain and Symptom Management Supportive Care Therapy Journal of Palliative Care 4. Invited Presentations and Workshops The next step in pain management. Comité d’éducation continue de La maison des soins palliatifs de la Rivière-du-Nord en association avec la compagnie Paladin-Laboratoires Inc. St. Jérome, Québec – 16 mai 2007. The next step in pain management. Paladin-Laboratoires Inc. Montréal, Québec – 28 septembre, 2007. The next step in pain management. Notre-Dame de la Merci, organisée par Paladin- Laboratoires Inc. Montréal, Québec – 1 novembre, 2007. La méthadone : Sa prescrire pour la douleur. CLSC St. Jean-sur-Richelieu, organisée par Dr. A.H. Dandavino. Laprairie, Québec – 12 décembre, 2007. Gagnon B. Un laxative sous-cutané? Pourquoi pas? Le traitement de la constipation réfractaire. 24 et 25 avril, 2008, 18e Congrès du Réseau des soins palliatifs du Québec : La vie qui prend son sens. Hôtel Hilton du Lac-Leamy et Ramada Plaza/Manoir du Casino, Gatineau, Québec. 5. Peer Reviewed Abstracts Eades M, Chasen M, Di Dio P, Lee V, Sharma R, Gagnon B. A Retrospective Descriptive Comparison of the Cancer Symptom Experience of Two Groups of Patients 49
  • 50. Department of Oncology Annual Report 2007/2008 Participating in an 8 Week Ambulatory Cancer Nutrition Rehabilitation (CNR) Service. 20th Anniversary International Symposium of the Multinational Association of Supportive Care in Cancer. St Gallen, Switzerland. June 27-30, 2007. (Poster) MacDonald N, Kasymjanova G, Agulnik J, Pepe C, Kreisman H, Cohen V, Sharma R, Gagnon B, Small D. Influence of baseline inflammatory markers on the response to first line chemotherapy in advanced NSCLC. The 20th Anniversary Conference of the European Chapter on Combinatorial Optimization (ECCO). Limassol, Cyprus. May 24- 26, 2007. (Poster) MacDonald N, Kasymjanova G, Gagnon B, Sharma R, Baracos V, Droege W, Kreisman H. Markers of a chronic inflammatory state of influence patient successful trial completion. Data from cancer cachexia trial. 44th ASCO Annual Meeting. Chicago, Illinois. May 30 – June 3, 2008. Local Peer-reviewed abstracts Chasen M, Sharma R, Zhang X, Bhargava R, Gagnon B, Vigano A, MacDonald N. Electrogastrography in cancer patients. McGill University, Cancer Nutrition Rehabilitation Program, Department of Oncology, Montreal, Quebec, Canada. McGill University Health Center Research Institute 6th Annual Health Outcomes Axis Research Day, Montreal, Canada. May 24, 2007. (Oral) 6. Hospital and University Activities Clinical trial coordinator, Cancer Nutrition-Rehabilitation Program. Department of Oncology, McGill University. MUHC Clinical Trials Director Committee member of the MUHC-RI Studentship/Fellowship competition. Committee member of the MUHC-RI Pilot Project Review Committee. Member, Supportive Care Section Committee Meeting, Department of Oncology, McGill University. PHIL GOLD 1. Teaching and Training Lectures- Physiology-10 hours Seminars-Professionalism-9 hours Tutorials-Physiology-2 hours Small Groups-Biology of Cancer;Biochemistry;Immunology-12hours Clinical-80 hours per year 50
  • 51. Department of Oncology Annual Report 2007/2008 ICM-B-50-60 hours per year Osler Fellowship-Physician Apprenticeship Course-24 hours 2. Scientific Reveiws Editorial Board Current Oncology, Deputy Editor 3. External Committees and Boards Chairman of Burroughs Wellcome Fund 4. Hospital and University Activities Executive Director, Clinical Research Centre and Office of Clinical Contracts of the RI- MUHC Progress of Office of Clinical Research; Phase I studies and development of a CRO by PPP under consideration Presently working strictly with pharmaceutical funds for clinical trials of all phases Mentoring of new staff initiated officially and actually ongoing Osler Physician Apprenticeship Program-Class of 2010 Auditing First Year Medicine MARK GOLDBERG 1. Summary of New and Ongoing Research The following projects are currently underway and most will be completed over the next five years: The most recently funded studies are: (1) “A longitudinal study of the health effects of air pollution”, funded by CIHR in the fall 2002 competition (PI: M. Goldberg; with Richard Burnett (Health Canada), and Kenneth Flegel, Nadia Giannetti, Michal Abrahamowicz, Robert Platt (McGill); 2003-2006). (2) A case-control study to investigate gene-environment interactions (funded by the Quebec Breast Cancer Foundation; with J. Simard and F. Durocher (Université Laval), F. Labrèche (Montreal Public Health Department), M.-É. Parent (INRS-Institut Armand-Frappier), B. Langholz (University of Southern California), and D. Sinnett (Université de Montréal)); (3) a study of traffic-related air pollution and socioeconomic gradients in the incidence of cancer (funded by CIHR; with Michael Jerrett (McMaster University), Nancy Ross (McGill), Nicolas Gilbert (Health Canada), Jeffrey Brook (Environment Canada), Renjun Ma (University of New Brunswick), Richard Burnett (Health Canada), Claire Infante-Rivard (McGill), and Jack Siemiatycki (Université de Montréal); (4) a cohort study of cancer incidence and mortality among adults from long-term exposure to outdoor air pollution (funded by CIHR, Paul Villeneuve(PI), Richard Burnett, Yang Mao); and (5) “A panel 51
  • 52. Department of Oncology Annual Report 2007/2008 study of the effects of changing lifestyle and environmental conditions on signs and symptoms heart failure”. Studies for which I am a co-investigator are: (1) “Estimating the need for radiotherapy for cancer: A population-based requirements analysis” (funded by the Canadian Institutes of Health Research; William Mackillop, PI); (2) “Estimating age-, gender- and risk factor-specific incidence rates of stroke and heart disease using longitudinal cohorts created from linkage of survey and administrative databases” (funded by the Canadian Institutes of Health Research; Nancy Mayo, PI); and (3) a study in palliative medicine of patterns of care among cancer patients in end-of-life (Bruno Gagnon, PI (McGill)). 2. Research Grants (new and ongoing) As Principal Investigator “Implementation of an Automated Artificial Intelligence System for Extracting Data and Coding Pathology Reports for Use in the MUHC Tumour Registry”, Funded by the Canadian Partnership Against Cancer Corporation (Christine Boutin and Mark Goldberg, Co-PI), $160,000. 2008-2010 “Gene-environment interactions in postmenopausal breast cancer: A case-control study” Funded by the Quebec Breast Cancer Foundation ($1.5 million for three years; the project is 8 years and other funding will be sought in two years; Goldberg MS (PI), Jacques Simard, Francine Durocher (Université Laval), France Labrèche (Direction de la santé publique, Montréal), Marie-Élise Parent (INRS Institut Armand-Frappier), Bryan Langholz (University of Southern California), Daniel Sinnett (Université de Montréal)) 2004-2010 “Traffic-related air pollution and socioeconomic gradients in the incidence of cancer”. Funded by the Canadian Institutes of Health Research ($108,642/year, $58,734 equipment, Goldberg MS (PI) / BROOK, Jeffrey R / BURNETT, Richard T / GILBERT, Nicolas L / INFANTE-RIVARD, Claire / JERRETT, Michael L / MA, Renjun / ROSS, Nancy A / SIEMIATYCKI, Jack ) 2004-2008 “Longitudinal study of acute effects of ambient air pollution in susceptible populations”. Funded by the Canadian Institutes of Health Research ($68,948/year, $3,398 equipment; Mark Goldberg (PI), ABRAHAMOWICZ,Michal / BURNETT,Richard T / FLEGEL, Kenneth M /GIANNETTI, Nadia /PLATT, Robert W). This was ranked 2nd of 23 (score=4.17) in the CIHR population health review panel. 2003-2008 Research Contracts As Principal Investigator “A panel study of the effects of changing lifestyle and environmental conditions on signs and symptoms heart failure” Contract with Health Canada, $418,277.92. (Mark Goldberg, PI, with Amanda Wheeler, Nadia Giannetti, Eileen O'Meara, Nancy E. Mayo, James Brophy, Richard T. Burnett) 2006-10 52
  • 53. Department of Oncology Annual Report 2007/2008 As Co-Investigator “Occupational and lifestyle factors in the etiology of prostate cancer, and establishing a platform for studying susceptibility biomarkers“. Renewed by the National Cancer Institute of Canada ($252,000 per year; M-E Parent (PI; INRS-Institut Armand-Frappier), J Siemiatycki (Université de Montréal), K Aronson (Queen’s University)). 2008-2011 “CIHR team of prediction and communication of familial risks of breast cancer”, Funded by the Canadian Institutes of Health Research (Simard, Jacques R (PI; CHUL), et al. $1,103,067) 2008-2013 “Cancer incidence and mortality among adults in relation to long-term exposure to outdoor air pollution: A general population cohort study of Ontario residents”, Funded by the Canadian Institutes of Health Research (Villeneuve, PJ (PI; University of Toronto), R Burnett, MS Goldberg, R Ma; $133,256 /year; ranked 2 of 31 in the committee). 2006- 2008 “Patterns of care during the last six months of life of patients dying of cancer: A study using administrative data”. Funded by the Canadian Institutes of Health Research (Gagnon, Bruno (PI), DESCHAMPS, Michèle, Goldberg, Mark S, HANLEY, James A , MAYO, Nancy E; $101,682/year) 2004-2009 “Estimating the need for radiotherapy for cancer: A population-based requirements analysis”. Funded by the Canadian Institutes of Health Research ($378,486; William Mackillop (PI), Queen’s University), George Browman, Carolyn Freeman, Mark Goldberg, Mary Gospodarowicz, Patti Groome, Eric Halowaty, Eric Pearcey, David Skarsgard, Jon Tonita, Scott Tyldesley). 2003-2009 “Estimating age-, gender- and risk factor-specific incidence rates of stroke and heart disease using longitudinal cohorts created from linkage of survey and administrative databases”. Funded by the Canadian Institutes of Health Research ($327,660; Nancy Mayo (PI), McGill University), James Brophy, Robert Coté, Mark Goldberg, James Hanley, Sydney Miller, Sylvie Robichaud-Ekstrand). 2003-2009 3. Education and Research Training Current students Crouse, Dan. McGill University, Department of Geography, co-supervisor with Dr. Nancy Ross. Provisional thesis topic: Breast cancer and its relationship to traffic-related exposures and contextual socio-demographic variables. Chen, Hong. McGill University, Department of Epidemiology, McGill University. Provisional thesis topic: Associations between lung cancer and chronic exposures to urban air pollution from a cohort study in Ontario. 53
  • 54. Department of Oncology Annual Report 2007/2008 Current supervision committees Peltier, Linda. The repercussions of a co-transplantation of pooled CD34 selected UCB units combined with a compatible UCB unit on actual stem cell transplantation therapy for the Canadian adult population. PhD student, Division of Experimental Medicine. Halpenny, Carli. A Holistic Scientific Investigation on the Impact of Conditional Transfer Programs on the Cycle of Poverty – Malnutrition – Gastrointestinal Parasite Infection PhD student, Department of Parasitology and the McGill School of the Environment. McGill Teaching Undergraduate Instructor, Independent Study Course (course number ENVR 490). This is a new three- credit course that I designed for undergraduate students doing the honours programme in the McGill School of the Environment. Small Group Tutor, “Unit 8: Basis of Medicine, Introduction to Epidemiology and Biostatistics” (Faculty of Medicine, Course co-ordinator, Charles Larson (2000, 2001), Joyce Pickering (2002), Fall term 2000, 2001, 2002. (Evaluations available.) Post-graduate Co-Instructor (with Prof. Peter Brown), “Foundations of Environmental Policy”, (ENVR 513-610), McGill School of the Environment. (Overall course evaluation (question 16): fall semester 2007: 4.4) Instructor, Reading Course, “Studying Gene-environment interactions in Cancer Research: Study design & Methodology” (course number 513-668). This is a new one- credit course that I designed for a student interested in gene-environment interactions. PhD Protocol Defenses Lu, Aihua. Thesis title: “Is the risk of lung cancer in relationship to cigarette smoking different between females and males?” Department of Epidemiology, McGill University. April 1, 2008. 4. Scientific Reviews Ad hoc reviews for peer-review journals American Journal of Industrial Medicine American Journal of Respiratory and Critical Care Medicine Archives of Environmental and Occupational Health Canadian Medical Association Journal Canadian Cancer Etiology Research Network Environmental Health Perspectives European Respiratory Journal Health and Place International Archives of Occupational & Environmental Health International Journal of Cancer 54
  • 55. Department of Oncology Annual Report 2007/2008 International Journal of Environmental Health Research Journal of Clinical Epidemiology Journal of Exposure Analysis & Environmental Epidemiology Occupational and Environmental Medicine Open Medicine Regulatory Toxicology and Pharmacology Editorial Boards Reviews on Environmental Health (editorial board member) Archives of Environmental and Occupational Health (consulting editor) Ad hoc reviews for grant applications British Columbia Health Research Foundation Canadian Fitness and Lifestyle Research Institute Canadian Institutes for Health Research Department of Environmental Protection, Western Australia Environment and Health Fund, Jerusalem, Israel (2008) Fonds de la Recherche en Santé du Québec Health Canada Institut de recherche en santé et en sécurité du travail du Québec National Health Research and Development Program Network de recherche en réadaptation de Montréal Nova Scotia Tumour Registry Statistics Canada Workers’ Compensation Board of British Columbia Wellcome Trust, United Kingdom 5. External Committees and Boards Committees National Chair, Research Programme Development Committee, Scientific Advisory Committee for Clean Air Regulatory Agenda (CARA), Health Canada Member, Health Canada Pest Management Advisory Council (4 days per year). (This committee advises the Minister of Health regarding scientific issues related to pesticides, insecticides, and herbicides.) Member, Health Canada Science Advisory Board (8 days per year). (This committee advises the Minister of Health regarding scientific issues.) Reappointed for a second three year term, 2006-2009. International Member of US Institute of Medicine expert panel (US National Academy of Science), “Veterans and Agent Orange: Seventh Biennial Update”. 55
  • 56. Department of Oncology Annual Report 2007/2008 Member of US Institute of Medicine expert panel (US National Academy of Science), “Veterans and Agent Orange: Sixth Biennial Update”. Member of Peer-Review Panels National Member, Career Population Health Research Evaluation Committee, Michael Smith Foundation for Health Research, Vancouver. Ad hoc reviews for regulatory and other agencies International Reviewer for a series of seven reports from the Public Health and Air Pollution in Asia, Health Effects Institute, Boston. National Reviewer for the Health Canada report “Respiratory Disease in Canada”. Reviewer for three Health Canada reports Canada-Us Border Air Quality Strategy (BAQS)): Population-Based Health Studies Of The Eastern Canada Regional Airshed, 2007. Reviewer for Cancer Trends in Prince Edward Island 1980 to 2006. National Cancer Institute of Canada, 2006. Reviews for conferences International Reviewer for abstracts: ISEE-ISEA 2008 Joint Annual Conference, Pasadena, CA. 6. Invited Presentations Invited lecturer, “Risk and global warming”, course of Prof. Peter Brown, Department of Geography, McGill University (course number GEOG 382), “PRINCIPLES OF EARTH CITIZENSHIP”, February 2008. Invited lecturer, “A primer on environmental epidemiology” course of Dr Shirley Lehnert, Division of Experimental Medicine, McGill University, “Environmental Carcinogenesis”, March 2008. 7. Hospital and University Activities Administrative Responsibilities McGill Executive Committee, Division of Clinical Epidemiology, MUHC McGill Working Group on the Environment (Office of the Provost) Admissions Committee, Department of Epidemiology and Biostatistics 56
  • 57. Department of Oncology Annual Report 2007/2008 Graduate Affairs Committee, McGill School of Environment Ad hoc committee to review the biostatistical programme for PhD students, Department of Epidemiology and Biostatistics Member, McGill University RUIS oncology committee (Réseaux universitaires integrés de santé), Department of Oncology Member, Curriculum Committee, Joint Departments of Epidemiology, Biostatistics, and Occupational Health Member of Scholarship Committee, McGill School of Environment, McGill University Hospital (MUHC) Member, MUHC Cancer Registry Committee Member, Oversight Committee for the McGill University Health Centre Tumour Registry Member, Executive Committee of the Oncology Program, McGill University Health Centre Member, Ad hoc interview team recruiting oncologists to the McGill University Health Centre, Department of Medicine Member, MUHC Research Ethics Board, Biomedical-C. JOHN HISCOTT 1. Summary of New and Ongoing Research We have been investigating a new type of cancer therapy, termed virotherapy, which takes advantage of the oncolytic (or ‘cancer killing’) properties of two innocuous non- human viruses - vesicular stomatitis virus (VSV) and Reovirus (Reo). Both viruses infect, replicate and kill a wide variety of tumor cell lines, while sparing normal cells and tissue. Although the basis of this selective killing is not completely understood, it appears that tumor cells cannot defend against the virus, while normal cells are able to mount an effective antiviral immune response. In collaboration with Dr. John Bell and the Canadian Oncolytic Virus Consortium, we are a part of a new NCIC Program to continue the development of oncolytic viruses as a novel form of cancer treatment. We are also engaged in studies to investigate the combination of oncolytic virus and a chemotherapeutic agent (called HDAC inhibitors) in prostate cancer. Our project is moving forward in three different directions: 1) analysis of oncolytic VSV in adult T cell leukemia; 2) analysis of the effects of VSV together with another drug that causes cell death (apoptosis) in chronic lymphocytic leukemia, the most common form of 57
  • 58. Department of Oncology Annual Report 2007/2008 leukemia; and 3) characterization of the oncolytic effects of VSV in a prostate cancer model that is normally resistant to VSV. We have succeeded in making this form of cancer sensitive to killing by VSV, using combination therapy with compounds known as HDIs. We believe this strategy may augment the types of cancer that are amenable treatment by virotherapy (summarized in Nguyen et al, PNAS, 2008). The type I interferon (IFN) a and b promoters have been a leading paradigm of virus- activated transcriptional regulation for more than two decades, and have contributed substantially to our understanding of virus-inducible gene regulation, the coordinated activities of NF- B and IRF transcription factors, the temporal and spatial recruitment of co-activators to the enhanceosome, and to TLR-dependent and –independent signaling pathways that triggering the innate antiviral response. The transcription factors interferon regulatory factor (IRF) -3 and IRF-7 contribute to a first line of defense against viral infection by inducing the production of IFN and cytokines that in turn stimulate the development of antiviral activity and immune response modulation. The absence of IRF- 3 or the closely related IRF-7 in murine knockout models dramatically reduces IFN production and increases viral pathogenesis, thus supporting a pivotal role for IRF3/IRF7 in the development of the host antiviral response. Our ongoing research has described the mechanisms of regulation of Type 1 interferon genes and identified the key signaling kinases involved in phosphorylation of the transcription factors IRF-3 and IRF-7. The central roles played by IRFs and the IKK-related kinases TBK1 and IKK are now integrated within the TLR and RIG-I signaling pathways that control the host innate immune response to virus infection (reviewed in Hiscott, JBC 2007). 2. Research Grants (new and ongoing) Canadian Oncolytic Virus Consortium, John Bell, John Hiscott, Nahum Sonenberg, Peter Forsyth, Patrick Lee, Harry Atkins, David Stojdl, NCIC, $210,000 per annum (JH portion), July 2007 – June 2012 Regulation of the host antiviral response to Hepatitis C Virus infection, Rongtuan Lin, John Hiscott, CIHR, $112,000, October 2006 – September 2009 Viral Oncolytic Therapy for Adult T cell leukemia, John Hiscott, NCIC , $145,000 per annum, July 2005 through June 2010 Regulation of TLR-dependent and independent signaling pathways during de novo HIV-1 Infection, John Hiscott, CIHR HIV/AIDS Initiative, $159,000 per annum, October 2007- September 2012 Gene expression profiling in during de novo HIV-1 Infection, John Hiscott, Canadian Foundation for AIDS Research, $60,000 per annum, November 2007-October 2009 Protein interactions regulating RIG-I mediated signaling to the innate antiviral response, John Hiscott, Rongtuan Lin, CIHR, $176,000 per annum, April 2008 – March 2013 58
  • 59. Department of Oncology Annual Report 2007/2008 3. Education and Research Training Mayra Solis, PhD 4 (Microbiology & Immunology) - Recipient of a CIHR Studentship Stephanie Oliere, PhD 4 (Microbiology & Immunology) - Recipient of a FRSQ Studentship Suzanne Paz, PhD 4 (Microbiology & Immunology) - Recipient of a FRSQ Studentship Peyman Nakhaei, PhD 4 (Microbiology & Immunology) - Recipient of a FRSQ Studentship Vanessa Tumilasci, PhD 4 (Experimental Medicine) - Recipient of a NSERC Studentship Simone Leveille, PhD 2 (Microbiology & Immunology) - Recipient of a NSERC Studentship Delphine Goubau, MSc 2 (Microbiology & Immunology) Thi Lien Anh Nguyen, (PhD, Universite Libre de Bruxelles) - Recipient of FRSQ Fellowship Thibault Mesplede, (PhD, Universite de Paris V) 4. Scientific Reviews Editorial Boards Cytokine and Growth Factor Reviews (Editor-in-Chief) Journal of Biological Chemistry Retrovirology Current HIV Research Grant Reviews Chair, CIHR HIV/AIDS Emerging Team Grants Panel Virology B Study Section, National Institutes of Health Virology and Viral Pathogenesis, CIHR 5. Conference Organization Chairman, ISICR-ICS Conference “Cytokines 2008”, Montreal Quebec 6. External Committees and Boards European Commission – FP7 Inflammation and Cancer 7. Invited Presentations The innate immune response to virus infection: cross-talk between antiviral and apoptotic signaling. Dept. of Cellular and Molecular Medicine, University of Ottawa (June 2007) 59
  • 60. Department of Oncology Annual Report 2007/2008 The NEMO/IKKgamma adapter bridges the NF-κB and IRF pathways during RIG-I signaling. ISICR Conference Oxford, UK (September 2007) The innate immune response to virus infection: lessons in evasion from hepatitis C virus Institut Pasteur, Paris France (January 2008) Innate Immunity to Virus infection: implications for oncolytic virus therapy. Université Paris V, Rene Descartes, Paris France (January 2008) The innate immune response to virus infection. Meakins-Christie Laboratories, McGill University (January 2008) Molecular interactions regulating the RIG-I signaling pathway. Dept, of Molecular Biology, University of Texas, Dallas Texas (February 2008) Molecular interactions regulating the RIG-I signaling pathway. Dept, of Microbiology, Queens University, Kingston Ontario (March 2008) Molecular interactions regulating the RIG-I signaling pathway. American Assoc. for Immunologists, San Diego CA (April 2008) Evasion of the Innate Immune Response by Hepatitis C Virus. International HCV Conference, Varadero Cuba (April 2008) THOMAS HUTCHINSON 1. Research Grants (new and ongoing) Qualitative Study on "Living with end-stage renal disease (ESRD): multiple perspectives on patients’ suffering and healing." Allied Health Research Grant awarded by the Kidney Foundation of Canada, April 2006 ($85,000). On-going. Application to the Canadian Health Services Research Foundation for a project regarding “Whole Person Tele-Health Care”, which focused on developing an Integrated e- Palliative Care Program, using video-telephone technology. Coordination of grant application through WPC office. Successful application to the St. Mary’s Hospital Foundation for a project regarding “Whole Person Tele-Health Care”, using video-telephone technology. Coordination of grant application through WPC office. ($250,000). The effects of Mindfulness-Based Stress Reduction on patients who had completed treatment for breast cancer. Funded by the JGH Weekend to End Breast Cancer. 60
  • 61. Department of Oncology Annual Report 2007/2008 2. Education and Training Physicianship 1: Introduction to Healing for Med 1 students. The McGill Programs in Whole Person Care have developed a set of six lectures for first year medical students on Healing in Medicine, each an introduction to one of the course concepts as reflected in the session titles. Physicianship 2 Physicianship 3: Relating to the Patient (Lecture, July 26, 2007. Hutchinson) Hutchinson. Concordia University. Dr. P. O’Rourke’s Religion and Healing course. “Healing, a Healthcare Revolution: Opportunities at the Bedside.” February 26, 2007. Hutchinson. Lecture to Nursing Students (Dr. Arnaert’s Chronic Illness & Palliative Care class). “Healing, a Healthcare Revolution: Opportunities at the Bedside.” February 16, 2007. Hutchinson, Small group teaching re. palliative care to medical students, ongoing. Hutchinson, Small group teaching to medical students re. Physician Apprenticeship, ongoing. Hutchinson, Small group teaching to medical students re. ICM Communication Skills. Hutchinson, Small group teaching to medical students re. ITP (Introduction to Patient). Hutchinson, Small group teaching to medical students re. POM (Practice of Medicine). Narrative Medicine “Spreading the Word – Creative writing as faculty development”. The goal of this 4-part workshop is to explore what we do as professionals through the creative medium of writing – September 28, October 12, 26, November 9 and December 7, 2007. 3. Conference Organization Participation in organizing committee for the 17th International Congress on Care of the Terminally Ill, September 2008. 4. External Committees and Other Activities Participation with GWISH (George Washington University): GWish Canadian Advisory Board on Spirituality and Health in Medical Education. Attendance at MBSR Research Conference: Integrating Mindfulness-Based Interventions into Medicine, Health Care, and Society, Worcester, MA. March 29 – April 1, 2007. 5. Presentations Dobkin & Hutchinson. Meditation Workshop. Royal Victoria Hospital, Palliative Care Week, May 10, 2007. 61
  • 62. Department of Oncology Annual Report 2007/2008 Hutchinson, T. McGill Seminars on Healing. “Longing for Virginia: Satir’s Genius for Healing.” April 27, 2007. Hutchinson, T. Nephrology Rounds. “Palliative Care in the Dialysis Unit: An overview for the diehard nephrologist.” MUHC, March 23, 2007. 6. Hospital and University Activities Dr. Hutchinson practices as a palliative care physician with the McGill University Health Centre. Participation in the MUHC non-cancer palliative care group. Hutchinson & Dobkin. “Practicing Medicine Mindfully: Cultivating Imperturbability and Equanimity”. A 1-day workshop for physicians, March 2, 2007. Hutchinson & Dobkin. “Mindfulness-Based Medical Practice”. An 8-week program for physicians, April 20 – June 8, 2007. 7. Public Outreach (McGill Programs In Whole Person Care) McGill Seminars on Healing January 26, 2007. Dr. Neil MacDonald and Dr. Martin Chasen. McGill’s Cancer Nutrition and Rehabilitation Program. February 23, 2007. Dr. David Kuhl. Physician Self-Care. April 27, 2007. Dr. Tom Hutchinson. Satir’s Genius for Healing. May 25, 2007. Dr. Marc Laporta. Emotions and Empathy: Music as a Vehicle. June 21, 2007. Craig Webb. The Healing and Spiritual Potential of Dreams. September 21, 2007. Dr. Gordon Crelinsten. Whole Person Care Book Club – “Bloodletting and Miraculous Cures”. October 26, 2007. Deborah Salmon. Bridging Music and Psychotherapy. November 16, 2007. Dawn Allen. Connection Quality of Life and Quality of Care in Chronic Kidney Failure: Conversations with Patients and Health Care Professionals. Film Series January 16, 2007. “Doing Time, Doing Vipassana.” With guest discussants Dr. John Seely and Dr. George Poland. February 13, 2007. “Joseph Guinta: A Silent Triumph.” With guest discussants Pepita Ferrari (filmmaker) and Dr. Howard Chertkow. 62
  • 63. Department of Oncology Annual Report 2007/2008 March 6, 2007. “This Beggar’s Description.” With guest discussants, Philip and Pierre Tetrault. April 17, 2007. “Born Into Brothels.” With guest discussant: Twinkle Rudberg (Leave Out Violence) May 15, 2007. “Murderball.” With guest discussant Maxime Toupin, Les Patriotes, Montreal wheelchair rugby team. June 12, 2007. “39 Pounds of Love.” With guest discussants Dr. Stephen Liben & Ms. Jackie Rohrer. BERNARD LAPOINTE 1. Summary of New and Ongoing Research A double-blind, randomized, placebo controlled, parallel group dose-range exploration study of Sativex in relieving pain in patients with advanced cancer, who experience inadequate analgesia during optimized chronic opioid therapy. B. Lapointe, PI A multicentre, long term efficacy and safety of subcutaneous tetrodotoxin (Tectin) for moderate to severe cancer-related pain. TEC-OO6, B Lapointe, co-lead investigator A multicentre, open-label, long term efficacy and safety continuation study of subcutaneous tetrodotoxin (Tectin) for moderate to severe cancer-related pain. TEC-006 OL, B. Lapointe co-lead investigator. ‘Natural Caregivers’ Experience of Oncology Patient’s Denial’. Qualitative research project focussing on the impact of the denial of patients with end-stage disease on their caregivers. Naomi Kogan, PI 2. Education and Training L'enseignement pré-doctoral de même que le programme de Fellowship en soins palliatifs est réalisé en partenariat avec la Division de soins palliatifs de la Faculté de médecine de l'Université McGill. Un comité inter-établissement auquel l'équipe de l'HGJ participe se réunit régulièrement et s'assure du développement et de la réalisation d'un curriculum de formation spécifique en médecine palliative en collaboration avec les collèges concernés, les responsables du curriculum d'enseignement de l'université et des recommandations de l'association canadienne des médecins en soins palliatifs. Première année de médecine. (Introduction au Patient) Toute la classe (188 étudiants en 2007-2008) participent à une session de deux heures en petits groupes. Cette session permet aux étudiants de rencontrer un patient en fin de vie et de discuter avec elle ou lui. Ces sessions sont encadrées et facilitées par un des médecins en soins palliatifs. 8 sessions de deux heures sont offertes à l'HGJ. 63
  • 64. Department of Oncology Annual Report 2007/2008 Introduction to Clinical Medicine Au cours de la rotation en oncologie: The management of cancer pain. Un cours d'une durée de deux heures offert en petits groupes à tous les étudiants de la classe (177). Cours portant sur la physiopathologie de la douleur cancéreuse et le développement d'un plan d'action reposant sur une approche mécaniste est donné par le Dr Bernard Lapointe (8 groupes de février à juillet) Programme de Formation en médecine palliative des résidents en médecine de famille de l'HGJ. L'ensemble des résidents en médecine de famille de l'HGJ effectueront un stage obligatoire en soins palliatifs au cours de leur première année de résidence. Oncologie/ hémato-oncologie avec le Dr Lapointe ( deux demi-journée semaine) Stage électif en médecine palliative A chaque année, 3-4 résidents en médecine interne, oncologie ou radio-oncologie effectuent un stage d'une période au sein de la Division des soins palliatifs. Les objectifs de ce stage sont déterminés lors d'une rencontre entre l'étudiant et le directeur médical. Programme d'enseignement aux résidents en neurologie et neuro-chirurgie Cours de deux heures sur le système opiacé et l'utilisation clinique des opioides. Dr. Bernard Lapointe. 2007. Programme d'enseignement aux résidents en urgentologie. L'utilisation des opioides. Dr Bernard Lapointe. 2007 Cancer Pain Management McGill University Faculty of Medicine Web-Based teaching modules 2006. Dr. Bernard Lapointe. 3. External Committees National Chair, International cooperation committee. Canadian Hospice Palliative Care Association. 4. Invited Presentations and Workshops La maitrise de la douleur cancéreuse. CLSC du Richelieu. Nov 2007 Revision de cas difficiles. Centre de soins palliatifs du West Island, Sept 2007 Les opiacés, rencontre de formation médicale continue, Drummondville, Sept 2007 Le contrôle de la douleur cancéreuse, nouveautés thérapeutiques, médecins en soins palliatifs de Laval, June 2007. 64
  • 65. Department of Oncology Annual Report 2007/2008 Postcards From The Edge: The Journey From Acute Care To Palliative Care, conférence plénière, Association des soins palliatifs du Nouveau Brunswick, Campbelton, May 2007. Advances in pain therapy for the patient in palliative care. Campbelton, May 2007 SHIRLEY LEHNERT 1. Summary of New and Ongoing Research Genetic profiling of radio- and drug resistant cells in order to develop methods for prediction of tumor radioresponse and understand radiation/drug interactions and cross- resistance. Development of novel methods of radiosensitization by targeting growth factor receptors and perturbation of signal transduction pathways.Research with biodegradable polymers and hydrogels to evaluate drug combinations in conjunction with external beam and interstitial radiation and the development of systems for intra-tumoral delivery of radionuclides.Characterization of the PET image as an indicator of the malignant phenotype. 2. Research Grants (new and ongoing) Infrastructure for basic research in radiation oncology, Shirley Lehnert, IOF for CFI grant. $83,000, 04/2004-03/2009 Evaluation of Biosyntechhydrogel as a vehicle for intra-tumoral drug delivery, Shirley Lehnert. CIHR/Industry, $180,000, 04/2004-04/2007 Radioprotectors against total body radiation, Shirley Lehnert, LABpreclinical, Contract $100,000, 2007- 3. Education and Training Radiation Biology Course M.Sc students in Medical Physics 3 credits 36 hours/year Course Director: Environmental Carcinogenesis (516-614B). 3 credits, 36 hours/year. Physical Carcinogens, Chemical Carcinogens, Molecular Epidemiology and Chemoprevention (In the Environmental Carcinogenesis Course). 16 hours/year Biology of Cancer: Physical Carcinogens (2 hours/year) Experimental/Clinical Oncology. (EXMD 635) Radiation Oncology (3 hours/year) Radiation Biology Course for Residents in Radiation Oncology and Nuclear Medicine from McGill and Université de Montréal and other graduate students (36 hours/year). Molecular Radiation Biology Seminars Residents in Radiation Oncology (8 hours/year). 65
  • 66. Department of Oncology Annual Report 2007/2008 4. Scientific Reviews Journal Reviews International Journal Radiation Oncology, Biology, Physics Radiation Research International Journal of Radiation Biology Biomaterials Grant Reviews CIHR NCIC 5. Conference Organization Radiation Oncology Research Retreat, June 2007 6. External Committees and Boards NASA Grant Review Panel, May 2007, Washington DC Founder and Chair North East Regional Radiation Sciences Research Group Scientific Advisory Committee: Biological Research Facility, AECL Labs, Chalk River Ontario. Scientific Advisory Board Resonant Medical Systems, Montreal 7. Invited Presentations Keynote address: International conference on natural polymers, bio-polymers, bio- materials their composites, blends, IPNs and Gels: Macro to Nano scales. Kottayam, Kerala, India. November 19th 2007. Delivery of Radiosensitizing Drugs by intra-tumoral drug release vehicles: Hydrogels and biodegradable polymers. Invited address at "Challenges in Drug development for pharmaceutics and cancer". United College of Engineering and Research. Allahabad, India. December 5th 2007. 8. Hospital and University Activities Training Committee, Residents in Radiation Oncology MUHC Radiation Safety Committee Co-leader Cancer Axis, MUHC Research Institute Member Research Council, MUHC Research Institute 66
  • 67. Department of Oncology Annual Report 2007/2008 STEPHEN LIBEN 1. Research Grants (new and ongoing) 2006-2008 CIHR #153244 Caregiving Parents of Children with Life-Limiting Illnesses: Beyond Stress & Coping to Growth. Principal applicant: Susan Cadell. Co-Applicants: S. Liben, H Siden, E Davies, R Steele, L Straatman, D Hemsworth. year 1 $ 101,318, year 2 $102,618, year 3 $59,510. 2. Education and Training Undergraduate Faculty of Medicine Osler Fellow for Class of 2009 Introduction to Pediatrics Course – 3rd year medical students. Small Group Leader. 14 hours Introduction to Pediatrics Course – 3rd year medical students: Yearly Lecturer: 4 hours/yr Pediatric Fluids and Dehydration. Communications Plus - Seminar Course – Final year medical students Small Group Leader – Talking to Children About Death. 5 hours/year Seminar in Palliative Medicine –(POM) 3rd & 4th year medical students. Yearly Lecturer: Pediatric Palliative Care. 4 hours/yr Pediatric Clinical Clerks (3rd year students). Bimonthly Lecturer: Approach to the Critically Ill Child. 1-hour/2 months Postgraduate Communication Issues for Pediatric Residents - Retreat; - Nov 2007 Pediatric Intensive Care Fellows – Palliative care in the PICU - Oct 2007 Narrative Medicine for Pediatric Residents - March 2007 Research Supervision Pediatric Palliative Care NET contributor –partner Mary Ellen MacDonald Clinical Supervision Ward Attending – Medical wards 2-3 months/year (4-5 medical students & 4-5 residents) Palliative Care Consultant – full time Fellow supervision: Dr. G Rizzo - Anaesthesia/Palliative Care Fellowship 67
  • 68. Department of Oncology Annual Report 2007/2008 Emergency Room Physician – 1 shift per month C.M.E. MCH MiniMed lecture Series; Pediatric Palliative Care Sept 2007 Osler Fellow Trainer’s Workshops; Narrative Medicine Feb 7th 2007, May 30 2007 McGill Faculty Development Workshop Facilitator: Designing Successful Workshops – 7 hours Dec 2007 3. Scientific Reviews Editorial Board Member The American Journal of Hospice and Palliative Care Manuscript Reviewer for Journals Pediatrics J of Palliative Care J of Palliative Medicine 4. Congress and Workshop Organization Organizer for pediatric section of International Congress on Care of the Terminally Ill. 5. External Committees The Lighthouse Foundation: Children and Families Member Board 6. Abstracts/Presentations MacDonald ME, Liben S, Carnevale FA, Rennick JE, Cohen SR. Office or bedroom? A Disconnect between family culture and professional culture in the PICU. 5th Congress on Pediatric Critical care. Geneva June 2007 7. Hospital and University Activities Hospital Director Palliative Care Service Member- Medical, Dental, and Pharmaceutical Evaluation Committee Member MCH Heme-Onc Director Search Committee McGill University Member -Flanders Chair Search Committee Member Palliative Care McGill Executive Committee. Member MUHC Palliative Care Education Committee. RUIS/OUTREACH 68
  • 69. Department of Oncology Annual Report 2007/2008 Teaching in RUIS Ongoing evaluation for Outreach to Gatineau – partnership development RUIS/OUTREACH Teleformation Phone consultations with Inuit and Cree Northern patients and healthcare networks. CARMEN LOISELLE 1. Summary of New and Ongoing Research New Projects 1. We have been awarded a grant from FRSQ-funded GRISIM (Groupe de recherche interuniversitaire en sciences infirmieres de Montreal) (Loiselle et al., 2008) to conduct a pilot study on the impact of a new Web-based multimedia cancer informational tool on oncology nurses perceptions of workload and work satisfaction as well as patients well being and satisfaction with care. We received ethics approval and the project is planned to begin in the summer of 2008. 2. We have initiated a mixed design study in the Intensive Care Unit of the Jewish General Hospital (Loiselle, Gelinas et al., 2008) to document the impact of an innovative role for nurses – that of interactive informational coach for family members with a hospitalized family member. Data collection is nearing completion and we have received the 2nd prize for this innovation by the Order of Nurses of Quebec regional chapter and 3M. 3. Two LOIs were accepted in the spring of 2008 from the The Quebec Breast Cancer Foundation in collaboration with The Cancer Research Society Strategic Research Program in Breast Cancer. Dr. Néron, et al.,are in the process of writing the full proposal due August 5, 2008 on the impact of hypnosedation and autohypnose on anxiety and pain among women undergoing a breast biopsie. The second LOI (Foulkes, W., Pastinen, T., Tischkowitz, M., Ghardirian, P., Tonin, P., & Loiselle, C. G. also through the same funding agency “Chipping away at hereditary breast cancer in Quebec: A multi-modal approach” is also being developed as a full proposal due August 5, 2008. Within these contexts, I am developing the psychosocial oncology aspect of these proposals and providing my expertise in research methodology. 4. With Carleton University, we are conducting a pilot study on psychological distress among women identified as high risk for breast cancer. The study is innovative as it includes psychosocial and biological markers related to stress and perceived high risk status. A team of transdisciplinary researchers has been assembled, the protocol is completed and data collection should start in the Fall of 2008. 69
  • 70. Department of Oncology Annual Report 2007/2008 Ongoing Projects 1. Data analysis and write up pertaining to a CIHR-funded project, the impact of interactive health communication on the health and well being of oncology patients (Loiselle, Edgar, & Batist) are completed and three main manuscripts on the findings are in press (Loiselle et al., 2008, Loiselle & Dubois, 2008; Dubois & Loiselle, 2008b). 2. Together with a faculty member from family medicine (Dr. Pierre Pluye), we have received funding from CIHR to explore the impact of IT on health care providers’ practices. Data collection is ongoing and we have published a book chapter on this project (Pluye et al., 2008). 3. With a research team at the University of Montreal, Côté, J. et al. we received FRSQ funding to evaluate a Web-based intervention among men with HIV to increase their adherence to their often complex medication regimen (using the « virtual nurse »). My experience with Web-based tools in cancer is being transferred to a new group of patients. 4. I continue as PI with the PORT program (Psychosocial Oncology Research Training) primarily funded by CIHR and NCIC. I am preparing for the renewal application due this Fall (November, 2008) and have increased university membership by adding Laval University, U. Toronto and U. Alberta in the recently submitted LOI (April, 2008). Publications continue to appear on the development of this initiative (e.g., Loiselle, 2007; Oliffe et al., in press). 5. International research collaboration continues with Dr. Brindha Sitaram, in Bangalore India. The main goal is to assist in the research training of young and promising researchers in the area of psychosocial oncology and oncology nursing. We have published on this initiative (Loiselle, Sitaram et al., 2008) and have received a seed development grant from the Shastri Foundation (Loiselle, 2008) to do a reconnaissance trip to India in November 2008. One particular aspect of research that will be further developed during this visit to COPER is the cross-cultural validation of a tool to assess distress among individuals newly diagnosed with cancer. In addition, a post-doctoral fellow under my supervision is planning an extended research stay in Bangalore starting in January 2009. 2. Research Grants (new and on-going) Loiselle, C. G. (Principal Investigator : 100%), Coté, J., Labrie-Gauthier, M., Seguin, C., Ehrler, A., Batist, G., Panasci, L., Basik, M., & McVey, L. (2008-2009). The impact of a comprehensive cancer supportive care approach by nurse navigators: A concurrent mixed methods pilot study. Groupe de recherche interuniversitaire en sciences infirmières de Montréal (GRISIM). Letter of Intent (LOI) accepted for the Winter 2008. Successful grant application: Amount awarded: 15,000.00. 70
  • 71. Department of Oncology Annual Report 2007/2008 Loiselle, C. G. (Principal Investigator: 100%) (2008-2009). Establishment of formal research collaboration between McGill and the Centre for Psychooncology in Bangalore. Partnership Development Seed Grant from the Shastri Indo-Canadian Institute and the Canadian International Development Agency (CIDA). Amount: $20,000. Co-Principal Investigators: Johnston, C., & Cossette, S. Co-Investigators (alphabetical order): Arnaert, A., Bonin, J-P., Caux, C., Cohen, R., Côté, J., Ducharme, F., Duhamel, F., Dupuis, F., Ezer, H., Feeley, N., Gélinas, C., Goudreau, J., Goulet, C., Larue, C., Lefebvre, H., Le May, S., Loiselle, C., Malo, D., Purden, M., Rennick, J., Ricard, N., Ritchie, J., & Semenic, S. Fonds de la recherche en santé Québec (FRSQ). “Groupe de recherche interuniversitaire en sciences infirmières de Montréal (GRISIM)”. Period of Award: April, 2008 – March 2012. Amount: $2,000,000. Infrastructure – renewal. Côté, J., Godin, G., Tremblay, C., Otis, J., Loiselle, C. G. (Co-Investigator : 20%), & Guéhéneuc, Y-G., (2008-2011). Évaluation d'une intervention virtuelle (application Web) visant à optimiser la prise des antirétroviraux auprès de personnes vivant avec le VIH. Fonds de la recherche en santé Québec (FRSQ). Amount: $229,160. Côté, J., Godin, G., Tremblay, C., Lalonde, R., Otis, J., Loiselle, C. G., Cox, J., Guéhéneuc, Y-G., & Ramirez, M.P. (2007-2010). Evaluation d'un programme d'interventions sur mesure "tailored" visant à optimiser l'adhésion à la prise des antirétroviraux auprès de personnes vivant avec le VIH. Amount: $241,491, Canadian Institutes of Health Research (CIHR) Operating Grant Program – Health Services Research (HSI). Wong, N., & Loiselle, C. G. (Co- Principal Investigator: 50%) (2008-2009). Mapping the decisional trajectory in breast cancer risk management among BRCA1 and BRCA2 mutation carriers. The Weekend to End Breast Cancer (WEBC) Research Fund, Segal Cancer Centre, SMBD Jewish General Hospital. Amount: $20,000. 1-year pilot project. Pluye, P., Grad, R. M., Repchinsky, C., Dawes, M., Loiselle C. G. (Co-Investigator: 15%), Bartlett, G., Rodriguez, C. & Cohendet, P. (2007-2010). Assessing and improving electronic knowledge resources in partnership with information providers. Operating grant application submitted concomitantly to the Canadian Institutes of Health Research (CIHR) - $140,494 and the Fonds de la recherche en santé Québec (FRSQ) - $80,000, in partnership with the Canadian Pharmacists Association (CPhA) – $75,200 (in kind resources) (total funding: $295,694), Program: Partnership for Health System Improvement. Loiselle, C. G., & McVey, L. (2005-2007). Impact of a nursing informational intervention on family coping in an intensive care unit. The Adler/Sheiner patient support program for the intensive care unit (ICU). SMBD Jewish General Hospital, Montreal. $192,000. 71
  • 72. Department of Oncology Annual Report 2007/2008 Loiselle, C. G. (Principal Investigator: 70%), Degner, L., Butler, L., Bottorff, J. (2003- 2009). Comprehensive research training program in psychosocial oncology. ($1,800,000, Canadian Institutes of Health Research (CIHR) Strategic Training Initiative in Health Research (STIHR)). Rhéaume, J., Descoteaux, S., Cognet, M., Hohl, J., Jaccoud, M., Leduc, N., Loiselle, C., McAll, C. et al. (2001-2004). Services de santé et services sociaux en milieu pluriethnique : la dynamique des acteurs dans l’intervention. Subvention de fonctionnement d’équipe. CLSC Côte-des-Neiges. CQRS, $186, 000/year. Renewed (FRSCQ, 2005-2008). Co-Principal Investigators: C. Johnston & N. Ricard. Co-Investigators (alphabetical order): A. Arnaert, C. Chapados, R. Cohen, S. Cossette, J. Côté, D. Ducharme, F. Duhamel, H. Ezer, N. Feeley, A. Gagnon, S. Gendron, J. Goudreau, C. Goulet, S. Le May, H. Lefebvre, C. Loiselle, S. Noiseaux, M. Purden, J. Rennick, N. Ricard, L. Richard, J. Ritchie. Le fonds de la recherche en santé du Québec (FRSQ)/Newton Foundation. “Groupe de recherche interuniversitaire en sciences infirmières de Montréal (GRISIM)”. Period of Award: April, 2006 – 2008. Amount: $1,000,000. Infrastructure – renewal. Co-Principal Investigators: McLeod, D., & Dumont, S. Project Partners (more than forty partners): Loiselle, C. G., et al. (2006-2008). An innovative national distance education initiative for interprofessional practice in psychosocial oncology. Health Canada, Amount: $749,608. 3. Education and Research Training Genest, Christine (Ph.D.) Member of the dissertation committee for Doctoral Candidate, University of Montreal Dubois, Sylvie (Ph.D.) School Of Nursing: 2002-2008 (CIHR/ONQ funded; MELS doctoral scholarship, GRISIM doctoral scholarship, PORT fellowship). Graduating, Defense August, 2008 Hadd, Valerie (Ph.D.) Co-direction. School of Human Kinetics, University of British Columbia: 2006 – (SSHRC funded) Biron, Alain (Ph.D.) School of Nursing: 2003-2008 (FRSQ/FERASI/MUHC/MELS funded) Lambert, Sylvie (Ph.D.) School Of Nursing: 2002-2008 (FRSQ/CIHR funded; Maysie MacSporan fellowship, PORT fellowship, GRISIM doctoral scholarship). Graduating, Defense July 2008 72
  • 73. Department of Oncology Annual Report 2007/2008 Matousek, Rosa (Ph.D.) Co-direction. Psychology: 2006 -2008 (NCIC/PORT Fellow funded). Graduated Megan McQuirter (M.Sc.(A)). School Of Nursing: 2008 - Present Luisa Luciani Castiglia (M.Sc.(A)). School Of Nursing: 2008 - Present Jack, Marjorie (M.Sc.(A)). School Of Nursing: 2007 - Present Peters, Okimi (M.Sc.(A)). School Of Nursing: 2007 - Present 4. Scientific Reviews Journal Reviews Healthcare Policy—Politiques de Santé International Journal of Public Health (IJPH) European Review of Applied Psychology Transcultural Psychiatry Education for Evidence-Based Practice Perspective Infirmière Cultural Diversity and Ethnic Minority Psychology (APA journal) Journal of Advanced Nursing (JAN) Canadian Journal of Nursing Research (CJNR) Grant Reviews External Grant Reviewer - Northwestern Ontario Regional Cancer Centre & Northern Cancer Research Foundation, August 12, 2007. External Grant Reviewer - Health Research Board, Dublin, Ireland. Building Partnerships for a Healthier Society Research Awards competition. Spring, 2007 5. Conference Organization Organized the fourth annual two-day scientific meeting which was held at the Delta Barrington, Halifax, Nova Scotia on May 6th & 7th, 2008. PORT Trainees’ presented highlights from their research within the cancer trajectory, received feedback and support from PORT Mentors, and participated in workshops, group discussion, and breakout sessions. 6. Invited Presentations Loiselle, C.G. Communication between patients with cancer and health care providers: A review of communication skills and evidence pertaining to process and outcome. Invited Lecturer, Centre of Psychooncology for Education and Research (COPER), Bangalore, India. October 26, 2007. 73
  • 74. Department of Oncology Annual Report 2007/2008 Loiselle, C.G. The impact of IT on psychosocial adjustment to cancer and health care service use. Invited speaker, Departmental lecture series, Faculty of Dentistry, McGill University. October 25, 2007. 7. Hospital and University Activities Member, Research Ethics Committee, SMBD Jewish General Hospital MARY ELLEN MACDONALD 1. Summary of New and Ongoing Research I started the first year of a funded project (SSHRC 2007-2010), looking at the cultural construction of parental bereavement. There are 4 Investigators (ME Macdonald, S Cadell, P Stephenson, L Mitchell) across 3 universities (McGill, Wilfrid Laurier University and University of Victoria) and a total of 4 research assistants. Since the fall, we have been looking at literature on parental bereavement – e.g., medical, nursing, psychological as well as popular culture and media representations. Our aim is to examine the understandings of what it means to be a ‘bereaved parent’. From this, we will build a semi-structured interview guide in order to interview bereaved parents, the goal being to understand their lived experience of living after their child has died. For this project, we have also started to design a systematic review of the literature that addresses the experiences of families who have lost a child. I also continue to work with Dr. Paul Brassard (Dept Epidemiology) on a project looking at TB in the Montreal Aboriginal population, and HPV/cervical cancer in the Northern Inuit population. Further, I continue working at the Centre for Medical Education on research projects looking at improving medical education at McGill. 2. Research Grants (new and ongoing) Pending Grants SR Cohen, V Baracos and multiple team members, including ME Macdonald, Palliative and End-of-Life Care Research Training. CIHR, Strategic Training Program Team Grant, LOI Submitted March 2008, $1 800 000, 2008-2014 SR Cohen and ME Macdonald, Graduate Student: L Chan, Experiences of Hospitalized Patients with End-Stage Illness, CIHR, Operating Grant, Submitted March 2008, $102,995, 2008-2011 P Brassard, F Coutlee, E Franco, ME Macdonald, Milestones for Human Papillomavirus Vaccine Introduction in Nunavik, CIHR, Operating Grant, Submitted March 2008, $207,570, 2008-2011 ME Macdonald, I Shrier, JF Boivin, J Brophy, FA Carnevale, AD Furlan, R Kakuma, RW Platt, M Rossignol, R Steele Meta-Analysis: Understanding the subjective 74
  • 75. Department of Oncology Annual Report 2007/2008 interpretation of an objective analysis, CIHR, Operating Grant, Submitted March 2008, $ 81,632 2008-2010 Rykov, MH, SR Cohen, A Leis, ME Macdonald, Palliative Care Music: Mapping the Canadian Terrain, Sociobehavioural Cancer Research Network (CBRPE), Submitted March 2008, $5 650, 2008-2009 Coholic, Diane S. Cadell, J Coates, J Graham, J, Waegemakers Schiff, Collaborator: ME Macdonald, Defining Best Practices for Spiritually-Sensitive Social Work in Health, CIHR Operating Grant, $ 300,000, 2008-2011 Current Grants ME Macdonald, S Cadell, L Mitchell, P Stephenson, An Anthropology of Bereavement: A sociocultural understanding of parental grief and mourning, SSHRC Operating Grant, $75,000 (+ $19,370 supplemental and in-kind from other institutions), 2007 – 2010 P Brassard, E Franco, ME Macdonald, Inuit Women’s Understanding of Human Papillomavirus: Implications for Health Education and Prevention in Nunavik, Quebec, SSHRC Northern Research Development Program, Operating Grant, $40,000, 2007-2009 P Brassard, E Franco, ME Macdonald, Acceptance and Comparability of Self-Collected Vaginal Swabs and Nurse-Practionner Collected Cervical Swabs for Detection of Human Papillomavirus Infections in Nunavik, Québec, MUHC Research Institute, Pilot Project Grants, $20,000, 2007-2009 Y Steinert, M Boillat, M Elizov, ME Macdonald, P McLeod, S Meterissian, S Razack Faculty Development: If You Build It, They Will Come. Royal College of Physicians and Surgeons, Faculty Development Grant, $5 000, 2007- 2008 SR Cohen and multiple team members, including ME Macdonald, Palliative Care Research, Sociobehavioural Cancer Research Network (CBRPE), Team Grant, $80,000, 2007-2008 ME Macdonald, L Lach, RA: AM Piché, Understanding Rigour in Qualitative Research, Centre for Medical Education, Research Grant, $1,000, 2007 ME Macdonald , Ensuring Quality in Qualitative Research, Sociobehavioural Cancer Research Network (CBRPE), Conference Grant, $900, 2007 ME Macdonald, Travel Grant: Geneva, International Congress on Pediatric Critical Care, Sociobehavioural Cancer Research Network (CBRPE), Travel Grant, $1,500, 2007 M Bennett, H Siden, R Adderleym, S Cadell, L D’Agincourt-Canning, ME Macdonald, T Northway, L Straatman, E Stephanson, Parental and Professional Decision-Making 75
  • 76. Department of Oncology Annual Report 2007/2008 Regarding Benefits and Burdens of Interventions for Children with Life-Limiting Conditions, Health Research Resource Office, UBC/MSF, Seed Grant, $5,000, 2007 P Brassard, ME Macdonald, R Menzies, K Schwartzman, Partnered with the Native Friendship Centre of Montreal, Tuberculosis among Urban Aboriginals in Montreal CIHR, Strategic Initiative: Aboriginal Community-based Research Competition, Operating Grant, $213,450, 2005-2008 K Stajduhar, SR Cohen, N Chappell, D Heyland, P Koop, A Williams, New Investigator: ME Macdonald, Family Caregiving in Palliative and End-of-Life Care, CIHR, New Emerging Team Grant, $1,363,586, 2004-2009 H Siden, S Cadell, E Davies, R Steele, L Straatman, Collaborator: ME Macdonald, Transitions in Paediatric Palliative and End of Life Care, CIHR, New Emerging Team Grant, $1,348,575, 2004-2009 3. Education and Training Teaching and Research Training: Postgraduate McGill / Ottawa/ Laval CIHR-NCIC Strategic Training Program in Palliative Care Research. Qualitative Inquiry in Palliative Care Research: Protocol Development Workshop , May 2007 (9hrs) McGill University: School of Nursing Clinical Project 1 in the Global Health Section (NUR2-630; Prof Anita Gagnon), Winter semester 2008, Guest Instructor McGill University: Division of Experimental Medicine Qualitative Research (EXMD – 628; Prof Steven Jordan), Fall semester 2007; Guest Instructor Undergraduate Teaching McGill University: School of Nursing Research in Nursing (NUR1 422; Prof Celeste Johnston), Fall semester 2007; Guest Instructor Continuing Medical Education (CME) McGill University: Centre for Medical Education a. Qualitative Inquiry in Medical Education (3hrs/yr), for the International Medical Education Exchange Program (IMEX): Dalhousie University, McGill University, Utrecht University, Karolinska Institute, May 2007 b. Qualitative Inquiry Seminar Series (6hrs/yr), for Core Faculty, 2007-2008 76
  • 77. Department of Oncology Annual Report 2007/2008 McGill University: Faculty Development Office Cultural Competency Workshop: Educating for Cultural Awareness: Avoiding Stereotypes, Assumptions and Other Traps (4 hrs/yr), 2007, co-instructor with S Razack, FA Carnevale, Y Steinert Research Trainees Supervised McGill University A) Oncology Dawn Allen, Postdoctoral Fellow, (Whole Person Care), Postdoctoral Co-Supervisor (with SR Cohen), 2008 – present, Topic: ESRD and Whole Person Care B) School of Nursing Lisa Chan, Doctoral Student, Doctoral Co-Supervisor, 2006 to present, Topic: Ethnographic Study of End-Stage Illness on an Acute Medical Unit Carly Lang, Masters Student, Research Supervisor, Global Health Section, 2008- present; Clinical and Research Placement: Rapid Lake, Northern Quebec Aboriginal Community. C) Psychiatry Emmanuelle Bélanger, Doctoral committee member, Spring 2008 to present, Topic: Patient-Physician Relationship in Primary Palliative Care. Ottawa University A) School of Nursing David Wright, Doctoral Student, Doctoral Committee Member, (October) 2007- present, Topic: Terminal Delirium and Palliative Sedation Research Assistants Supervised A) Epidemiology (MUHC-Royal Victoria Hospital) Ebba Oloffson, PhD, Mentorship + RA Supervision, 2007, Supervision in research techniques, protocol writing, analysis B) Pediatric Palliative Care (MUHC-Montreal Children’s Hospital) William Affleck, MA (Bioethics) student, RA Supervision, 2007-present, Supervision in research techniques. Gillian Chilibeck, MA (Anthropology), RA Supervision, 2007-present, Supervision in research techniques. Research Trainees Mentored McGill University A) School of Nursing Sylvie Lambert, Doctoral Student, Doctoral mentor; methodology consultant; 2007 to present, Topic: Understanding Cancer Patients’ Health Information Seeking 77
  • 78. Department of Oncology Annual Report 2007/2008 Behaviour. B) Division of Experimental Medicine (Biomedical Ethics Unit) Matthew Hunt, Doctoral Student, Doctoral mentor; methodology consultant, 2007- present, Comprehensive Exam Committee member, (Nov) 2007 McGill / Ottawa / Laval: CIHR-NCIC Strategic Training Program in Palliative Care Mary Rykov, Postdoctoral Fellow, McGill University (Oncology), Postdoctoral Mentor, 2006 to present, Topic: Music therapy and cancer care Nicolas Vonarx, Postdoctoral Fellow, Laval University (Bioethics and Nursing), Postdoctoral Mentor, 2006 to present, Topic: Les figures du religieux dans les épisodes de maladie marqués par une souffrance existentielle: pour une meilleure lecture de ces figures dans le cadre des soins palliatifs Lisa Chan, Doctoral Student, McGill University (School of Nursing), Doctoral Mentor, 2006 to present, Topic: Ethnographic Study of End-Stage Illness on an Acute Medical Unit David Wright, Doctoral Student, Ottawa University (School of Nursing), Doctoral Mentor, (October) 2007 to present, Topic: Psychiatry and Palliative Care 4. Scientific Reviews Scientific Manuscript Reviewer Journal of Aboriginal Health (1 review) Medical Anthropology: Cross-Cultural Studies in Health and Illness (1 review) Canadian Journal of Nursing Research (2 reviews) Pediatrics (2 reviews) Canadian Medical Association Journal (1 review) Journal of Child Health Care (1 review) Journal of Hospice and Palliative Medicine (1 review) Grant Reviewer Operating Grant Review, Scientific Officer, National Cancer Institute of Canada (NCIC), Operating Grant Panel K: Supportive Care, Palliative Care and Psychosocial Issues, 2008 (2 day meeting/year) Ad hoc Grant Reviews Operating Grant Review, Social Science and Humanities Research Council (SSHRC) Operating Grant (declined because of conflict of interest) Scientific Review, Montreal Children’s Hospital Research Institute, McGill University Health Centre (1 review) REB Review, Institutional Review Board, Faculty of Medicine, McGill University (1 78
  • 79. Department of Oncology Annual Report 2007/2008 review) 5. Congress and Workshop Organization Organizer and Chair, McGill Qualitative Health Research Group Annual Conference: Ensuring Quality in Qualitative Research. (Funded by NCIC-Sociobehavioural Cancer Research Network, and Palliative Care Program, Montreal Children’s Hospital), April 5, 2007 6. Invited Presentations and Workshops Macdonald, ME, Where is the Family in Family-Centred Care: Qualitative Research Findings in the ICU, Pediatric Advanced Care Team Rounds, Dana-Farber/Children's Hospital, Boston, April 2008. Cohen, SR, and Macdonald, ME, Palliative Care Researchers: The Next Generation, Department of Oncology Research Retreat, Vaudreuil, QC, March 2008 Macdonald, ME, An Anthropology of Bereavement, Team Meeting of the CIHR NET: Family Caregiving in Palliative and End of Life Care, Toronto, November 2007. Macdonald, ME, Culture in the ICU. Team Meeting of the Parental and Professional Decision-Making Regarding Benefits and Burdens of Interventions for Children with Life-Limiting Conditions, Vancouver, September 2007. Macdonald, ME, Ensuring Quality in Qualitative Health Research at McGill, 1st annual McGill Qualitative Health Conference, Ensuring Quality in Qualitative Health Research, Montreal, April 2007. 7. Peer Reviewed Abstracts Accepted Peer Reviewed Abstracts Affleck, W, Chilibeck, G, Mantulak, A, Cadell, S, Macdonald, ME. Parental Experience? Apparently not. The Misrepresentation of Fathers in Pediatric Palliative Care Research. Canadian Hospice Palliative Care Conference, October 2008, Charlottetown, PEI. Chilibeck, G, Affleck, W, Mantulak, A, Cadell, S, Macdonald, ME, Parental Experience? Apparently not. The Overrepresentation of Mothers in Pediatric Palliative Care Research. Canadian Hospice Palliative Care Conference, October 2008, Charlottetown, PEI. Rykov, MH., Cohen, SR., Leis, A., Macdonald, ME., Pringle, A., Cadrin, M. L., Salmon, D. & Weeks, V. Palliative care music therapy: insights from patients, family and staff. 17th International Congress on Palliative Care. Montreal, September 23-26, 2008. [oral presentation abstract submission] [As postdoctoral mentor, I contributed 6%] 79
  • 80. Department of Oncology Annual Report 2007/2008 Lambert, S, Loiselle, C, Macdonald, ME, An in-depth exploration of information- seeking behavior among individuals with cancer: Understanding differential patterns of active information-seeking, 10th World Congress of Psycho-Oncology, 9 - 13 June 2008, Madrid, Spain. Peer Reviewed Abstracts Rykov, MH, Macdonald, ME, Leis, A, Cohen, SR (November 2007) Qualitative Outcome Research of Palliative Care Music Therapy, 4th Annual IN-CAM Symposium, Coming of Age: Emerging Issues and New Directions in CAM Research, Vancouver, British Columbia. Published in Journal of Complementary and Integrative Medicine: Vol. 4: Iss. 1, Article 9 Rykov, M, Cohen, SR, Leis, A, Macdonald, ME, Pringle, A, Cadrin, ML, Salmon, D (November 2007) Understanding Palliative Care Music Therapy Experience, Canadian Hospice Palliative Care Conference, Toronto, Ontario. Published in J Pall Care 2007 23(3): 214 Steinert, Y, McLeod, PJ, Boillat, M, Meterissian, S, Elizov, M, Macdonald, ME (November 2007) Faculty Development: A Field of Dreams? 46th Annual Conference on Research in Medical Education, Association of American Medical Colleges (AAMC), Washington, DC. Macdonald, ME, Liben, S, Carnevale, FA, Rennick, JE, Cohen, SR (June 2007) Office or Bedroom? A Disconnect Between Family Culture and Professional Culture in the PICU, 5th World Congress on Pediatric Critical Care, Geneva. Published in Pediatric Critical Care Medicine 8(3) suppl, A262-A263. McLeod, P, Chalk, C, Zanelli, P, Wiseman J, Macdonald, ME (May 2007) A Problem Becomes an Opportunity: The Emergency Department Consult Service for Students in Internal Medicine, Conference of the Canadian Association of Medical Education, Victoria. Published in proceedings. Boudreau, JD, Jagosh, J, Slee, R, Macdonald, ME, Steinert, Y (May 2007) Incorporating the Patient Perspective in Curricular Renewal, Conference of the Canadian Association of Medical Education, Victoria. Published in proceedings. Razack, S, Macdonald, ME, Steinert Y, Carnevale, FA (May 2007) Training in Cultural Competence: What We Want to Learn vs. What We Ought to Learn. Conference of the Canadian Association of Medical Education, Victoria. Published in proceedings. Peer Reviewed Abstracts (in Review) Macdonald, ME, Cadell, S., Understanding growth, grief and bereavement for parents of children with life-limiting illness. 2nd Congress of the European Academy Pediatrics Nice, France, October 2008 80
  • 81. Department of Oncology Annual Report 2007/2008 8. Hospital and University Activities Member, End of Life Care in Non-Cancer Patients Committee, McGill University Health Centre (Chair, A Towers, MD), 2007 to present Member, PhD Advisory Committee, School of Nursing, McGill (Chair, M Purden, PhD), 2007 to present NEIL MACDONALD 1. Summary of New and Ongoing Research New Emerging Team Grant (CIHR) – studies on cachexia. McGill co-PI. A collaboration with the University of Alberta. Dr Vickie Baracos is the overall PI. Clinical Trials – PI study on dronabinol – effects on appetite, taste and smell. A collaboration with the University of Alberta. Co-investigator – AVR 118 in the management of cancer anorexia (Dr Martin Chasen PI.) Studies on the role of a chronic inflammatory state in cancer prognosis and symptomatology. Grant submitted – Terry Fox Research Institute – ‘Toward an Understanding of the Anorexia-cachexia syndrome: linking molecular mechanisms with novel treatment options. Co-PI Current studies include: 1. A continuing analysis of overall prognosis 2. Relationship of inflammation to chemotherapy response 3. Impact of inflammation on early dropout rate in clinical trials 4. Relationship of PET intensity to inflammatory markers 5. New study - Longitudinal changes in inflammatory markers over the full course of non-small cell lung cancer 6. New study – Cancer Staging System based on Inflammatory Markers Other Research Activities Continuing interaction with physiotherapy colleagues who are studying the role of exercise activities in NSCLC patients 2. Education and Training Shared supervision of a Master’s student (Ms Swinton) 3. Scientific Reviews Editorial Boards Journal of Palliative Care Journal of Pain and Symptom Management 81
  • 82. Department of Oncology Annual Report 2007/2008 Journal of Supportive Oncology Palliative and Supportive Care Oncology Exchange Book and Journal Reviews Book review: Abrahm JL (2005): A Physician’s guide to pain and symptom management in cancer patient - second edition. Baltimore: The Johns Hopkins University Press Book review: Richard Dawkins: The God Delusion: Journal of the Royal College of Physicians Edinburgh Open Society Institute: Global Advocacy for Palliative Care Progress in Palliative Care Cancer Journal of Palliative Medicine Journal of Palliative Care Journal of Clinical Nutrition Journal of Supportive Oncology Journal of Clinical Nutrition Nature Oncology Grant Reviews CIHR Grant 4. External Committees World Health Organization Expert Committee on Cancer International Association of Hospice and Palliative Care 5. Invited Presentations and Workshops Neil MacDonald, Janet Abrahm, Lydia Schapira. Issues in Communication: withholding and withdrawing therapy. Optimizing Oncology Care: Symptom Management and Communication Skills. Categorical course. ASCO Annual Meeting. Chicago Illinois. May 2007. “How to Identify and Approach the Malnourished Patient”. Issues in Palliative Care Conference. Antigonish, Nova Scotia. May 13, 2007. “Ethics and End-of-Life Care”. Issues in Palliative Care Conference. Antigonish, Nova Scotia. May 14, 2007. Grand Rounds. Jewish General Hospital. Montreal, QC. December 3, 2007. Grand Rounds Foothills Hospital/Alberta Hospitals Provincial Videoconference. Calgary, Alberta. December 6, 2007. 82
  • 83. Department of Oncology Annual Report 2007/2008 The Calgary Pain Conference - trends and treatments. Ethics and Symptom Management. Calgary, Alberta. December 7, 2007. The Calgary Pain Conference. Improving Function in Palliative Care. Calgary, Alberta. December 7, 2007. Canadian Association of Medical Oncologists. Palliative/Supportive Care Endpoints. Toronto, Ontario. May 1, 2008. 6. Abstracts N. MacDonald, G. Kasymjanova, J. Agulnik, C. Pepe, H. Kreisman, V. Cohen, R. Sharma, B. Gagnon, D. Small. Influence of baseline inflammatory markers on the response to first line chemotherapy. Poster presentation. ECCO. Barcelona. September 2007 E. Dajczman, G. Kasymjanova, N. Swinton, D. St-Pierre, T. Swanson, H. Kreisman, J. S. Agulnik, V. Cohen, N. MacDonald, and D. Small. Does NSCLC patient-rated performance status predict survival more accurately than physician ratings? ASCO Meeting Abstracts 2007;25: 9022 Steinberg. T, Dobson. S, Kasymjanova. G, Lajeunesse. L, Dajcman. E, Kreisman. H, MacDonald. N, Agulnik. J, Cohen. V, Rosberger. Z, Chasen. M, Small. D. Prevalence of Emotional Distress in Newly Diagnosed Lung Cancer Patients. MASCC, 2007 MacDonald N, Kasymjanova G, Agulnik J, Pepe C, Kreisman H, Cohen V, Sharma R, Gagnon B, Small D. Influence of baseline inflammatory markers on the response to first line chemotherapy in advanced NSCLC. ECCO Annual Meeting, Barcelona, Spain. Sept. 2007. N MacDonald, N Swinton, G Kasymjanova, H Kreisman, J Agulnik, N Grant, T Tran, C Bromberg, R Sharma, D Small. The Role of a Cancer Nutrition-Rehabilitation Program (CNRP) in the Care of Non Small Cell Lung Cancer Patients (NSCLC). MASCC June, 2007 N. Swinton, G., Kasymjanova, T. Steinberg, L. Lajeunesse, E. Dajczman, H. Kreisman, D. Small, J. S. Agulnik, J. Kawadoi, N. MacDonald; Do most newly diagnosed advanced NSCLC patients need nutritional intervention? ASCO abstract 9108 and poster presentation. June 2007. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings (Post-Meeting Edition) Vol 25, No 18S (June 20 Supplement), 2007: 9108 MARKUS MARTIN 1. Scientific Reviews Doctor’s Review 83
  • 84. Department of Oncology Annual Report 2007/2008 2. External Committees and Boards Royal College of Physicians and Surgeons of Canada: Board Member Medical Council of Canada: Board Member College des medecins du Québec: Board Member SARKIS METERISSIAN 1. Summary of New and Ongoing Research Education Research Assessment of clinical reasoning in surgical trainees Novel methods for improving feedback in the operating room Clinical Research Accuracy of axillary ultrasound in early stage breast cancer S-classification of melanoma sentinel node metastases as a predictor of non-sentinel node metastases Basic Research Application of the stromal-derived prognostic predictor (SDPP) in early breast cancer Promotion of protein anabolism in colorectal cancer patients perioperatively 2. Research Grants (new and ongoing) Optimizing the anabolic effect of hypocaloric nutrition after surgery by increasing the level of Protein intake, PI: Schricker T., Co-Investigators: Wykes L., and Meterissian S CIHR, $70,645/annum , 2006-2009 Faculty Development: If you build it, they will come, PI: Yvonne Steinert, Co-PI: Sarkis Meterissian, Royal College Faculty Development Grant, $5,000/annum, 2007-2008 3. Research Training July/06 – Dec./07, MaryLise Boutros, Fellowship in Education, Center for Medical Education July/07 – Dec./07, Awad Al-Qahtani, Research in the area of Breast Cancer July/07 – Dec/07, Eric Poirier, Prediction of non-sentinel node metastases in breast cancer patients with a positive sentinel node 84
  • 85. Department of Oncology Annual Report 2007/2008 4. Scientific Reviews Editorial Board American Journal of Clinical Oncology Reviewer Annals of Surgery World Journal of Surgery 5. Conference organization Organizing Committee of the International Surgery Symposium held in Montreal in 2007, Chair: Dr. Gilles Beauchamp Scientific Committee (McGill Rep.) 3e Congres De Chirurgie De La Francophonie, Member of the SubCommittee on Surgical Oncology 6. External Committees and Boards Cedars Cancer Institute, Medical Advisory Board, Chair: Dr. H. Shibata McGill NCIC Representative for the Breast Disease Site Committee Member of the Accreditation Committee, Royal College of Surgeons and Physicians of Canada Member of Accreditation Site Visit Programme Quebecois de Lutte Contre le Cancer Review: CHUM Colorectal program, April 2007, Chair: Jean Latreille President of the Canadian Society of Surgical Oncology, Serving a 2-yr term Member of the Canadian Surgical Forum Steering Comm., President of a Major Participating Society Member of Committee on Medical Education andAccreditationCollege des Medecins du Quebec, Chair: Dr. Markus Martin Member of the Committee on Medical Disciplines, College des Medecins du Quebec Chair: Dr. Markus Martin Member Advisory Board of the Medical Simulation Center, Chair: Dr. Kevin LaChapelle Member Administrative Committee of the College des Medecins, Chair: Dr. Yves Lamontagne, Representing McGill University 7. Invited Presentations International Surgical Week, Breast Surgery International, Talk: Approach to Hereditary Breast Cancer in Canada (August 2007) 85
  • 86. Department of Oncology Annual Report 2007/2008 International Surgery Week, Breast Surgery International, Symposium: Hereditary Breast Cancer, Moderators: Dr. Sarkis Meterissian, Dr. Kerstin Sandelin The Breast Course – International Symposium, Plenary Session: Fundamentals of Breast Surgery, Debate: The Value of MRI (Con) 8. CME Activities Attended Canadian Surgery Forum – Sept. 2007 Society of Surgical Oncology Meeting – March 2008 The Breast Course – April 2008 Canadian Association for Medical Education – May 2008 9. Hospital and University Activities Associate Dean of Postgraduate Medical Education Director of the Cedars Breast Center of the MUHC WILSON MILLER 1. Summary of New and Ongoing Research Basic Research Collaboration within McGill Dr. H. Schipper, Neurology, Jewish General Hospital. Dr. J. Hoffer, Endocrinology, Jewish General Hospital. Dr. D. Scott Bohle, Department of Chemistry, McGill University. Dr. J. White, Department of Physiology, McGill University. Dr. M. Basik, Surgery/Oncology, Jewish General Hospital. Basic Research Collaboration outside of McGill Dr. Sam Waxman, Mount Sinai Medical School, New York, New York. Dr. Clara Nervi, University of Rome "La Sapienza", Rome, Italy. Dr. Sylvie Mader, University of Montreal/Institute for Research in Immunology and Cancer. Dr. Kathy Borden, University of Montreal/ Institute for Research in Immunology and Cancer. Dr. Albert Baldwin, University of North Carolina. Dr. Paul Fisher, Columbia University, New York. Dr. Philip Komarnitsky, Ziopharm Oncology, Inc. 86
  • 87. Department of Oncology Annual Report 2007/2008 2. Research Grants (new and ongoing) CIHR Training Program grant to the Montreal, Centre for Experimental Therapeutics in Cancer, 2002-2008: Co-Applicant, (PI - Dr Gerald Batist). Canadian Institute of Health Research, operating grant: "Mechanisms of response and resistance to transcriptional therapies in acute promyelocytic leukaemia," 2003-2008: PI. Canadian Institute of Health Research, operating grant: "Mechanisms of the anti-cancer actions of arsenic," 2004-2009: PI. Susan B Komen Foundation, operating grant, “Regulation of SXR Activation by Rexinoids- Role of Drug Resistance”, 2006-2008: PI. Cancer Research Society, operating grant, “DARPP32 in resistance to trastuzumab in breast cancer,” 2006-2008: Co-Applicant, (PI-Dr Mark Basik). Canadian Institute of Health Research, operatimg grant, “Molecular mechanisms of retinoid/paramyxovirus interactions”, 2006-2009: Co-Applicant, (PI-.Dr. Brian Ward). The Leukemia and Lymphoma Society, operating grant, “The eukaryotic translation initiation factoir eIF4E: a novel therapeutic target in myeloid leukemia”, 2006-2009: Co- Applicant, (PI - Dr. Katherine Borden). Leukemia Lymphoma Society of Canada, operating grant, “Trolox enhances anti- leukemic effects of arsenic: the role of ROS”, 2007-2009: PI. Canadian Institute of Health Research, operating grant: "Novel mediators of response and resistance to epigenetic therapy of leukemia," 2008-2013: PI. National Cancer Institute of Canada, operating grant, “The Role of ROS in the enhanced tumor specificity of arsenic when combined with the vitamin E-derivative trolox.”, 2008- 2011: PI. 3. Research Training Koren Mann, post-doctoral fellow, 9/1999-8/2006. Transcriptional mechanisms of response and resistance to retinoids. Filippa Pettersson, post-doctoral fellow, 10/2000-3/2007. Molecular interactions among nuclear receptors in breast cancer. Zuanel Diaz-Heredia, PhD student in Experimental Medicine, 9/2002-. Mechanisms of induction of apoptosis by arsenic. Suzan McNamara, PhD student in Experimental Medicine, 1/2003-. Mechanisms of response and resistance to transcriptional therapies in acute promyelocytic leukemia. 87
  • 88. Department of Oncology Annual Report 2007/2008 Clair Trottier, PhD student in Microbiology and Immunology, 9/2004-. Molecular mechanisms of suppression of measles virus by retinoic acid. Co-sponsored with Dr. Brian Ward. Anna Laurenzana, PDF 10/2004-9/2007. Epigenetic approaches to overcome retinoid resistance in acute promyelocytic leukemia. Ms Marina Lagodich, Honours Immunology undergraduate research student, “Regulation of SXR by rexinoids”, 2005-2006. Sophie Marcoux, MS student in Experimental Medicine, 9/2006-11/2007. Mechanisms of arsenic-induced apoptosis: the role of caspases and reactive oxygen species. Andy Petruccelli, PhD student in Experimental Medicine, 1/2007-. Potential therapies exploiting the synergy between histone diacetylase and DMNT inhibitors. Myranda Tomensen, Honours Immunology undergraduate research student, Defining novel mechanisms by which HDAC-inhibitors induce apoptosis in cancer cells, 2006- 2007. Jessica Nichol, PhD student in Expermental Medicine 9/2007-. Kaitlin Soye, PhD student, co-supervised with Dr. Brian Ward, Dept. Experimental Medicine, 9/2007-. Maria Kourelis, MS student in Experimental Medicine 09/2007-. Characterization of the apoptotic mechanisms induced by arsenic trioxide in acute promyelocytic leukemia. 4. Scientific Reviews Editorial Boards Cancer Research (Associate Editor) Journal Reviews Blood Leukemia Cancer Research JNCI Annals of Oncology Clinical Cancer Research Biochimica et Biophysica Acta J Clinical Oncology Oncogene Leukemia Research Cancer Cell Nature Reviews Cancer 88
  • 89. Department of Oncology Annual Report 2007/2008 Brit. J Pharm The Hematology Journal Mol Cell Biol. Mol Ca Res Cancer Letters J Biol Chem Free Radical Biology and Medicine Science J Cellular Biochem. Grant Reviews Peer Review Panel Member, Samuel Waxman Cancer Research Foundation, New York, NY May 5, 2008. Peer Review Panel Member, Leukemia Lymphoma Society of Canada, Toronto, ON, May 20, 2008. 5. Conference Organization Co-Organizer Montreal Centre for Experimental Therapeutics in Cancer Annual Meeting, Montreal, QC Dec 3-4, 2007. 6. External Committees and Boards Member, NSABP Foundation Research Program Steering Committee, June 2005-June 2008. 7. Invited Presentations Invited Speaker, Tri-Institutional MD-PhD Program Annual Retreat, “Translational Research in Leukemia”, Westchester, NY, August 18, 2007. Invited Speaker, Ziopharm Oncology, “Mechanisms of action of arsenical in cancer treatment”, NY NY, November 29, 2007. Invited speaker, Samuel Waxman Cancer Research Foundation Scientific Advisory Meeting, “Molecular mechanisms of synergy between arsenic trioxide and Trolox”, New York, NY May 4-5, 2008. 8. Hospital and University Activities Hospital Director, Clinical Research Unit, Jewish General Hospital, Montreal PQ, 12/1997-. Director, Program Advisory Committee of the CIHR Training Program in Oncology, Montreal Centre for Experimental Therapeutics in Cancer 2002-2008. Member, Executive Committee of Lady Davis Institute of Research Member, Radiation Oncology Chair Search Committee at JGH 89
  • 90. Department of Oncology Annual Report 2007/2008 McGill University Professor, Departments of Oncology and Medicine, McGill University, Montreal, PQ, Canada Scientific Member and Member, Board of Directors, McGill Centre for Translational Research in Cancer Montreal Centre for Experimental Therapeutics in Cancer (MCETC) Training Program: Program Director Director, McGill University Department of Oncology Developmental Therapeutics Program Co-Director, Clinical Research Program, McGill University Department of Oncology Member, Institutional Review Board of the Faculty of Medicine, McGill, August Member, Management Committee, McGill University Department of Oncology Member, Department of Oncology Tenure and Promotion Committees for Dr. William Foulkes and Dr. Té Vuong ALAIN NEPVEU 1. Summary of New and Ongoing Research The role of CUX1 in myeloid leukemias. Collaborators: Dr. Alan Peterson, Molecular Oncology Group, McGill University, Montreal; Dr. Sylvie Fournier, Department of Microbiology and Immunology, McGill University, Montreal; Dr. Christian Bédard, Faculty of Veterinary Medicine, Université de Montréal; Dr. Barry Bedell, Department of Pathology, McGill University. The role of cathepsin L in cancer Collaborators: Dr. Matthew Bogyo, Stanford University School of Medicine, USA. Dr. Ekkehart Weber, Institute of Physiological Chemistry, Martin Luther University, Germany, Dr. Shyam S. Chauhan, All India Institute of Medical Sciences, India. Cell cycle control in T cells. Collaborator: Dr. Jacques Bertoglio, Université de Paris X1, France. Role of caspases in cell proliferation Collaborators: Dr. Guy S. Salvesen and Dr. Jean-Bernard Denault, The Burnham Institute, USA. Signal transduction downstream of the PAR2 receptor. 90
  • 91. Department of Oncology Annual Report 2007/2008 Collaborators: Dr. Morley D. Hollenberg and Dr. Nathalie Vergnolle, University of Calgary, Ca. Cooperation between CUX1 and ErbB2 in breast cancer. Collaborator: Dr. William Muller, Molecular Oncology Group, McGill University, Montreal, Ca. Transcriptional control of cell migration and invasion Collaborator: Dr. Morag Park, Molecular Oncology Group, McGill University. 2. Research Grants (new and on-going) CIHR Team in Cancer Progression and Metastasis, Canadian Institute of Health Research $99,814/year, 2006-2011, Co-Applicant (total 8 Co-Applicants), PI: Morag Park Structure/function analysis of the mammalian CDP/Cux protein, Canadian Institute of Health Research, $154,408/year, 2003-2008. PI: Alain Nepveu Function and modulation of CDP/Cux in cell cycle progression, National Cancer Institute of Canada, $143,909/year, 2003-2008. PI: Alain Nepveu The role of nuclear Cathepsin L in cellular proliferation and cancer, Canadian Breast Cancer Research Alliance, $149,271/year, 2003-2008. PI: Alain Nepveu 3. Education and Research Training Laurent Sansregret, Biochemistry, 2002-present, Ph.D. Expected Chantal Cadieux, Biochemistry, 2003-present, Ph.D. Expected Charles Vadnais, Biochemistry, 2006-present, Ph.D. Expected Laura Hulea, Biochemistry, 2006-present, Ph.D. Expected Valérie Kedinger, PDF, 2006-present Course Coordinator 507-312B, Biochemistry of Macromolecules (Dep. of Biochemistry) Lecturer 507-312B, Biochemistry of Macromolecules, 16 hours 507-454A, Nucleic Acids, 4 hours 4. Scientific Reviews Ad hoc reviews Molecular and Cellular Biology Cancer Research Blood Oncogene Journal of Biological Chemistry Gene 91
  • 92. Department of Oncology Annual Report 2007/2008 Carcinogenesis. 5. Invited Presentations Goulet, B., L. Sansregret, L. Leduy, M. Bogyo, E. Weber, S. Chauhan and A. Nepveu. Increased Expression And Activity Of Nuclear Cathepsin L In Cancer Cells Suggests A Novel Mechanism Of Cell Transformation. 5th General Meeting of the International Proteolysis Society. Patras, Greece. October 20-25, 2007. JERRY PELLETIER 1. New and Ongoing Research The cancer cell phenotype is thought to be a manifestation of six essential alterations in cell physiology that collectively dictate malignant growth: self-sufficiency in growth signals, insensitivity to growth-inhibitory signals, evasion of programmed cell death, limitless replicative potential, sustained angiogenesis, and tissue invasion and metastasis. Our previous studies on cancer genetics have suggested that several of these physiological states may be collectively achieved by changes that affect the mRNA translational apparatus of a cell. Our lab is interested in defining the role that deregulated translational regulation plays in the process of transformation and chemoresistance using genetically defined mouse cancer models. One model we use is the Em-myc transgenic mouse model which is prone to B-cell lymphomas and leukemias due to constitutive expression of a c-myc transgene under control of the Ig heavy chain enhancer. The tumor histopathology resembles that of Burkitt’s lymphoma, which typically shares a c-myc translocation to an immunoglobulin locus. Tumor manifestation and clinical course during treatment are easily monitored by palpation of the enlarged lymph nodes and by peripheral blood smears. Tumor response to chemotherapy is measured as the time between remission-to-recurrence of enlarged lymph nodes. In addition, these tumors are transplantable and can be genetically modified ex vivo by retroviral transduction prior to reinjection into syngenic mice. Several features of transgenic mice make them an attractive alternative to cell culture based assays or xenotransplant models: (i) spontaneously arising tumors are never exposed to selective pressure from in vitro growth conditions; (ii) tumors can be treated in their natural environment; (iii) additional genetic alterations can be bred into transgenic mice allowing tumor development and drug response to be correlated with defined genetic lesions, and; (iv) transgenic mice are usually immunocompetent, hence allowing immunological tumor surveillance to occur during tumor progression or treatment phases. We are also interested in applying the tool of chemical genomics to dissect and elucidate the process of eukaryotic protein synthesis. Small molecule ligands, such as rapamycin, have provided formidable insight into the complexity of translational regulation. We propose that similar inhibitors of eukaryotic translation would be valuable tools to better understand the intricacies and regulation of this pathway. Moreover, only from a more 92
  • 93. Department of Oncology Annual Report 2007/2008 complete picture of eukaryotic protein synthesis can one obtain the necessary means to design therapies that target translation to treat disease. Consequently, we have established a research program aimed at identifying inhibitors of mammalian protein synthesis, elucidating their mode of action, and identify their molecular targets. 2. Research Grants (new and ongoing) Support Period: 2005-2008 Amount/yr: $170,640 Agency: NIH Title: High Throughput Assays Targeting Ribosome Recruitment. Investigator: M. Pollak (P.I), N. Sonenberg, G. Fantus, J. Brisson, J. Woodget, S. Dunn, J. Pelletier Support Period: 2005-2009 Amount/yr: $75,000 (my share) Agency: CBCRA Title: IGF and Insulin Signaling Pathways in Breast Cancer Support Period: 2005-2010 Amount/yr: $140,858 Agency: CIHR Title: Translation initiation and cancer: role of the ribosome recruitment step. Support Period: 2006-2009 Amount/yr: $125,735 Agency: NCIC Title: Chemical Dissection of Translation Initiation Support Period: 2006-2011 Amount/yr: $141,000 Agency: CIHR Title: Linking Translation to Chemotherapy Support Period: 2006-2011 Amount/yr: $112,769 (My Share) Agency: CIHR Team Grant (N. Sonenberg – Team Leader) Title: Molecular Basis of Translational Control of Memory Formation: Drug Discovery to Enhance Learning and Memory 3. Education and Research Training Teaching Course Coordinator – Biochem. 507-460A Student Mentor for undergraduate students performing a 3 month research project in my lab. for Biochem 507-491B. Graduate Students Abba Malina 2002- Present Subject: Characterization of Novel Protein Synthesis Inhibitors. Gabriella Vasquez 2007-Present 93
  • 94. Department of Oncology Annual Report 2007/2008 Subject: Structure-Function Relationships of eIF4A Zeina Nasr 2008-Present Subject: Inhibiting Translation Initiation as a Chemotherapeutic Approach John Mills 2003-Present. Subject: Molecular Genetics of Lymphomas. Lisa Linqvist 2005-Present Subject: Chemical Dissection of Translation Initiation. Jason Chen 2006-Present Subject: Molecular Genetics of Lymphomas. Betty Lin 2004-Present Subject: Molecular Genetics of Lymphomas. Rami Sukharieh 2004 – Present (Co-supervised with N. Sonenberg). In Vivo FRET Analysis of Translation Initiation Post-Doctoral Fellows Francis Robert 2003-Present Subject: Role of Translation Initiation in Cancer Initiation and Progression. Regina Cencic 2005-Present Subject: Chemical Inhibitors of Translation Initiation. Urmila Tawar 2007-Present Subject: Chemical Inhibitors of Translation Initiation. Undergraduate Students Natalie Danyliuk Svea Rawe 4. Scientific Reviews Journal Reviewer (ad hoc) Mol. Cell. Biol. J. Biol. Chem. Cell PNAS Grant Reviewer (ad hoc) NCIC CIHR 5. Invited Presentations Invited Speaker: AACR Annual Meeting 2007 (April14th-April 17th) “Therapeutic Potential of Translation Initiation Inhibitors” April 14th, 2007 Los Angeles, CA Pelletier, J. (2007). Therapeutic Potential of translation initiation inhibitors. 50th conference of the CSBMCB on Systems and Chemical Biology. Montreal, Canada (July 5-9, 2007). 94
  • 95. Department of Oncology Annual Report 2007/2008 Pelletier, J. (2007). Therapeutic Potential of translation initiation inhibitors. Boston U. Nov. 5, 2007 Pelletier, J. (2007). Therapeutic Potential of translation initiation inhibitors. U of Mississippi. Nov. 13, 2007 Pelletier, J. (2008). Therapeutic Potential of translation initiation inhibitors. Dartmouth Medical School. Jan 9th, 2008 6. University Activities Administrative Activities Member of Chemical Biology Studentship review panel. Scientific Co-director of McGill High Throughput Screening Facility. Member of the Biochemistry Advisory Committee for Graduate Students. 2007 Kate (March 7th) (Dr. Imed Gallouzi) Ryna Dowling (June 20th, 2006) (April 12, 2007) (Dr. N. Sonenberg) Olivier Binda (Sept. 18th) (Dr. P. Branton) Natasha Chang (Oct. 3) (Dr. Gordon Shore) Matthew Warr – Gordon Shore (Nov. 17th) Barbara Herdy (Nov. 30) (Dr. N. Sonenberg) RAC Meeting Lillian Eochner (Vincent Giguere’s student) 2008 David Shahbazian (NS) Feb. 7th, 2008 Nazhat (Galle), Feb. 11th, 2008 DiPaola Dominique (Hadjoupolous) March 6 ,2008 Mohammed Moustafa (Joe Teodoro) March 10, 2008. Alana Nyugen (Maxime Bouchard) April 28th, 2008 Member of Merck-Frosst Biohazard Safety Committee (2000-Present) ERVIN PODGORSAK 1. Research Grants (new and ongoing) Pre-operative high dose rate brachytherapy in preparation for sphincter preservation surgery for patients with advanced cancer of the lower rectum. T. Vuong, P. Belliveau, J. Couture, E. Franco, J. Jass, E.B. Podgorsak, L. Portelance, C. Reinhold, C. Richard, L. Stein. National Cancer Institute of Canada (NCIC), Toronto $ 254 200. 2004-2009 95
  • 96. Department of Oncology Annual Report 2007/2008 Monte Carlo-based modulated electron beam inverse planning and delivery. Jan Seuntjens, Frank Verhaegen, George Shenouda, Carolyn Freeman, Ervin B. Podgorsak National Cancer Institute of Canada (NCIC), Toronto $ 185 600. 2005-2008 4D Monte Carlo planning, 4D PET/CT based delineation and post-treatment evaluation of lung cancer radiotherapy treatments Canadian Institutes of Health Research (CIHR) J.P. Seuntjens, R. Lisbona, E.B. Podgorsak, L. Souhami, C. Thompson. $ 162 000. 2005- 2008 Educational Grants E.B. Podgorsak. Ministère de la santé et des services sociaux du Québec. “Bourses” for students in medical physics. $ 68 000. 2005-2007 E.B. Podgorsak. Ministère de la santé et des services sociaux du Québec. “Bourses” for students in medical physics. $ 68 000. 2006-2008 E.B. Podgorsak. Ministère de la santé et des services sociaux du Québec. “Bourses” for students in medical physics. $ 68 000. 2007-2009 2. Education and Training Ph.D. Degree Student Completion Edwin O.H. Sham, Physical parameters of very small diameter x-ray beams for linac- based stereotactic radiosurgery. Department of Physics, McGill University, degree granted in March 2008. Current employment: medical Physicist. Nova Scotia Cancer Centre, Halifax, Nova Scotia Web-Based Teaching Material E.B. Podgorsak (editor), Radiation Oncology Physics: A Handbook for Teachers and Students (16 chapters, 696 pages), International Atomic Energy Agency; Vienna, Austria, 2005, STI/PUB/1196 (ISBN 9201073046). Available on-line at: http://www- naweb.iaea.org/nahu/dmrp/syllabus.shtm E.B. Podgorsak and G. Hartmann, Radiation Oncology Physics: A Handbook for Teachers and Students, a set of 2500 slides covering the 16 chapters of the book, available on-line at:http://www-naweb.iaea.org/nahu/dmrp/slides.shtm 3. Scientific Reviews Medical Physics journal Int. J. radiat Oncol Biol Physics Journal of Applied Physics Physics in Medicine and Biology 4. External Committees and Boards Member, Radiotherapy Technology Training Program Committee, Dawson College, Montreal 96
  • 97. Department of Oncology Annual Report 2007/2008 Member, Editorial Board, "Radiology and Oncology" journal Member, Secondary Standards Dosimetry Scientific Advisory Committee (SSC), International Atomic Energy Agency (IAEA), Vienna, Austria Member, Human Resources Action Group (HR-AG) Canadian Strategy for Cancer Control (CSCC), Ottawa, Ontario Member, Commission on Communications, American College of Medical Physics (ACMP) Member, Therapy Standards Subcommittee, American College of Medical Physics Member, Education Council, American Association of Physicists in Medicine (AAPM) Chairman, Education and Training of Medical Physicists Committee, American Association of Physicists in Medicine (AAPM) Member, Medal committee, Canadian Organization of Medical Physicists (COMP) Member, Committee on Radiation Source Use and Replacement, The National Academies, Washington, D.C. Secretary, Board of Chancellors, American College of Medical Physics Member, Board of Directors, CAMPEP, Commission on Accreditation of Medical Physics Teaching Programs 5. Invited Presentations E.B. Podgorsak, Medicinska fizika kot znanost in poklic (Medical Physics: A Science and Profession), Keynote Address, Fifth Congress of Slovenian Physicians from Slovenia and Abroad, Slovenian World Congress, Ljubljana, Slovenia, 31 May - 2 June, 2007. E.B. Podgorsak, Poucevanje in praksa medicinske fizike (Teaching and Training in Medical Physics), Physics colloquium, Department of Physics, University of Ljubljana, Ljubljana, Slovenia, 4 June, 2007. E.B. Podgorsak, Teorija in praksa sevalne dozimetrije (Theory and Practice of Radiation Dosimetry), Student seminar, Department of Physics, University of Ljubljana, Ljubljana, Slovenia, 5 June, 2007. E.B. Podgorsak, Medical Physics: A Science and Profession, Medical Physics seminar, Military University, School of Medicine, Tri-Service Hospital, Taipei, Taiwan, April 15, 2008. 97
  • 98. Department of Oncology Annual Report 2007/2008 E.B. Podgorsak, High Technology Equipment used in Radiotherapy, Seminar for Medical Physicists, Department of Radiotherapy, Tri-Service Hospital, Taipei, Taiwan, April 15, 2008. E.B. Podgorsak, Basics of Radiation Dosimetry and Treatment Planning, Seminar for Medical Physicists, Department of Radiotherapy, Tri-Service Hospital, Taipei, Taiwan, October 16, 2008. E.B. Podgorsak, Special Techniques in Radiotherapy, Seminar for Medical Physicists, Department of Radiotherapy, Tri-Service Hospital, Taipei, Taiwan, October 16, 2008. E.B. Podgorsak, Crisis in Health Care Financing in North America: A Medical Physicists Perspective, Radiation Oncology Rounds, Department of Radiotherapy, Tri- Service Hospital, Taipei, Taiwan, October 17, 2008. E.B. Podgorsak, Gold Medal acceptance speech, Canadian Organization of Medical Physicists (COMP) 54-th annual meeting, Quebec City, Quebec, June 26-28, 2008. 6. Hospital and University Activities Member. Residency Training Committee for Radiation Oncology. Department of Radiation Oncology, McGill University, Montreal Chairman, Graduate committee, Medical Physics Unit, McGill University, Montreal Chairman, Residency Training Committee for Radiation Oncology Physics, Medical Physics Unit, McGill University, Montreal Chairman, Radiation Oncology Physics Residency Training committee, Medical Physics Unit, McGill University, Montreal Member, Radiation Protection Committee, McGill University Health Centre, Montreal MICHAEL POLLAK 1. Summary of New and Ongoing Research We continue to have ongoing collaborations with investigators at Harvard, NIH, and MD Anderson related to IGF-I physiology and cancer. We also have established relationships with pharmaceutical companies including Pfizer and Oncogenix with respect to clinical trials. We have agency funding from Prostate Cancer Foundation (Los Angeles), NIH, NCIC, and CBCRA. 2. Research Grants (new and on-going) IGF and Insulin signaling pathways in breast cancer. Pollak M (PI). Canadian Breast Cancer Research Alliance, $3,000,000, 2005-2009 98
  • 99. Department of Oncology Annual Report 2007/2008 The goal of this study is to conduct translational research regarding the signaling pathways of insulin like growth factor and insulin in breast cancer. Biology of the prostate cancer prevention trial. Lippman SM (PI). National Cancer Institute, ~$18,000,000. 2005-2009. Role : Leads one of six sections of the overall project. The goal of this study is to conduct translational research concerning the biology of prostate cancer prevention Translation Companion Study to PRP.1. Fleshner N (PI) . Ontario Cancer Research Network ~$500,000. 2004-2009. Role: Collaborator The goal of this study is to conduct research related to IGF physiology in prostate cancer. Epidemiology of IGF and Cardiovascular Events, Kaplan RC (PI). National Institute of Health, ~$1,000,000. 2003-2009. Role: Collaborator The goal of this study is to conduct research related to IGF physiology and cardiovascular disease. Glycemic load and obesity: effects in cancer biomarkers, McTiernan Anne (PI) National Cancer Institute. ~$50,000.00. 2005-2010. Role: Co-PI for a component. The goal of this study is to conduct research related the effects of gylcemic load and obesity on cancer biomarkers. Dietary factors influencing IGF signaling in prostate cancer. Pollak M (PI) National Cancer Institute of Canada. ~$350,000.00. 2007-2010. Role: PI The goal of this project is to define the role of macronutrients in influencing cancer growth rate via mechanisms involving insulin and IGF signaling. Prevention of treatment and disease-related morbidity during androgen deprivation therapy: a multicenter proposal. Smith Matthew (PI). Prostate Cancer Foundation (Los Angeles). ~$2,000,000.00. 2008-2011. Role: Co-PI for a component. 3. Education and Research Training Carolyn Algire, Graduate student Matei Mireuta, Graduate student Carly Dool, Graduate student Marie-Jose Blouin, Postdoc Mahvash Zakikhani, Postdoc Esther Piura, Postdoc Takamitsu Inoue, Postdoc 4. Scientific Reviews Editorial Board Cancer Prevention Research 99
  • 100. Department of Oncology Annual Report 2007/2008 5. External Committees and Boards Scientific Advisory Board, Pfizer Global Research 6. Invited Presentations 2007 ASCO Annual Meeting, educational session, Los Angeles, June Endocrine Society Annual Meeting, Toronto, June “Weekend to End Breast Cancer” Scientific Symposium, Toronto, July “Molecular Targeting in Oncology” Symposium, Washington DC, August Amgen Pharmaceuticals Retreat, Washington DC, August US Army Prostate Cancer Research Program Symposium, Atlanta, September Canadian Prostate Cancer Foundation Scientific Meeting, Toronto, September Astra Zeneca Pharma, San Francisco, September Antibody Therapy in Oncology, Quebec, September Medical Oncology Rounds, Cancer Control Agency of BC, October Amgen Pharma, Thousand Oaks, California, October Abbott Pharmaceuticals, Abbott Park, Chicago, October Prostate Cancer Foundation (Capcure) Annual Scientific Retreat, Lake Tahoe, October Invited Plenary Speaker Astra-Zeneca Pharma, Boston, November, Invited Speaker Pfizer (Endocrinology), Miami, November, Invited lecture to clinical trials group University Lund, Sweden, November, Invited Speaker and visiting Professor Bristol Myers Squibb, New York, December, Speaker/organizer, meeting of academic consultants AACR Cancer Prevention Meeting, Philadelphia, December, Invited Speaker Annual San Antonio Breast Cancer Symposium, San Antonio, December, Invited Plenary Speaker (audience of 8000) 100
  • 101. Department of Oncology Annual Report 2007/2008 2008 NCIC Prostate Cancer Alliance, Novel Therapies Symposium, Vancouver, January, Organizing Committee and Speaker NCIC Clinical Trails Group – Breast and I.N.D. Committees, Toronto, January, Invited participant in clinical trial planning session ASCO Genito-urinary cancers symposium, San Francisco, February, Invited Plenary speaker (declined) Pfizer Global Research, New York, February Advisors’ Meeting AACR-NCI Conference on Energetics and Cancer, Washington DC, February University of Toronto, Department of Surgery, Toronto, February 3 rd European Cancer Prevention Meeting, St Gallen, Switzerland, March, Invited Plenary Speaker NCI-EORTC “Targeted Therapy in Oncology” Meeting, Washington, March, Invited Plenary Speaker Canadian Breast Cancer Research Alliance, Reason for Hope Conference, Vancouver, April, Invited Plenary Speaker 7. Hospital and University Activities Director, Cancer Prevention Centre, JGH and Divison of Cancer Prevention, Department of Oncology. McGill University. LORRAINE PORTELANCE 1. Summary of New and Ongoing Research 1) Co Principal Investigator RTOG 0418 A phase II study on the use of pelvic IMRT for the adjuvant treatment of patients with endometrial and cervical cancer This study was activated in March 2006. We have now completed the accrual of the patients receiving treatment for endometrial cancer. An analysis of this subgroup was done and the results of this analysis will be presented at the next American Society of Therapeutic Radiation Oncology in September 2008 in Boston. 2) Dosimetric study comparing IMRT treatment planning to standard treatment planning for the management of vulvar cancer. This dosimetric analysis project was done from August 2007 to April 2008. The results of this analysis will be presented at the next meeting of the Canadian Association of 101
  • 102. Department of Oncology Annual Report 2007/2008 Radiation Oncologists in September 2008 in Montreal and at the next American Society of Therapeutic Radiation Oncology in September 2008 in Boston. 3) Cone beam CT imaging for Image Guided Brachytherapy for cervical cancer On a prospective basis a bank of Ct-studies acquired during brachytherapy implants for patients with cervix cancer is being built. This bank was used to generate dose-volume histogram of the dose delivered to the bladder and to the rectum during High Dose Rate brachytherapy implants. As a first step a comparison was made between the dose assessed by dose-volume histogram and the dose assessed by the standard bladder and rectal points defined by an international convention (ICRU). The results if this analysis will be presented at Canadian Association of Radiation Oncologists in September 2008 in Montreal, at the next American Society of Therapeutic Radiation Oncology in September 2008 in Boston and at the Gynecology Oncology Society meeting in Bangkok in October 2008. We will continue to build this bank of radiological studies for the next 2 years. Outcome in terms of toxicity to the bladder and the rectum are monitered during the follow up of all patients with cervix cancer. An analysis will be done to define if there is any correlation between dose volume histogram showing a high dose to the critical organs and complicatins to the bladder and the rectum. 2. Research Grants (new and ongoing) RTOG 0418 study is a study funded by the NIH through RTOG 3. Research Training Graduate students Dr Hani Elhalabi, 3rd year resident in the McGill Radiation Oncology program; under my supervision Hani is doing an analysis of the Cone Beam CT studies acquired during High Dose Rate brachytherapy implants for patients with cervix cancer. He will do an oral presentation of the results from this analysis at the Canadian Association of Radiation Oncologists (CARO) meeting in September in Montreal, and a poster presentation at the American Society of Therapeutic Radiation Oncology (ASTRO) meeting in September in Boston. In May a second analysis of the data was done and the second analysis results will be presented at the International Gynecologic Cancer Society meeting in Bangkok in October 2008 Fellows Dr. Monique Bloomers, Fellow from Amsterdam, sponsored by a UICC for learning in innovative technology. August-April 2008. Monique was involved in doing dosimetric analysis of Intensity Modulated Radiation Therapy (IMRT) for the treatments of patients with vulvar cancer. She will do a poster presentation of the results of this analysis at the Canadian Association of Radiation Oncologist (CARO) meeting in September in Montreal, and a poster presentation at the American Society of Therapeutic Radiation Oncology (ASTRO) meeting in September in Boston. 102
  • 103. Department of Oncology Annual Report 2007/2008 Dr Wael Elshetawi, Fellow from Egypt, doing an observership at the MUHC; working under my supervision since February 2008. Dr Elshetawi is doing a review of the MUHC experience in the treatment of patients with cervical cancer treated by High Dose Rate Brachytherapy. A poster presentation of the results of a preliminary analysis of this retrospective study will be presented at the International Gynecocologic Cancer Society meeting in Bangkok in October 2008. Wael is also involved in the development of a Web based teaching module on head and neck cancer for the Radiation Oncology residents. 4. Scientific Reviews Journal Reviews Brachytherapy Journal European Journal of Radiation Oncology 5. Conference Organization UICC, Montreal 2012, Member of the organizing committee, for the UICC meeting coming to Montreal in 2012 February 2008, Member of the organizing committee for the McGill Oncology research retreat 6. External Committees and Boards Member of the NCIC audit committee Member of the Board exam writing committee, Royal College of Physicians of Canada Member of the Cervix cancer steering committee, NCIC Member of the cervix cancer task force, NIH McGill liaison for the NCIC -Gynecology cancer division Member of the RTOG, Gynecological cancer steering committee Member of the RTOG Image Guided steering committee (Gynecology committee liaison) Member of the Fondation Quebecoise du Cancer (FQC) board of directors; Vice president of the FQC since December 2006 September 2007, Moderator for the gynecological cancer paper session, Canadian Association of Radiation Oncologists annual meeting, Toronto 103
  • 104. Department of Oncology Annual Report 2007/2008 7. Invited Presentations Invited speaker, Canadian Association of Radiation Oncologists annual meeting September 2007, Toronto. Invited speaker at the workshop on Image Guided External Beam radiation for Gynecological cancer. Invited speaker, Canadian Association of Radiation Oncologists annual meeting September 2007, Toronto. Invited speaker at the workshop on Image Guided Brachytherapy for Gynecological cancer . Invited speaker, RTOG semi annual meeting Image guided committee meeting, update on the research activities of the gynecological cancer committee, January 2008, San Diego Annual meeting of the Quebec Gyneco-Oncologist, February 2008, Quebec city; The role of IMRT in the treatment of patients with gynecological cancer Invited speaker RTOG semi-annual meeting Image guided committee meeting, Update , on the research activities of the gynecological committee, June 2008, Philadelphia 8. Continuing Education Activities Activities attended The use of imaging in gynecological cancer and the role of targeted therapy in the treatment of gynecological caner GOG semi annual Symposium. January 2008, San Diego Cervix cancer management updates GOG semi annual Symposium. July 2008, Chicago 9. Hospital and University Activities Member of the advisory committee to plan the future MUHC, Glenn site campus Chair of the electronic file project, MUHC Radiation Oncology department McGill Principal Investigator for the Gynecology Oncology Group Physician advisor member of the MUHC-CHUM electronic file committee Member of the MUHC cancer registry advisory committee Chair of the Multidisciplinary Oncology Education committee, McGill University Member of the McGill Radiation Oncology residency program; I served 4 years as the residency program director. 104
  • 105. Department of Oncology Annual Report 2007/2008 SHAFAAT RABBANI 1. Summary of New and Ongoing Research Investigation of the roles of growth factors and proteases in tumor progression and skeletal metastasis; novel therapeutic strategies. My laboratory is focused on understanding the molecular mechanisms of development and progression of hormone dependent malignancies (breast and prostate cancer). Towards theses objectives we are examining the roles of proteases like urokinase type plasminogen activator (uPA) and its receptor (uPAR) in the process of tumor invasion, growth and metastasis. The change in the methylation status of uPA promoter is being evaluated as the epigenetic mechanism regulating uPA gene transcription in normal, early, and late stage breast and prostate cancer. Using our well established models of breast and prostate cancer which closely mimics the behavior of these cancers including their propensity to develop skeletal metastasis, we are examining the efficacy of small molecules, peptides, monoclonal antibodies, oligonucleotides, and gene therapy for further evaluation in patients with these common cancers. DNA methylation status of pro-invasive and pro-metastatic genes is being examined to determine disease stage, prognosis and response to therapies targeting these genes. Since both breast and prostate cancer have a high propensity to develop skeletal metastases we are continuing to examine the role of parathyroid hormone related peptide (PTHrP) in hypercalcemia of malignancy. Using our syngeneic and xenograft models of prostate and breast cancer we are examining the capacity of peptides and small molecules directed against prostate secretory proteins, integrins and intracellular signaling pathways to block the development and progression of skeletal metastases. 2. Research Grants (new and ongoing) Examination of the Role of Urokinase (uPA) in Tumor Invasion and Metastasis. C.I.H.R. 1994-2013 Role of Wnt/β-Catenin signaling pathway in prostate cancer. Cancer Research Society of Canada. 2007-2009 3. Research Training Mr. Nicholas Shukeir, Ph.D. student 4. Scientific Reviews Journal Reviews Cancer Research Clinical Cancer Research Current Cancer Drug Targets 105
  • 106. Department of Oncology Annual Report 2007/2008 JANUSZ RAK 1. Summary of New and Ongoing Research Since last year our laboratory concentrated on explorations in three major areas, as documented by the papers listed below. First, we pursued our studies in to the role of oncogene-containing microvesicles (oncosomes) that tumor cells release into their vicinity and circulation. This work concentrated around the oncogenic receptor tyrosine kinases (EGFR, EGFRvIII) and included the biological consequences of microvesicle incorporation by indolent cancer and host cells for tumor progression. Second, our work on vesicular EGFR is a continuation of another ongoing effort in our laboratory, that is to understand the role of tissue factor (TF) in cancer progression. Like EGFR, TF is a signaling receptor produced and shed as microvesicles by cancer cells, and capable of incorporation to other cells. We continue to study how TF is regulated (e.g. by EGFR) and contributes to tumor progression through its signaling and procoagulant functions, including as an element of the putative cancer stem cell niche. Third, we continued our studies on the role of vascular aging and atherosclerosis in tumor progression, metastasis, angiogenesis and responses to therapy. 2. Research Grants (new and ongoing) Canadian Institutes of Health Research (CIHR) – Regional molecular heterogeneity in glioblastoma multiforme - operating grant; Co-applicant (PI – Abhijit Guha); Apr. 2007 – Apr. 2012; $ 830,000 (administered by the Guha Laboratory) Canadian Institutes of Health Research (CIHR) – Studies on venous thromboembolism; Operating Team Grant; Co-applicant (PI - Jeffrey Weitz); Apr. 2006 – Apr. 2011; $ 4,000,000 ($30,000 annually were administered by the Rak Laboratory) Cancer Research Society (CRS) - Vascular aging and atherosclerosis as modifiers of tumor progression, angiogenesis and responsiveness to therapy , operating grant, Sep 2007 - Sep 2009; $120,000 National Cancer Institute of Canada (NCIC), Canadian Cancer Society (CCS) – The role of oncogene-containing microvesicles in tumor angiogenesis, operating grant; Principal Investigator; Jul. 2008 - Jul. 2011; $ 408,000 (100% of these funds were administered by the Rak Laboratory National Cancer Institute of Canada (NCIC), Canadian Cancer Society (CCS) – Tissue factor in tumor progression and angiogenesis operating grant; Principal Investigator; Jul. 2007 - Jul. 2010; $ 360,000 (100% of these funds were administered by the Rak Laboratory) National Cancer Institute of Canada, Canadian Cancer Society (CCS) Reaearch Scientist Award – Targeting oncogene-driven tumor angiogenesis, Salary award 2002 – 2008 – app. $ 90,000 annually 106
  • 107. Department of Oncology Annual Report 2007/2008 National Cancer Institute of Canada (NCIC), Canadian Cancer Society (CCS) – Tagreting oncogene driven tumor angiogenesis. Dissecting the role of angiogenesis inhibitors. operating grant: Jul. 2004 - Jul. 2007 348,000 (100% of these funds were administered by the Rak Laboratory); National Cancer Institute of Canada (NCIC), Canadian Cancer Society (CCS) – Tissue factor in tumor progression and angiogenesis operating grant; Principal Investigator; Jul. 2004 - Jul. 2007; $ 427,800 (100% of these funds were administered by the Rak Laboratory) National Cancer Institute of Canada (NCIC) – Vascular tumor microenvironment as a regulator of tumor progression: studies on K-ras mutations in colorectal cancer under the influence of antiangiogenic therapy - operating grant; Co-applicant (PI – B. Coomber); Jul. 2005 – Jul. 2008; $ 284,784 (funds administered by Coomber Laboratory) 3. Education and Research Training 1 PhD Student 2 MSc Students 2 Postdoctoral Fellows 2 Research Assistants McMaster, Hamilton Chloe Milsom, PhD student in training at McMaster University, expected to graduate in the Fall of 2008 Showkat Hosseini, PDF, recruited for a short period of time to facilitate completion of a collaborative study at HRC (June-September 2007) MCHRI Khalid Al-Nedawi, PDF, in training at McGill University (MCHRI), 2005-present Nathalie Magnus, MSc student, MCHRI/ McGill: Jan. 2007 – present Alexander Dombrovsky, MSc student, MCHRI/McGill; Sep. 2007 – present Brian Meehan, Senior Research Assistant, MCHRI/McGill: Apr. 2006 – present Rocksan Dube, Junior Research Assistant, MCHRI/McGill, 2006- Dec 2007 4. Scientific Reviews Grant review panels and invitations Canadian Breast Cancer Foundation; Region Ontario – Research Fellowship Panel Member, Feb. 2008 – 5 grants 107
  • 108. Department of Oncology Annual Report 2007/2008 Canadian Institutes of Health Research – Grant Review Panel; Cancer B/CPT – Invitation declined (scheduling conflict) Spring 2008 Cancer Research Society – Grant Review Panel D, 2008 – 10 grants NCIC, Clinical Fellowship Panel Member- In November 2007 panel did not have a formal session due to drop in applications) McGill University CFI Stage IV Internal Review Panel, McGill; Mar. 2008 – 4 grants Montreal Children’s Hospital Research Institute – Fellowship Review Panel, Panel Chair – 3 applications were appraised in detail, all 12 files were reviewed. Editorial Board Member AITE Ad hoc Journal Reviewer Amer. J. of Physiology (Heart&Circ) Arterioscletosis Thrombosis&Vasc. Biol. Blood Cancer CELL FASEB Journal J. of Clinical Investigation(JCI) J. of Investigative Dermatology (JID) J. of Thrombosis and Haemostasis(JTH) Neoplasia Thrombosis and Haemostasis (TH) Thrombosis Research (TR) 5. Conference Organization Montreal Symposium on Angiogenesis and Metastasis 2009 - Co-organizer 6. External Committees and Boards Grant panels as indicated above Scientific Advisory Board - Mendel Oncological Centre, Novi Jicin, Czech Republic 7. Invited Presentations Local Montreal Regional Brain Tumour Interest Group (MRBTIG), Montreal Brain Tumor Centre, MNI - Unique challenges of developing antiangiogenic therapy for pediatric brain tumors; May 23, 2008, Montreal, QC 108
  • 109. Department of Oncology Annual Report 2007/2008 Department of Oncology, McGill University, MUHC, Montreal General Hospital – Are we ready to use antiangiogenic and oncogene-directed agents? The advent of molecularly based (targeted) therapies in pediatric brain tumors. April 28, 2008, Montreal, QC Department of Oncology Annual Retreat, McGill University, Jewish General Hospital – Vascular co-pathogenesis in cancer. Implications of age-related blood vessel diseases for antiangiogenic therapy; Chateau Vaudreuil, March 13-14, 2008; Montreal, QC Montreal Children’s Hospital, Pediatric Grand Rounds – The advent of molecularly based (targeted) therapies in pediatric brain tumors. Are we ready to use antiangiogenic and oncogene-directed agents; Jan. 30, 2008, Montreal, QC Regional and National Guest Lecture Series, Le Centre de Recherche de L’Hôtel-Dieu de Québec - Vascular determinants of tumor progression; Nov. 30, 2007; Quebec City, QC Cell Biology Seminars, University of Toronto - The role of tumor cell derived microvesicles in disease progression; Dec. 7, 2007, Toronto, ON BTRC Seminars, Arthur and Sonia Labatts Brain Tumor Research Centre, University of Toronto - Age-related vascular comorbidities as modulators of tumor angiogenesis and antiangiogenesis; Dec. 6, 2007, Toronto, ON 2nd Bi-annual Conference for Canadian Pediatric Hematology/Oncology Program Directors and Residents - Progress and unique challenges in antiangiogenic therapy of pediatric malignancies Fairmont, Le Chateau Montebello, April 17 - 19th, 2008, Montebello, Quebec Canadian Prostate Cancer Research Initiative (CPCRI/NCIC) Canadian Opportunities and Experiences Workshop, Vancouver - 2008: The Roadmap from Discovery to the Clinic – Thrombin and coagulation signaling as potential therapeutic targets in prostate cancer; Jan. 12, 2008, Vancouver, BC International Invited Plenary Speaker, Fourth International Conference on Thrombosis and Hemostasis Issues in Cancer (ICTHIC) - The role of tumor- and host-related tissue factor pools in oncogene-driven tumour progression; October 26-28, 2007, Bergamo, Italy Seminar Series, Institute of Oncology, Gliwice – Oncogenes, angiogenesis and the vascular age in tumor development, Oct. 23, 2007; Gliwice, Poland Polish Academy of Sciences, L. Hirszfeld Institute of Immunology and Experimental Therapy – Quo vadis – goals and methods of medical training in the era of information overload; Oct. 17, 2007; Wroclaw, Poland 109
  • 110. Department of Oncology Annual Report 2007/2008 8. Continuing Education Activities attended or lectured Pediatric Oncology Grand Rounds - Jan 30, 2008 (lectured, as above) McGill Oncology Grand Rounds - Apr 28, 2008 (lectured, as above) 9. Hospital and University Activities Member of the Animal Facility Visitation Team (Animal User Committee) involved in exploring the optimal administrative solution implemented in animal facilities of research facilities in Montreal (2007) – 7 hours; visits to: MGH Animal Facility Medical Sciences McIntyre Building Animal Facility MCHRI on site discussion Member of the Animal User Committee at the MCHRI Member of the Occupational Health and Safety Committee at the MCHRI Hosting or co-hosting invited speakers of the MCHRI Seminar Series. Dr. Nigel Mackman, University of North Carolina, Dr. Aghijit Guha, University of Toronto, Toronto ON Dr.Arnim Pause, McGill Cancer Centre, Montreal, QC Dr. Willam Muller, McGill Cancer Centre, Montreal, QC Hosting or co-hosting invited speakers of the MCH Hematology-Oncology Dr. Mark Kieran, Pediatric Oncology, Dana Farber Cancer Centre, Harvard Medical School, Boston, MA Participation in MCH Hematology-Oncology review and accreditation meeting Member of the CFI/LSIE Grant writting team (June-September) – Theme 6 – Cancer – The grant of nearly $ 100M was awarded, Theme 6 was highly appraised. Hosting or co-hosting invited speakers of the McGill Cancer Centre Seminar Series - 2007-2008: This amounts to 10 hours for each external invitee (total of 30 hours) Dr. Donald McDonald, UCSF, San Francisco, CA Dr. Gavin Thurston, Regeneron, Tarrytown, NY Dr. Giannoula Klement, Dana Farber Cancer Centre, Boston, MA Seeking invitees for the upcoming MCH and MCC Seminar Series A time investment of approximately 5 hours thus far. (Drs. Ellis, Gilbertson and Coussens have been identified and contacted) 110
  • 111. Department of Oncology Annual Report 2007/2008 DAVID ROBERGE 1. New and Ongoing Research Current Clinical Research A Phase I-II trial of stereotactic body radiation therapy / radiosurgery (SBRT) in the treatment of pulmonary metastases Principal investigator (in preparation) A Phase II study of hair sparing intensity modulated whole brain radiotherapy plus topical Tempol in the treatment of brain metastases Principal investigator (in preparation) A Phase I dose escalation trial of Temozolomide delivered concurrently with stereotactic radiosurgery in the treatment of recurrent brain metastases Principal investigator Utility of 3D ultrasound for assessing sarcopenia through measurement of muscle volume and surface area Principal investigator Tazarotene 0.1% cream for the treatment of cutaneous T-cell lymphoma: a prospective study. Principal investigator GEN #07-019 An observational study of skin elasticity as a measure of late radiation toxicity Principal investigator RTOG 0320: A phase III trial comparing whole brain radiation and stereotactic radiosurgery alone versus with temozolomide or erlotinib in patients with non-small cell lung cancer and 1 to 3 metastases. Local principal investigator RTOG 0330: A Pilot Phase II Study Of Pre-Operative Radiation Therapy And Thalidomide (IND 48832; NSC 66847) For Low Grade Primary Soft Tissue Sarcoma Or Pre-Operative MAID/Thalidomide/Radiation Therapy For High/Intermediate Grade Primary Soft Tissue Sarcoma Of The Extremity Or Body Wall. Local principal investigator RTOG 0438: A Phase I trial of highly conformal radiation therapy for patients with liver metastases Local principal investigator RTOG 0630: A Phase II trial of image guided preoperative radiotherapy for primary soft tissue sarcomas of the extremity Local principal investigator RTOG 0618: A Phase II Trial of Stereotactic Body Radiation Therapy (SBRT) in the Treatment of Patients with Operable Stage I/II Non-Small Cell Lung Cancer Local principal investigator 111
  • 112. Department of Oncology Annual Report 2007/2008 RTOG 0614: A randomized, Phase III, double-blind, placebo-controlled trial of memantine for prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy Local principal investigator Effects of fractionated whole brain radiotherapy on the permeability of blood brain and blood tumor barriers as measured with MRI. Wong P, Pike B, Tampieri D, Chankowsky J, Mihalcioiu C, Roberge D, Muanza T Local principal investigator 2. Teaching and Training McGill University Residency in Radiation Oncology: Supervision and evaluation of residents and medical students Residents supervised Dr William Tong (R3, period 10-11) Dr Ronny Rotondo (R2, period 12-13) Dr Fleure Gallant (R2, period 1-2) Summer Students Tanya Skamene (medical student) Canadian Preparatory Course in Clinical and Radiation Oncology, Ottawa Regional Cancer Center, Ottawa ON Instructor & examiner Canadian Radiosurgery Society (CaRS) Annual Scientific Meeting, Mont Tremblant, QC, Meeting Director 3. Scientific Reviews Journal Reviews International Journal of Radiation Oncology Biology and Physics Journal of Technology in Cancer Research and Treatment Clinical Medicine: Oncology Canadian Association of Radiotherapy (CARO) 2007 annual meetings 2007 and 2008, Scientific review committee - member Canadian Association of Radiosurgery (CaRS) 2008 annual meeting, Scientific review committee - head 4. Presentations Use of platinum embolization coils for targeting liver lesions in stereotactic body radiotherapy/radiosurgery. Roberge D, Ruo R, Parker W, Patroccinio H, Valenti D. Congress of the International Steretactic Radiosurgery Society, San Francisco, June 23rd- 27th 2007 112
  • 113. Department of Oncology Annual Report 2007/2008 Proposal for a randomized trial of a post-operative radiosurgery boost following whole- brain radiotherapy for single resected brain metastases. Roberge D. Canadian Radiosurgery Society (CaRS) Meeting, Niagara on the lake Feb 29th 2008 Radiochirurgie de lit opératoire suivant l’excision de métastases cérébrales uniques. Roberge D, Souhami L Association des radio-oncologues du Québec (AROQ), congrès annuel, St-Sauveur, Québec June 6-8, 2008 5. Hospital and University Activities Hospital Equipment purchasing committee Portal imaging committee Radiosurgery committee Residency research committee McGill University Soft tissue sarcoma site leader, McGill Radiation Oncology RUIS URI SARAGOVI 1. Research Grants (new and ongoing) Targeting receptors, Cancer Research Society, 60,000 per year , 11/2006-11/2008 Neurotrophic Mechanisms in Neuroblastoma, Role: co-PI (with Nina Schor), NIH, $55,000 per year , 02/2004-09/2008 Small Molecule Ligands of TrkC and p75 Receptors, Role: co-PI (with Kevin Burgess), NIH, $143,00 per year, 2005-2009 Allosteric Regulators of G-coupled receptors, Role: co-PI (with Michel Bouvier and 9 others), CIHR Group Grant, $60,000 per year (my share), 2005-2009 Alzheimer’s Society of Canada Research Grant, Role: PI, AD Society, $110,000 per year, 2006-2009 Chemistry and Biology of Gangliosides, Role: PI with Bill Lubell (U. de Montreal), CIHR, $150,000 per year, 09/2005-08/2008 Research Contract with Mimetogen Pharmaceuticals, Role: PI Managed by the Office of Tech. Transfer , $ 1.1 Million, 11-2007 – 03-2009 113
  • 114. Department of Oncology Annual Report 2007/2008 2. Patents Filed and active under prosecution Pharmaceutical composition with neurotrophic-like activity. Authors: H. Uri Saragovi, Sergei Maliartchouk. CA2,212,315 (1997); PCT/CA98/00749; EP98938559.6 Ligands of Gangliosides and their activity. Authors: H. Uri Saragovi, Martin Gagnon (2002). US Patent Application No. 10/528,542 Neurodegeneration as a consequence of regulation of expression of pressure-regulated genes. Author: H. Uri Saragovi. US filing (2005). Methods for neuroprotection. 2008 Ligand-targeted AMF-toxin conjugates for cancer therapeutics (lead applicant Robert Nabi, University of British Columbia). 2008 Compounds targeted for specific cells, with reduced systemic toxicity. Authors: H. Uri Saragovi, Veronique Guillemard. US filing (2000) 3562-003 PCT 3. Contracts & Licenses (Managed By OTT) Mimetogen Pharmaceuticals Inc Neubody Inc ProsCan Pharma Inc 4. Education and Research Training Students Lubjica Ivanisevic Wenyong Tong Tony Li (now somewhere else) Michael Perron Post-doctoral Fellows Paul Hein Fouad Brahimi Shafinaz Chahudary 5. Scientific Reviews Editorial Boards Journal of Biological Chemistry Current Medicinal Chemistry -CNS Medicinal Chemistry Reviews Ad Hoc Reviews Journal of Neuroscience Journal of Medicinal Chemistry Nature Chemistry and Biology 114
  • 115. Department of Oncology Annual Report 2007/2008 Journal of the American Chemical Society ACS Chemical Biology Neuron Nature Medicine Grant Panels Panel Member. Cancer Research Society, Panel D. Panel Member. Agencia Nacional de Promoción Científica y Tecnológica de la Republica Argentina. Ad-Hoc External reviewer CIHR Neuroscience National Cancer Institute of Canada NSERC 6. Conference Organization Organizing Committee, American Peptide Society, Montreal June 2007 Organizing Committee, Katzir Conference of the Nervous System (the NGF Conferences), Jerusalem Sept 2008 7. External Committees and Boards Scientific Advisory Board Mimetogen Pharmaceuticals (Montreal) Proscan Pharmaceuticals (Montreal) Thetis Pharma (San Francisco, California) 8. Hospital and University Activities Lady Davis Institute Health and Safety Committee GEORGE SHENOUDA 1. Summary of New and Ongoing Research Phase II trial of neo-adjuvant Temozolomide prior to combined Temozolomide and concurrent accelerated hypofractionation external beam radiotherapy followed by adjuvant Temozolomide in patients with newly diagnosed Glioblastoma Multiforme. Assessment of hippocampus volumetric changes and neuro-cognitive functional deficits in patients with limited stage small lung cancer and receiving prophylactic cranial irradiation 2. Research Grants (new and ongoing) Unrestricted educational fund from Astra-Zeneca: 2000 $ 115
  • 116. Department of Oncology Annual Report 2007/2008 Unrestricted educational fund from Abbott laboratories: 5000 $ 3. Education and Research Training Hamdy Sakr: Fellow CNS Ahmed Tael: Fellow Head and Neck Wael El-Sheshtawi: Fellow head and Neck Valerie Panet Raymond: Resident 4 David Hauerstock: Resident 4 4. Scientific Reviews Journal Reviews International Journal of Radiation Oncology Biology Physics International Journal of Radiation Oncology Canadian Journal of Ophthalmology 5. Conference Organization Radiation Oncology Research retreat McGill University (Co-organizer) 6. External Committees and Boards Canadian Association of Radiation Oncology: Specialty Committee Radiotherapy Oncology Group (RTOG): Head and Neck steering committee. 7. Continuing Education Activities attended or lectured Attendance of two semi-annual meetings of the RTOG 8. Hospital and University Activities Radiation Oncologist MUHC Program Director Radiation Oncology McGill University Oncology Undergraduate ICM Chair, department of Oncology, McGill University (until June 2008) Basis of Medicine: Unit 1, small group session coordinator Back to Basis: small group leader Communication skills course. 116
  • 117. Department of Oncology Annual Report 2007/2008 HENRY SHIBATA 1. Summary of New and Ongoing Research National Surgical Adjuvant Breast and Bowel Project (NSABP) as principal investigator prospectively randomized clinical trials group ongoing patient accrual to B-39 40 41 etc 2. Resarch Grants (new and ongoing) Ongoing NSABP FUNDED Research since 1974. As part of the NCI USA funding of the NSABP 3. Scientific Reviews Editorial Boards Cancer Control Journal of the Moffitt Cancer Center Journal of the American Association of Cancer Education Oncology Exchange The Journal for Canadian Cancer Professionals 4. Invited Presentations Lectured to the Montreal Academy Club Feb 2008 5. Hospital and University Activities Board member of the Executive Committee of the MUHC Cancer Care Mission Board member of the Executive committee of the Cedars Breast Clinic On the Board of Directors of the Cedars Cancer Institute, a fund-raising organization for the RVH and now the MUHC for the Oncology Program. Serving as the Medical Advisor to the Cedars Cancer Institute 4 days/month As Medical Advisor since 2001, he is the Chair of the Medical Advisory Committee which sets priorities for the requests for funds from the oncology-related activities of the MUHC. Also chair the Medical Advisory Committee of the MUHC Cancer Registry Member of the Sarah Cook Fund for Oncology at the Montreal Children’s Hospital GWEN SPURLL 1. Summary of New and Ongoing Research Audit of albumin use MUHC. Outcomes in low molecular weight heparin bridging. Anticoagulation in patients with previous adverse pregnancy outcomes 117
  • 118. Department of Oncology Annual Report 2007/2008 2. External Committees Hemovigilance (advisory to the Minister of Health on blood safety.) Royal College Committee on Transfusion Medicine Laboratory oversight committee for Canadian HLA Laboratories 3. Invited Presentations Rotation of Blood Stocks to the far north, to Hemovigilance 4. Continuing Education Activities attended or lectured Canadian Society for Transplant American Society for Histocompatibility and Immunogenetics Canadian Society for Transfusion Medicine LUIS SOUHAMI 1. Research Grants (new and ongoing) TMPRSS2-ERG gene fusion and time to LHRH agonist refractoriness in prostate cancer patients with biochemical failure. M Tamim, L Souhami, Sanofi Aventis $230,000 2008-2010 Prospective study assessing the predictive value of TMPRSS2-ERG gene fusion in prostate cancer patients treated with radical radiation. M Tamim, L Souhami, Tarek Bismar. Abbott CARO Uro-Oncology Radiation Awards Competition (ACURA) $28,500 2008-2010 Stereotactic radiosurgery and temozolomide in recurrent brain metastases . D Roberge, L Souhami, T Muanza. Schering-Plough $ 20, 000 2005-2007 A randomized trial of a shorter fractionation schedule for localized carcinoma of the prostate. C Catton, H Lukka, P Warde, M Levine, J Julian, A Gafni, G Bauman, M Parliament, J Wu, T Pickles, L Souhami, JP Bahary. Canadian Institutes of Health Research $2,209,971 2005-2012 4D Monte Carlo planning, 4D PET/CT-based delineation and post-treatment evaluation of lung cancer radiotherapy treatments. J P Seutjens, L Souhami, E Podgorsak, R Lisbona, C J Thompson . Canadian Institutes of Health Research $138,562. 2005-2008 2. Scientific Reviews Editorial Boards Revista Brasileira de Cancerologia Current Oncology Journal of Radiosurgery International Journal of Radiation Oncology Biology Physics 118
  • 119. Department of Oncology Annual Report 2007/2008 Technology in Cancer Research & Treatment Applied Cancer Research Our Voice HU Revista Journal of Oncology Ad Hoc Reviews: Radiology International Journal of Gynecological Cancer Canadian Journal of Neurological Sciences Cancer The Canadian Journal of Oncology Journal of Palliative Care Canadian Journal of Urology Expert Review of Anticancer Therapy Gynecologic Oncology 3. Conference Organization Canadian Radiosurgery Society meeting. Mont Tremblant, QC, February 29-March 1, 2008 4. External Committees and Boards Member, Gynecology Committee, National Cancer Institute of Canada Principal Investigator (McGill University), Radiation Therapy Oncology Group Member, Brain Committee, Radiation Therapy Oncology Group Member, Executive Gynecology Committee, National Cancer Institute of Canada Chairman, Cervix Cancer Working Group. National Cancer Institute of Canada. Member, Neuro-Oncology Committee. National Cancer Institute of Canada. Member, Executive Neuro-Oncology Committee. National Cancer Institute of Canada. Member, Executive Committee of the Lung Cancer Committee. Radiation Therapy Oncology Group Member-at-Large (elected), Radiation Therapy Oncology Group Consultant, International Atomic Energy Agency (IAEA) on 3D planning in cervix cancer: principles and critical review. 119
  • 120. Department of Oncology Annual Report 2007/2008 Regional Training Course on Evidence based treatment of Cervical Cancer. Sao Paulo, Brazil, March 10-14, 2008. Abstract reviewer, Annual Meeting of the American Society of Therapeutic Radiology and Oncology, 2007. Site visit surveyor - NCI sponsored RTOG Quality Control Committee site visit of the H Lee Moffitt Cancer Center, Tampa, Florida, April 16-17, 2007. Site visit surveyor - NCI sponsored RTOG Quality Control Committee site visit of the University of Utah Cancer Center, Salt lake city, Utah, April 28-29, 2008. 5. Invited Presentations Souhami L, Bayley A. IMRT in prostate cancer. GUROC meeting. Toronto, ON, January 12-13, 2007. Souhami L. Completely resected stage III NSCLC: the role of post-operative radiotherapy. Improving outcomes in the management of lung cancer. Gold Coast, Australia, March 8-10, 2007 Souhami L. Brain metastases in NSCLC. Role of new agents and preventive brain radiotherapy. Improving outcomes in the management of lung cancer. Gold Coast, Australia, March 8-10, 2007 Souhami L. The role of radiotherapy in post-prostatectomy patients. II Congresso Cearense de Cancerologia. Fortaleza, Brazil, April 28-30, 2007. Souhami L. Brain metastases. State of the art. II Congresso Cearense de Cancerologia. Fortaleza, Brazil, April 28-30, 2007. Souhami L. Current management of brain metastases. Grand Rounds, Hospital do Cancer. Fortaleza, Brazil. May 4, 2007. Souhami L. The role of radiosurgery in the treatment of gliomas. II International Symposium on Stereotactic Body Radiation Therapy and Stereotactic Radiosurgery. Orlando, FL. February 22-24, 2008. Souhami L. Radio-chemotherapy in locally advanced cervix cancer. Regional Training Course on Evidence based treatment of Cervical Cancer (sponsored by the International Atomic Energy Agency). Sao Paulo, Brazil, March 10-14, 2008. Souhami L. Post-operative radiotherapy in cervix cancer. Regional Training Course on Evidence based treatment of Cervical Cancer (sponsored by the International Atomic Energy Agency). Sao Paulo, Brazil, March 10-14, 2008. 120
  • 121. Department of Oncology Annual Report 2007/2008 Souhami L. Brachytherapy fractionation. Regional Training Course on Evidence based treatment of Cervical Cancer (sponsored by the International Atomic Energy Agency). Sao Paulo, Brazil, March 10-14, 2008. Souhami L. 3D planning in cervix cancer: principles and critical review. Regional Training Course on Evidence based treatment of Cervical Cancer (sponsored by the International Atomic Energy Agency). Sao Paulo, Brazil, March 10-14, 2008. Souhami L. Radiation and hormone therapy for localized prostate cancer: what the past holds for the future? Regional Urologic Cancer Update Symposium. Burlington, Vermont, March 28, 2008. SIMON TANGUAY 1. Education and Training Renal angiogenesis – Clinical implication, Experimental and Clinical Oncology Course 516-635D, Faculty of medicine – McGill University February 18 2008 2. Scientific Reviews Editorial Boards Co-Editor of Our Voice, Publication for patients with prostate cancer 3. Conference Organization World Uro-Oncology update, Société Internationale d’Urologie, Santiago, Chile, November 19-22 2008. Member of the scientific committee National Kidney Cancer Registry Planning Meeting, January 11 2008, Toronto. Co-Chair with Dr M. Jewett 4. External Committees and Boards Member of the Test Committee in Urology Royal College of Physician and Surgeons of Canada Canadian Prostate Health Council National Cancer Institute of Canada, Chair – Kidney Disease Oriented Group National Cancer Institute of Canada, Member of executive committee Quebec Urological Association, Treasurer Quebec Urological Association – Foundation Treasurer Nominating Committee – Member, Canadian Urological Association 121
  • 122. Department of Oncology Annual Report 2007/2008 Adjunct General Secretary, Société Internationale d’Urologie Deputy delegate – Canadian section, Société Internationale d’Urologie 5. Invited Presentations Highlight from AUA on renal cancer. Quebec Urological Association, Montreal June 2nd 2007 Treatment options in advanced prostate cancer. CanSupport lecture; Cedar institute (Public Lecture). Montreal General Hospital September 25th 2007 Active surveillance for prostate cancer: Can we predict progression. Urologic Oncology: Advances in Clinical Practice. M.D. Anderson Cancer Center. Houston, TX October 27 2007 Why a national registry? National Kidney Cancer Registry Planning Meeting. Toronto January 11 2008 Role of cytoreductive nephrectomy in new era. Canadian Kidney Cancer Forum. Mont- Tremblant February 1 2008 6. Hospital and University Activities Co-director, Clinical research, McGill Urology Associates Director urologic oncology, McGill University Health Center Finance committee –– Chair, McGill Urology Associates McGill Oncology Management committee Promotion and Tenure Committee, Department of Surgery, McGill University Recruitment and Retention Committee, Department of Surgery, McGill University MARC TISCHKOWITZ 1. Summary of New and Ongoing Research Study of DNA repair genes in breast cancer predisposition (McGill) Analysis PALB2/FANCN breast cancer familes (Program in Cancer Genetics, McGill University, Departments of Oncology, Human Genetics and Pathology, McGill University, The Research Institute, McGill University Health Centre, McGill University and Genome Québec Innovation Centre, Dana-Farber Cancer Institute and Harvard Medical School, The Breakthrough Breast Cancer Research Centre, Institute of Cancer 122
  • 123. Department of Oncology Annual Report 2007/2008 Research, London UK, Division of Experimental Therapy, Netherlands Cancer Institute, Amsterdam, The Netherlands, Women's College Research Institute, Women's College Hospital, Toronto. 2. Research grants (new and on-going) Canada Foundation for Innovation: $103,795 awarded in March 2006 for laboratory infrastructure. Rethink Breast Cancer: $70,000 awarded July 2006: Characterization of the Fanconi Anemia and Bloom Syndrome genes in sporadic and hereditary breast cancer. FRSQ Chercheur-bousier clinicien Junior 1 awarded July 2007 Susan G. Komen for the Cure Career Catalyst Research Project Title: PALB2 - A new hereditary cancer gene: implications for treatment $290,000 awarded March 2008 Weekend to End Breast Cancer – Ten genes for breast cancer $50,000 awarded November 2007 3. Education and Research Training Undergraduate students, graduate students, postdocs/fellows Rachel Kyle May 2008 – summer student David Novak – postgraduate student 4. Scientific Reviews Editorial Boards Member of Editorial board, Clinical & Investigative Medicine 5. External Committees and Boards Clinical Practice Committee, Canadian College of Medical Genetics 6. Invited Presentations PALB2/FANCN – Another link between Fanconi Anemia and breast cancer Invited Speaker BRCA: Today & Tomorrow conference, Montreal What has Fanconi Anemia taught us about breast cancer? CIHR Strategic Training Program, Winnipeg. May 8th, 2008 7. Continuing Education Activities Attended or Lectured Attended JGH tumor boards (regular) NCIC conference, Toronto, Oct 2007 BRCA today and Tomorrow, Montreal, Oct 2007 123
  • 124. Department of Oncology Annual Report 2007/2008 Lectured August 3rd 2007 Urological tumors in the cancer genetics clinic Montreal Children’s Hospital Friday Lecture and Seminar Series February 18th, 2008 Colorectal Cancer – who should be referred? JGH CRC rounds February 21st, 2008 Genetic screening for breast cancer Jewish General Hospital Surgical Rounds February 25th, 2007 Familial Mediterranean Fever Jewish General Hospital Medical Rounds 8. Hospital and University Activities JGH Molecular Diagnostics Steering Committee McGill RUIS Genetics Subcommittee Director, Visiting Speakers Program in Oncology, Department of Oncology, McGill University Curriculum Committee, McGill Genetic Counselling MSc program McGill University Oncology Committee Member of Fellowship training committee, McGill Medical Genetics Residents. PATRICIA TONIN 1. Summary of New and Ongoing Research Research interests and accomplishments There are two principal areas of research conducted in my lab. The areas of research are described on the web site: www.toninlab.mcgill.ca. The first involves the identification of genetic factors that are implicated in the development and/or progression of human epithelial ovarian cancer. 124
  • 125. Department of Oncology Annual Report 2007/2008 A. The Molecular study of Human Epithelial Ovarian Cancer More than 70% of women diagnosed with ovarian cancer die of the disease. Our knowledge of the molecular events associated with the development and progression of epithelial ovarian cancer has been limited by the lack of a suitable model system. Also, since the disease is often diagnosed at a late stage when numerous complex chromosomal changes have already taken place, the early molecular events remain largely unknown. Research in the lab is focused on the identification of tumour suppressor genes, particularly those physically associated with chromosomes 3p and 17q. Various molecular genetic techniques are used to identify them, which include, allelic content analysis such loss of heterozygosity studies and single nucleotide (SNP) polymorphism analyses, large-scale gene expression assays (Affymetrix platform), and more recently functional approaches based on chromosome transfer fragment and gene complementation. Recent accomplishments include the generation of chromosome 3 and 17 specific transcriptome maps of ovarian cancer. In collaboration with our colleagues at the CHUM-Notre Dame, we investigate gene expression profiles of ovarian cancer samples with the aim of identifying signature patterns of gene expression in order to elucidate molecular pathways important in ovarian tumourigenesis. Recent accomplishments include the identification of apoptotic molecular network identified by microarray associated with the TRAIL pathway and TF4/BTNA3.2 and GCS as candidate mRNA prognostic markers in epithelial ovarian cancer. B. Breast and Ovarian Cancer Susceptibility Genes Hereditary breast and ovarian cancer accounts for approximately 5-10% of all breast and ovarian cancers. A large majority of cancer families are attributed to germline mutations in BRCA1 and BRCA2. However, about 40% of cancer families are negative for mutations in these known genes. Our group is also focused on the determining the contribution of known and unknown cancer susceptibility genes to inherited predispositon to breast and ovarian cancer. Recent accomplishments include the analysis of high risk families for germline TP53 mutations and further characterization of the contribution of BRCA1/2 to hereditary breast and ovarian cancer families of French Canadian descent. Also see web site for summary of main research activities: www.toninlab.mcgill.ca Ovarian cancer collaborators: Drs. Anne-Marie Mes-Masson and Diane Provencher (CHUM, Montreal). Breast cancer research collaborators: Mark Basik (LDI) Hereditary breast-ovarian cancer research collaborators: Drs. Christine Maguard, Diane Provencher, and Parviz Ghadirian (CHUM), and Will Foulkes (MUHC-RI). 125
  • 126. Department of Oncology Annual Report 2007/2008 2. Research Grants (new and ongoing) A robust clinico-molecular platform to support the care of ovarian cancer patients. PN Tonin (Team Leader), W. Gotlieb, A. Kousik, A-M Mes-Masson, DP Provencher, Terry Fox Research Institute (Montreal Node), $98,000 [for Year 1 – renewed every year to 3 years, 3 years-start date pending] A model for modulating genetic and epigenetic events that influence the metastatic potential of ovarian cancer. PN Tonin and A-M Mes-Masson (Co-PIs), M Chevrette, D Provencher, Cancer Research Society, Inc. $150,000/annum, September 1, 2007 – August 31, 2009 Successful renewal of CRS-Strategic Grant “A model for modulating genetic and epigenetic events that influence the metastatic potential of ovarian cancer. Banque de tissues et de données pour le cancer du sein et du l’ovaire. D Bachvarov, M Basik, G Batist, J Brisson, W Foulkes,P Ghadirian, W. Gotlieb, T Hudson, A-M Mes- Masson, C Maugard, M Park, G Poirier, D Provencher, C Rancourt, B. Tetu, PN Tonin. Fonds de la Recherche en Santé du Québec: Reseau cancerologie. $900,000/annum, April 1, 2007 – March 31, 2012 Successful renewal of FRSQ Cancer Reseau/Network grant “Banque de tissues et de données pour le cancer du sein et du l’ovaire” An integrated functional and genomics approach at elucidating the chromosome 3 genes important in ovarian cancer. PN Tonin (PI), M Chevrette, A-M Mes-Masson , D Provencher, J Squire. Canadian Institutes of Health Research. $98, 517/annum. October 2006 – September, 2009 A model for modulating genetic and epigenetic events that influence the metastatic potential of ovarian cancer. PN Tonin and A-M Mes-Masson (Co-PIs), M Chevrette, D Provencher. Cancer Research Society, Inc. $150,000/annum. September 1, 2005 – August 31, 2007 Successful renewal of “CRS: A model for modulating genetic and epigenetic events that influence the metastatic potential of ovarian cancer” Selection and validation of target genes implicated in the clinical and biological features of ovarian cancer. A-M Mes-Masson (PI), PN Tonin, D Provencher. Canadian Institutes of Health Research $135,000/annum, Oct 1, 2005– Sept 30, 2008 Successful renewal of “CIHR: Selection and validation of target genes implicated in the clinical and biological features of ovarian cancer” Contribution of TP53 and novel suspected cancer susceptibility genes in high risk breast and/or ovarian cancer families of French Canadian descent. PN Tonin (PI) Cancer Research Society, Inc. $60,000/annum, September, 2006 – August, 2008 126
  • 127. Department of Oncology Annual Report 2007/2008 The Discovery of Novel Tumor Suppressor Genes in Breast Cancer. M Basik (PI), S Mader, C Rancourt, PN Tonin, Quebec Breast Cancer Foundation. $1,499,128 [Total]. July 1, 2004– June 30, 2008 Expansion of genomics and proteomics infrastructure in Québec. J Bergeron, H Bussey, K Dewar, T Hudson (Project Leader), BM Knoppers, C Laberge, F Labrie, S Michnick, D Sinnett, PN Tonin. Canadian Foundation for Innovation (CFI). $12,800,000 (Total). July 1, 2002 –June 30, 2006 [extended to 2011] 3. Education and Training Graduate Students Kathleen Klein, Sept. 2000-present, MSc (2000-2002); fast track Ph.D.(2002-present) Neal Cody, Sept. 2002-present, MSc (2002-2004); fact track PhD (2004-present) Paulina Wojnarowicz, Sept. 2005-present, M.Sc. (2005-2007); fast track Ph.D. 2007- present Ashley Birch, Sept. 2005-present, M.Sc. (2005-2007); fast track Ph.D. 2007-present Vanessa Rossiny, Sept. 2004-2008 [Includes personal leave of absence], M.Sc. Postdoctoral Trainees Michael Quinn, PhD, April 2005-present Luca Cavallone, PhD, June 2005 - present Karen Gambaro, PhD, April 2007 -present RESIDENCY/FELLOWSHIP COURSES IN MEDICINE Back to basics: Unit 8 - Genetics in Everyday Medicine II Department: Medicine Coordinator: Feigi Kaplan Format: Small group sessions Title: The genetics of inherited adult onset cancer Role: Animator, coordinated sessions on hereditary cancer genetics Level: Second year medical students Time (hrs/yr): 7 hours (Fall sessions) Years: 2007 BOM: Unit 1- Molecules, cells and Tissues Department: Medicine Coordinator: Dr. George Shenouda Format: Small group session Title: Cancer and Oncogenes 127
  • 128. Department of Oncology Annual Report 2007/2008 Role: Animator, coordinated sessions on cancer and oncogenes Level: First year medical students Time (hrs/yr): 2 hours (September session) Years: 2007 UNDERGRADUATE COURSES (NON-MEDICAL) EXMD 504A Biology of Cancer Department: Medicine (Division of Experimental Medicine) Coordinator: Dr. David M.P. Thompson Format: Lecture Title: Screening Breast Cancer Genes Role: Lecturer Level: Graduating students and graduate students Time (hr/yr): 1-2 hrs (Fall Session) Years: 2007 (2 hrs) GRADUATE COURSES (NON-MEDICAL) EXMD 635D Experimental & Clinical Oncology Department: Medicine (Div. Experimental Medicine) Coordinator: Dr. Maria Zannis-Hadjopoulos Format: Lecture Title: Cancer Genetics/Prevention Role: Lecturer Level: Graduate students Time (hr/yr): 1.5 hrs Years: 2007 (Fall) HGEN 690B Inherited Cancer Syndromes Department: Human Genetics and Medicine (Div. Experimental Medicine) Coordinator: Dr. Patricia Tonin Format: Lecture Role: Coordinator and Lecturer Level: Graduate students (fundamental and genetic counseling), (open to residents as well) Time (hr/yr): 8 hrs (Winter Session) Years: 2008 4. Scientific Reviews Journal Reviews BMC: Cancer Breast Cancer Research Cancer Detection and Prevention Clinical Genetics 128
  • 129. Department of Oncology Annual Report 2007/2008 Familial Cancer In Vitro Cellular & Developmental Biology - Animal Nature Reviews Cancer Grant Committees Canadian Institutes of Health Research Panel: Cancer Progression and Therapeutics Panel (Formerly Cancer B) Years: 2007 (Fall) 5. Conference Organization 7ieme Réunion Scientifique Annuelle, Association des Médecins Généticiens du Quebec, Session Chair: From Breast to Leukemia, December 5-6, 2007 The 4th Canadian Conference on Ovarian Cancer Research, Montreal, Quebec, Member of the organizing committee, May 4-7, 2008 6. Invited Presentations BRCA1, BRCA2, and TP53 mutations in French Canadian breast and ovarian cancer families, Hereditary Breast and Ovarian Cancer Foundation, The 2nd International Symposium on Hereditary Breast and Ovarian Cancer, Montreal, Quebec, October 17-19, 2007 Terry Fox Research Institute, Representing ovarian cancer researchers, Pan-Canadian Biomarker Workshop, MaRS Centre, Toronto, Ontario, October 28 -28, 2007 Integrating genomic, gene expression and functional complementation strategies to identify chromosome 3p genes implicated in ovarian cancer, Samuel Lunenfield Research Institute, Mount Sinai Hospital, Toronto, Ontario, March 26, 2008 The identification of chromosome 3 genes important in ovarian cancer through integration of genomic, gene expression and functional complementation strategies. Centre for Cancer Therapeutics, Ottawa Health Research Institute, Ottawa, Ontario, March 31, 2008 7. Continuing Education Activities Attended or Lectured Ovarian Cancer Canada, Lecture for Trainee session, Genetics of Hereditary Ovarian Cancer, Trainee Session for a Pre-Meeting of The 4th Canadian Conference on Ovarian Cancer Research, Montreal Quebec , May 3, 2008 8. Hospital and University Activities Academic Advisor, Chair Thesis Committee Meetings, Div. Experimental Medicine, Dept. Medicine Chair, Curriculum Committee – Basic Research, Dept. Human Genetics 129
  • 130. Department of Oncology Annual Report 2007/2008 Member Representing the Department of Human Genetics, Program Study Group 6B – Academic CREPUQ Review Process, Faculty of Medicine Invited reviewer, Departmental Tenure Review Committee, Department of Family Medicine, McGill University 9. Other Focus on Canadian Research: Patricia N. Tonin McGill, Genetic and Epigenetic Events in Sporadic & Hereditary Ovarian Cancer. 2007. The Genetics Society of Canada Bulletin, 38(1): 4-5. “The disease that whispers”: An interview with Dr. Patricia N. Tonin on ovarian cancer. 2007. The Canadian Cancer Society Newsletter, 2(10) - December 2007. ANNA TOWERS Over the next academic year my objectives will be to focus on four research and evaluation studies, on international palliative care development and the organization, as Chair, of a major international congress. The research studies are in the area of rehabilitation following cancer treatment. Clinical experience shows us that many patients present with co-morbidities: pain, numbness, range of motion limitations etc. I am part of a group that is conducting a multisite Canadian study, aiming to chart the incidence and course of three types of arm morbidity – pain, range of motion (ROM) restrictions and lymphoedema - in 750 women during the first five years post-surgery. What is striking is the degree of pain and functional problems that these women present (Thomas-MacLean, Towers et al 2008). Preliminary data show that these problems are not transient. The first year data (gathered 6-12 months post surgery) on 347 breast cancer patients shows that 39.4% have pain, 12% experienced swelling and ROM restrictions were observed in over half the sample. Women reported difficulties in completing tasks of everyday living, including heavy household chores, gardening/yard work, making a bed, carrying a shopping bag or briefcase or anything other than light objects. Pain was also correlated with problems with work and recreational activities involving arm motion. Despite the impact of pain upon their lives, most women reported that they did not discuss arm morbidity with health care professionals. Clearly there is a need for additional, longitudinal research into the trajectory of all types of arm morbidity, along with their inter-relationships, in order to demonstrate the need for comprehensive rehabilitation. How many of our programs integrate oncologists, family physicians, physiotherapists, kinesiologists, pain experts and social workers to adequately cover all the issues that our patients face, and early on in the trajectory? There is much work to be done in this area. For this study I have 1.5 full-time equivalent research assistant and we have so far recruited 350 patients in Montreal and 750 across the country. This study has been renewed via a CIHR provincial program for another two years. 130
  • 131. Department of Oncology Annual Report 2007/2008 The second study, funded by NCIC, investigates the effectiveness of exercise interventions for lymphedema. In this study I am co-PI with the Director of Graduate Studies at the McGill School of P and OT. The patients were recruited from my clinic and we are now in the data analysis stage. The third project, of which I am PI, is funded by Fondation Québecoise du Cancer This study that looks at educational interventions to help improve quality of life and prevent arm morbidity following breast cancer treatment. We are in the intervention phase. The fourth study is a development project funded by the Lymphedema Association of Quebec, looking at the role of a lymphedema therapist in providing support to cancer patients. We are assessing needs and will begin interventions in 2008. I continue to chair the biennial four-day International Congress on Palliative Care. The next Congress will take place in September 2008. For the first time this will be a trilingual offering -- English, French and Spanish, to encourage participation from Latin American delegates During 2008 I will be traveling to Latin America to try to encourage the participation of young leaders on the international scene. Over the last year I have traveled to Europe and Africa to meet with colleagues from National Associations to promote palliative care initiatives. We have formed collaborations with the aim of enhancing palliative care development worldwide under the theme of “Palliative Care- A Basic Human Right”. These ideas will be presented in a day-long symposium in Montreal in September 2008. In early 2008 I will be applying for a Soros grant and to the Commonwealth Foundation to fund travel and expenses for young palliative care leaders from developing countries to attend a training course which I am organizing as part of the Congress. 1. Summary of New and Ongoing Research My main area of research interest is cancer rehabilitation and lymphedema in particular. I am coordinator of the McGill Lymphedema Research Program (www.mcgill.ca/lymphedema-research) that aims to improve the quality of life of cancer survivors who have this and related problems. I am currently involved in projects to investigate arm morbidity following breast cancer treatment with the objective of helping create knowledge that will inform rehabilitation programs. I work in close collaboration with the Lymphedema Association of Quebec to advocate for adequate services for this population. I have an interest in international palliative care development, symptom control and ethical issues at the end of life. I have training and experience in qualitative methodology and will partner with other researchers on quantitative studies. I am interested in helping build research capacity by organizing international and national conferences and seminars on palliative care and on lymphedema. 131
  • 132. Department of Oncology Annual Report 2007/2008 2. Research Grants (new and ongoing) Thomas-MacLean R, , Kwan W, Hack T, Miedema B, Towers, A. Arm Morbidity after Breast Cancer: Building a Foundation for Education, Prevention and Rehabilitation. Canadian Institutes of Health Research/Saskatchewan Health Research Foundation, Regional Partnership Program. Appl no 174188 $260,693. 2007-2009 Towers A, Cohen R, Letellier ME. Réduire L’incidence de la morbidité du membre supérieur suite aux traitements pour le cancer du sein: développement et évaluation d’un projet pilote en kinésiologie. Fondation québécoise du cancer. Programme de recherche portant sur la qualité de vie des patients atteints de cancer. $15,000. 2006-2008 St. Pierre D, Towers A, Cohen R, Collet JP. Evaluation of group remedial exercises for chronic breast cancer related lymphedema. Canadian Cancer Society Feasibility Grant no. 016221. $34,380. Apr 1, 2005-31 Mar 2008 Anna Towers. Evaluation of an interdisciplinary program for lymphedema prevention and treatment Lymphedema Association of Quebec, $15,000. 2008-2009 Anna Towers. 17th International Congress on Palliative Care- Bursary Program, Foundation Open Society Institute, $15,000. 2008 3. Education and Training Undergraduate Teaching Physician Apprenticeship. 102 hours/year. Faculty of Medicine ICMB-Seminars on communication. 18 hours/year. Organized by Anna Towers. ITP Palliative Care Seminar. 18 hours/year. Organized by Anna Towers and the Palliative Care Education Committee/ Clinical Teaching Royal Victoria Hospital, Montreal General Hospital, MUHC, Palliative Medicine residents, Rotating Residents from other Departments, International Trainees. Depts. Oncology, Medicine, Family Medicine, Division of Palliative Medicine. 440 hours/year Research Trainees Supervised Marie-Ève Letellier, Doctoral student, Morbidity following breast cancer treatments. 2007- Present 4. Scientific Reviews Editorial Board Journal of Lymphedema Grant Reviews (Ad Hoc) NCIC 132
  • 133. Department of Oncology Annual Report 2007/2008 CIHR Social Sciences and Humanities Research Council MUHC research institute 5. Conference Organization Chair 17th International Congress on Palliative Care, Montreal, Sept 23-26, 2008 Member, Organizing Committee, Journée interuniversitaire en soins palliatifs, Université de Sherbrooke, Drummondville, Qc. Nov 23, 2007 6. External Committees and Boards International International Consensus Group on Best Practice Guidelines for Compression Treatment for Lymphoedema National Lymphedema Association of Quebec, Scientific Advisor and Member of the Board. 32 hrs/year Canadian Association of Palliative Care Physicians, Member of the Board, 24 hrs/year Provincial Réseau des Soins Palliatifs, Association Québecoise des Soins Palliatifs (organization regrouping 1900 palliative care professionals and volunteers) Member of the Board, 40 hrs/year Réseau Universitaire Québecois des Soins Palliatifs (RUQSP) – regrouping palliative care leaders from the four Quebec Faculties of Medicine), Founder and Chairperson, 48 hrs/year 7. Invited Presentations and Session Leadership Lymphedema Treatment and Management : an Integrative approach. Lymphedema Association of Quebec, Cedars CanSupport, McGill University Health Centre, Apr 8, 2008 ‘Historique et réalisations du RUQSP’ Journée interuniversitaire en soins palliatifs. Réseau universitaire québécois de soins palliatifs, Drummondville, Qc, November 23, 2007. Miedema, B, Towers, A, Thomas-MacLean R, Hack T, Tilley A, Kwan W, Tatemichi S. “Who is on paid sick leave and who is going back to work 6-12 months post breast cancer surgery? The impact of medical, psychological and social issues.” Presentation to the International Psycho-Oncology Society Conference, September 16-20, 2007 London UK” 8. Hospital and University Activities MUHC Pain Pharmacotherapy Committee Member, 12 hrs/year 133
  • 134. Department of Oncology Annual Report 2007/2008 Dept Medicine Educational Priorities Committee, Member, 8 hrs/year RUIS Table d’Oncologie, Member, 24 hrs/year Executive Committee, MUHC Department of Family Medicine, Member, 8 hrs/year MUHC Non-Cancer End of Life Care Interest Group, Co-Chair, 24 hrs/year Scientific and Research Advisory Board, Hope and Cope Wellness Center, Department of Oncology, JGH, Member, 3 hrs/year Executive Committee, Department of Oncology, Member, 20 hrs/year Women’s Cancer Section, Clinical trials Committee, Department of oncology, Member, 6 hrs/year Council on Palliative Care, Member, 20 hrs/year Education Committee, Palliative Medicine McGill, Member, 6 hrs/year Executive Committee MUHC Division of Palliative Care, Chair, 36 hrs/year ANTONIO VIGANO 1. Summary of New and Ongoing Research Summary of research activities 2007-2008 1. Completed the final stages of data collection and analysis for the project entitled, “Prognostic value of clinical correlates of cancer cachexia: a prospective, multicenter, population-based study” Including the recruitment and testing of an inception and representative cohort of 200 patients 18 years or older, recently diagnosed with advanced Non-Small Cell Lung and gastrointestinal cancer within the McGill University Health Centre. Manuscripts for this study have either been submitted for publication or are in final stages of preparation 2. Established of a bank of over 300 frozen samples of plasma, whole blood, and urine 3. Created a research environment, the CFI Funded McGill Nutrition and Performance Laboratory (www.MNUPAL.mcgill.ca) containing the required equipment and human resources to assess the clinical and biologic changes associated with wasting disorders in CC. 4. Developed a comprehensive database, the human cancer cachexia database (HCCD), for the repository and analysis of the data collected. 134
  • 135. Department of Oncology Annual Report 2007/2008 5. Created of a web-based research portal, to facilitate communication and collaboration among researchers participating in different projects involving MNUPAL. 6. Have almost completed data collection for a new study entitled, “Frailty and “Homeostenosis”: the contribution of inflammatory and oxidative factors on the criterion of fatigue in the Frailty Syndrome” in collaboration with José A. Morais, Abdelouahed Khalil, Tamas Fulop, Isabelle Dionne, Daniel Tessier from the McGill Nutrition Centre 7. Have recently submitted to the MUHC REB, the protocol and consent form for ethical approval of a new study entitled, “Investigating the link between markers of nutrition and performance with surgical outcomes in patients with liver and pancreatic cancer: a pilot study”. Principal investigators: Antonio Vigano, MD, MSc and Prosanto Chaudhury, MD, MSc, FRCSC Co-investigators: Drs Peter Metrakos, Jeffry Barkun, Petr Kavan, Mazen Hassanain, Thierry Alcindor, Jose Morais, Robert Kilgour, Stephanie Chevalier, Michel Tremblay. 2. Research Grants (new and ongoing) Funding Information: Salary Awards • Epidemiology and prognostic value of clinical and biological markers of cancer cachexia: a prospective, multicenter, correlative study.New Investigator career award for project entitled: July 2005-May 2010 Canadian Institutes for Health Research (CIHR) Funding Information: Operating Grants • Laboratory for correlative and interdisciplinary research on cancer nutrition and rehabilitation; Amount $ 303,582.00; Agency: Canadian Foundation for Innovation. (Support period; 11/2004 to 11/2009) PI: Antonio A.L. Vigano • Prognostic value of clinical correlates of cancer cachexia: a prospective, multicenter, population-based study; Amount $ 211,925.00; Agency: Canadian Institutes for Health Research. (Support period; 06/2004 to 05/2007) PI: Antonio A.L. Vigano; Co-applicants: V. Baracos, N. MacDonald, E. Franco, S. Cohen, M. Dalzell, S. Thirlwell, J. Morais • The McGill Nutrition and Performance Laboratory: from identification to clinical application of cachexia markers in advanced cancer patients; Amount $ 40,000; MUHC Cancer Mission, Dr A. Aprikian, bridge funding (Support period; 01/2008 to 08/2009) PI: Antonio A.L. Vigano 3. Education and Training Teaching and Research Training Initiated, organized and participate in weekly 2hr interdisciplinary research round “McGill Nutrition and Perfomance Laboratory interdisciplinary research round” which includes teaching of graduate students. Registration with the Royal College of Physician and Surgeons as a self-approved rounds group learning session is ongoing. Once this activity is registered with the Royal College's Office of Professional Affairs the 135
  • 136. Department of Oncology Annual Report 2007/2008 educational sessions are automatically included within Section 1 of the MOC (Maintenance of Certification) program (http://rcpsc.medical.org/opd/moc- program/index.php) Postgraduate Teaching Barbara Trutschnigg BSc: MSc in Experimental Medicine, 09/2007-06/2009. Research project: Characterizing frailty and cancer cachexia in elderly patients: a pilot study. (Main Co-Supervisor, Thesis Director) (Note: Barbara is the recipient of both CIHR and FRSQ salary awards under my supervision) Haneen Molla BSc: MSc in Dietetics, 09/2007-06/2009. Research project: Pre-operative nutritional and functional optimization for elective surgery in pancreatic and colorectal cancer patients: a pilot study. (Main Co-Supervisor, Thesis Director) Undergraduate Teaching At the undergraduate level, I have participated as a group leader in small group teaching related to the ICM, and as both a group leader and a teacher in small group discussions and formal teaching related to the POM series. I taught apprximately10 hours last year. Clinical Teaching As a clinical supervisor of health care professionals doing their first rotation on a palliative care unit, I directly monitor and evaluate their work on a one-to-one basis, stimulating students to solve problems using a case-based learning approach. This teaching is supplemented by regular formal teaching through journal club and case presentations. Research Trainees Supervised Jason Reinglas: Major in Exercise Science, Concordia University, 05/2007-present. Research project: Assessing quadriceps muscle strength in newly-diagnosed, advanced cancer patients: test-retest reliability and correlational analyses. (Project supervisor). Melissa Piccioni BSc: MSc in Exercise Science, Concordia University, 01/2008- 06/2009. Research project: Hypogonadism in male patients with advanced cancer: nutritional, functional and quality of life correlates. (Project supervisor) 4. Scientific Reviews Scientific Manuscript Reviewer Cancer Annals of Oncology Palliative Medicine Journal of Palliative Care Social Science & Medicine The American Journal of Managed Care Grant Reviewer CIHR “ad hoc” external reviewer 136
  • 137. Department of Oncology Annual Report 2007/2008 NCRI Lung Cancer Supportive and Palliative Care (SuPaC) Research Grants (see below) 5. External Committees Advisory committee member of the National Cancer Research Institute (NCRI) Supportive and Palliative Care (SuPaC) Research Collaboratives (Department of Health, Marie Curie Cancer Care, Macmillan Cancer Relief, Cancer Research UK and the Medical Research Council in the UK). 6. Invited Presentations and Workshops (National and International) Vigano A. Palliative Prognostic Score. International workshop on: The art and science of prognosis. Victoria B.C. May 2007. Vigano A. Are there clinical symptoms or psychosocial characteristics that can help physicians in predicting prognosis? International workshop on: The art and science of prognosis. Victoria B.C. May 2007. Vigano, A, J. Morais, R. Kilgour Action-research in palliative care: the McGill Nutrition and Performance Laboratory (MNUPAL) research program. Canadian Hospice Palliative Care Conference, “Hospice Palliative Care: At a Crossroads” in Toronto, Ontario, November 4-7, 2007 7. Peer Reviewed Abstracts Vigano, A, N. Hamel, J. Morais, W. Foulkes, R. Kilgour, R. Bond, B. Trutschnigg, S. Brar, J. Theberge, M. Tremblay Angiotensin-converting enzyme gene polymorphism (ACEGP) and cancer cachexia (CC): is there a link? Poster presentation American Society of Clinical Oncology at the 43rd ASCO Annual Meeting, in Chicago, Illinois, June 1-5 2007. Vigano Antonio, Trutschnigg Barbara, Bond Rachel, Brar Seema, Hamel Nancy, Theberge Jean-Francois, Foulkes William, Morais Jose. Body composition changes in advanced cancer associated with Angiotensin-Converting Enzyme (ACE) gene polymorphism: preliminary results. Poster presentation European Association for Palliative Care at the 10th EAPC Congress in Budapest, Hungary, June 7-9 2007. Vigano, A, B. Trutschnigg, R. Bond, L. Hornby, J. Morais, R. Kilgour; Taxonomy for cancer cachexia: usefulness of blood counts, albumin and C-reactive protein. Poster presentation Multinational Association of Supportive Care in Cancer at the Supportive Care Cancer Research 20th International Anniversary Symposium in St. Gallen, Switzerland, 27-30 June 2007. Vigano, A, N. Hamel, J. Morais, W. Foulkes, R. Kilgour, R. Bond, B. Trutschnigg, S. Brar, J. Theberge, M. Tremblay Angiotensin-converting enzyme gene polymorphism (ACEGP) and cancer cachexia (CC): is there a link? Poster presentation American Society of Clinical Oncology at the 43rd ASCO Annual Meeting, in Chicago, Illinois, June 1-5 2007. 137
  • 138. Department of Oncology Annual Report 2007/2008 Vigano Antonio, Trutschnigg Barbara, Bond Rachel, Brar Seema, Hamel Nancy, Theberge Jean-Francois, Foulkes William, Morais Jose. Body composition changes in advanced cancer associated with Angiotensin-Converting Enzyme (ACE) gene polymorphism: preliminary results. Poster presentation European Association for Palliative Care at the 10th EAPC Congress in Budapest, Hungary, June 7-9 2007. R. Kilgour, A.Vigano, B. Trutschnigg, L. Hornby, S. Bacon, J.A. Morais Body composition and functional performance characteristics of newly-diagnosed cancer patients with and without weight loss. Poster presentation at the 4th Cachexia Conference in Tampa, Florida, 6-9 December 2007. B. Trutschnigg, R. Kilgour, J. Reinglas, L. Rosenthall, L. Hornby, A. Vigano Handgrip dynamometry measurements in elderly cancer patients: a comparison of two instruments (Jamar versus Biodex). Poster presentation at the 4th Cachexia Conference in Tampa, Florida, 6-9 December 2007. J. Reinglas, R. Kilgour, L. Hornby, B. Trutschnigg, L. Rosenthall, A. Vigano Assessing quadriceps muscle strength in newly-diagnosed, advanced cancer patients: test-retest reliability and correlational analyses. Poster presentation at the 4th Cachexia Conference in Tampa, Florida, 6-9 December 2007. Recipient of the, "Young Investigator's Award" for a poster presentation. A. Vigano, B. Trutschnigg, J.A. Morais, E. Lucar, R. Kilgour, L. Rosenthall. Precision of dual energy X-ray absorptiometry and bioelectrical impedence in patients with advanced cancer. Poster presentation at the 4th Cachexia Conference in Tampa, Florida, 6-9 December 2007. Vigano , Antonio, Barbara Trutschnigg1, Robert Kilgour2, E. Lucar1 and José A. Morais Effects of Age On Measures of Nutrition Quality Of Life, Physical Function And Body Composition in Patients with Advanced Cancer. Accepted for poster presentation at the Canadian Geriatrics Society 28th Annual Scientific Meeting in Montreal, Qc , 10-12 April 2008. Rosenthall, L, B. Trutschnigg, A. Vigano Precision of total body and regional tissue measurements by DXA densitometry Accepted for poster presentation at the 35th European Symposium on Calcified Tissues in Barcelona, Spain , 24-28 May 2008 TE VUONG 1. Summary of New and Ongoing Research 1. The role of IMRT for patients with unresectable rectal cancer (PI). 138
  • 139. Department of Oncology Annual Report 2007/2008 2. The value of Immunochemistry markers to predict response to high dose rate brachytherapy (PI). 3. The value of Botox-A in the treatment of patients with radiation induced proctitis.(PI) 4. Anal Canal Carcinoma and expression of Epidermal Growth Factors.(PI) 5. Techical transfert study: High dose rate endorectal brachytherapy for operable rectal cacner (PI) 6. A phase multicenter phase III study testing the value of high dose rate endorectal brachytherapy for patients with rectal cancer(PI) 7. A phase III study testing the value of Botox in the treatment of radiation induced proctitis. 8. The predictive value of pelvic MRI for systemic disease in patients with rectal cancer. 2. Scientific Reviews ASTRO 2007 and 2008 scientific reviewer of colo-rectal GI abstracts. Ontario Cancer Research Network Grant reviewer, 2008 3. Conference and Workshop Organization McGill Second International Workshop on High dose rate lower GI brachytherapy for patients with rectal cancer, September 19-21 2007 (Principal organizer) 4. External Committees Member of the scientific Committee of the International meeting on Optimal use of advanced Radiotherapy in Multimodality Oncology (Rome, Italy), 2007 and chair of the GI session. Co-chair of the colo-rectal and esophageal session of the 2007 Annual meeting of the American Society of Therapeutic Radiation Oncology Organization. October 2007 (Los Angeles.), 2007 5. Invited Presentations High dose rate endorectal brachytherapy as a neoadjuvant modality: Long-term follow data of a phase II study (12th International conference on optimal use in advanced radiotherapy in multimodality Oncology. Rome, Italy, June 24-26th 2007). Invited speaker and Chairman of the GI section. An objective scoring methodology for radiation induced dermatitis. Invited speaker, 139
  • 140. Department of Oncology Annual Report 2007/2008 Paris, France. Institut Curie, April 17th 2007. 12th International conference on optimal use in advanced radiotherapy in multimodality oncology. Rome, Italy, June 24-26th 2007). Therapeutic paradigms in the treatment of patients with curable rectal cancer. Principles and applications of high dose rate endorectal brachytherapy in the treatment of curable rectal cancer. Nucletron Excellence in Radiation Therapy invited speaker. ASTRO meeting: Los Angeles. October 30th 2007. New Radiation technologies in the treatment of patients with rectal cancer. Ficare. International rectal cancer Forum. Sao Paulo, Brazil. Nov 22-24.2007. High dose rate endocavitary brachytherapy in the treatment of patients with rectal cancer. Rio de Janeiro, National Institute of Cancer, Brazil, November 28, 2007. Clinical applications of High dose rate endorectal brachytherapy in the multimodality treatment of locally advanced rectal cancer. European multidisciplinary colorectal congress. Berlin, Germany, February 24-26th, 2008. 3D image guided high dose rate endorectal brachytherapy for patients with rectal cancer Amsterdam, National Cancer Institute (Netherlands) February 27-29th, 2008. High dose rate endorectal brachytherapy in the treatment of patients with rectal cancer. Essentiels in Brachytherapy Quebec, April 12th 2008. Curiehérapie versus chimio-radiothérapie externe en thérapie néoadjuvante dans l’adénocarcinome du rectum. III congrès de chirurgie de la francophonie. Québec (Juin 25-27, 2008). T.Vuong, S. Faria, K.Waschke, S.Liberman, B.Stein, P.Charlebois, S.Devic The use of high dose rate endorectal brachytherapy as a boost in inoperable patients with locally advanced rectal tumors. ABS/GEC-ESTRO World Congress of Brachytherapy. (Boston May 5-7 2008.). T.Vuong, S. Faria, K.Waschke, S.Liberman, B.Stein, P.Charlebois, S.Devic. Neoadjuvant high dose rate endorectal brachytherapy leads to a high sphincter preservation rate in patients with low rectal cancer. ABS/GEC-ESTRO World Congress of Brachytherapy. Boston May 5-7 2008 140
  • 141. Department of Oncology Annual Report 2007/2008 JIAN HUI WU 1. Summary of New and Ongoing Research As androgen receptor (AR) is a critical mediator of prostate cancer, the hormone- sensitive prostate cancer responses to the treatment of antiandrogens, such as flutamide and bicalutamide. However, prostate cancer almost always undergoes transition to the hormone-refractory state and become resistant to antiandrogens. It has been established that mutation in AR is a key mechanism that contributes to antiandrogen resistance. In particular, clinically relevant T877A and W741C mutations are found to result in antagonist-to-agonist conversion for flutamide and bicalutamide, respectively. To identify novel chemical compounds against drug-resistant prostate cancer, Dr Wu’s ongoing research projects involve the following aspects: i) Theoretical investigation of the impact of drug-resistant mutations, such as T877A and W741C, on the structure and dynamics of androgen receptor. Our investigation revealed putative structural basis of the antiandrogen resistance and generated testable hypothesis for the design of pure antiandrogens (a manuscript has been submitted); ii) Chemical synthesis and in vitro evaluations of novel nonsteroid antiandrogens. We have discovered four antiandrogens with new chemical scaffolds, which show sub- micromolar cytotoxicity in human prostate cancer cells LNCaP and PCa 2b. In luciferase assays using plasmid expressing full-length of AR, the four lead compounds show potent activity in suppressing DHT-induced transactivation of the wild-type, T877A, W741C and H874Y mutated ARs (A patent to protect these novel antiandrogens is pending. Two manuscripts have been submitted and another two in preparation); iii) Development of novel methods for computational target fishing from chemical structure of the bioactive compounds. As some of our antiandrogens show potent cytotoxicity in both androgen-dependent LNCaP and androgen-independent PC3 cells, we have initiated a project to develop software for in silico target fishing. This involves development of software modules to correlate chemical structures of bioactive compounds with the binding sites of protein targets. One of the modules, binding-site match maker (BSMM), is intended to identify proteins that have binding sites similar to the query binding site; iv) Identificaiton of bioactive compounds from traditional medicinal herbs. Currently, our effort is focusing on identifying antiandrogens from ethanol extract of Chinese medicinal herbs. We have identified a compound (#101) with a IC50 of 0.3 μM against LNCaP cells. However, the solubility of this compound is low. We are in the process to chemically modify this compound by introducing a polar group to the location suggested by molecular modeling. 2. Research Grants (new and ongoing) Combination of multiple compounds as potential anti-cancer agents: Mining of traditional Chinese medicine. Jian Hui Wu, Dr. Qingwen Shi, Heibei Medical University, China. Award funded jointly by FRSQ and Nature Science Foundation of China. $13,500. April 1, 2007 through March 30, 2008. 141
  • 142. Department of Oncology Annual Report 2007/2008 The major goal of this project is to investigate the extract of herba Scutellaria barbatae, a traditional Chinese medicinal herb used for the treatment of ovarian cancer. Regulation of glutathione and related enzymes: dissection of the Nrf2-master regulator and generation of novel potential chemopreventive molecules. Gerald Batist, Jian Hui Wu, CIHR, $326,000 in total, 04/2006 to 03/2009 The major goal of this project is to investigate the regulation of Nrf-2, and develop novel small molecules to induce phase II detoxifying enzymes by targeting Nrf-2/Cul3 interface. Mining of traditional medicinal herbs for multi-component therapeutics against breast cancer, Jian Hui Wu. The Weekend to End Breast Cancer and the Jewish General Hospital Foundation. $30,000 in total. 01/2008-01/2009 The major goal of this project is to to exploit traditional medicinal herbs for combination of compounds that kill breast cancer cells by inhibiting multiple targets simultaneously. This could lead to novel therapeutics for overcoming resistance to anti- estrogen therapy. Chemical modulators that inhibit inappropriate activation of androgen receptor: towards novel AR antagonists against hormone-refractory prostate cancer. Jian Hui Wu. CIHR, $321,891 in total, January 1, 2005 through March 31, 2008 (tenure until March 31, 2009). The major goal of this project is to develop novel antagonists of androgen receptor and its pathogenic mutants as potential anti-prostate cancer agents. 3. Education and Research Training Postdoctoral Fellows Bing Liu, 2005-2007 Jinming Zhou, 2006-present. Member of the Ph.D. thesis examination committee for Sabrina Perri, “The use of plasminogen kringle domains as novel anti-angiogenic agents for the treatment of brain and breast cancer”, McGill University. 4. Scientific Reviews Journal Reviews J Med Chem J Biol Chem Human Mutation Grant Reviews CIHR Research Grants Council of Hong Kong. 142
  • 143. Department of Oncology Annual Report 2007/2008 5. Invited Presentations Wu, J.H., “Circumventing drug-resistant mutants by molecular design”, Lady Davis Institute, SMBD-Jewish General Hospital, McGill University, April 2, 2008. 6. Continuing Education Activities attended or lectured. Participating in “Course Design and Teaching Workshop”, Teaching and Learning Services, McGill University, 2007. 7. Hospital and University Activites Building and configuration of a high performance computer cluster (20-node, 40-CPU) for bio-computing at Montreal Centre of Experimental Therapeutics in Cancer (MCETC), SMBD-Jewish General Hospital. Supervision and administration of the state-of-the-art hardware and software for bioinformatics and drug design at MCETC. MARIA ZANNIS-HADJOPOULOS 1. Summary of New and Ongoing Research as PI 1. Characterization of mammalian replication origins and interacting proteins regulating the initiation of DNA replication 2. Comparative analysis of replication origin activity between tumor and normal cells 3. Purification and characterization of human DNA replication proteins 4. Analysis of the role of cruciform DNA in the regulation of DNA replication and characterization of the cruciform binding protein CBP/14-3-3. as co-PI With Dr. Edward Bradley, Institut du Cancer de Montréal, Université de Montréal; project on ‘Genome-wide mapping of asynchronous replication in cancer cells’. 2. Resarch Grants (new and ongoing) Differentially active human origins of DNA replication in tumor versus normal cells. National Cancer Institute of Canada, $116,868, 2005-2008 Genome-wide mapping of asynchronous replication in cancer cells. PI: Maria Zannis- Hadjopoulos with Drs. Edward Bradley and Mark Basik (co-applicants). Canderel Innovative Research Award, Pilot Research Grant distributed through the McGill Cancer Centre, $15,000 May 2007-May 2008 143
  • 144. Department of Oncology Annual Report 2007/2008 3. Research Training Postdoctoral Fellow Wafaa Yahyaoui Graduate students Domenic DiPaola, Ph.D. 4 (Biochemistry, 2002-present). Emmanouil Rampakakis, Ph.D. 3 (Biochemistry, 2004-present). Albe Man Kid Chan M.Sc. 2 (Biochemistry, 2007-present) Undergraduate students Bapat Ashwini Charusheel BIOC460A Rajashree Sen BIOC460A Summer students Vincent Lavallée Colin Bell Raminder Gill Amy Sur Amine Benmassaoud 4. Scientific Reviews Editorial Boards International Society for Gene Therapy and Molecular Biology Journal Reviews Proceedings of the National Academy of Sciences (USA) Molecular and Cellular Biology Journal of Biological Chemistry Journal of Cellular Biochemistry Journal of Cell Science DNA and Cell Biology Gene Biochemistry Genomics Trends in Biochemical Sciences (TIBS) Oncogene Nucleic Acids Research Grant Reviews CIHR FRSQ NSERC National Science Foundation (U.S.A.) European Science Foundation Israel Science Foundation 144
  • 145. Department of Oncology Annual Report 2007/2008 5. External Committees and Boards External Reviewer, European Science Foundation External Evaluator of grant applications submitted to the Greek Ministry of Research and Technology (PENED) 6. Invited Presentations FASEB Summer Research Conference on "Nuclear Structure & Cancer", Saxtons River, Vermont, June 16-21, 2007. 12th World Congress on Advances in Oncology and 10th International Symposium on Molecular Medicine, Creta Maris, Hersonissos, Crete, Greece, 11-13 October, 2007 7. Hospital and University Activities Member (elected), MAUT Council 2007-2009 Senator (elected representative for the Faculty of Medicine), McGill University Senate 2007-2009 Member (elected), Senate Nominating Committee, McGill University 2007-2009 145
  • 146. Dept. of Oncology Appendix I: Honours, Awards and Prizes June 1, 2007-May 31, 2008 Appendix I: Honours, Awards and Prizes Paul Allison Howard Katz Award for Excellence in Teaching (2007): $1000 awarded to an individual at the Faculty of Dentistry, McGill University for excellence in teaching Gerald Batist 2007, Minda de Gunzburg Chair in Oncology, McGill University Nicole Beauchemin “Faculty Honour List for Educational Excellence” 2007. Robin Cohen Associate Professor (tenured), Departments of Oncology and of Medicine, Faculty of Medicine, McGill University. June 2007 – present Lucy Gilbert APOG (Association of Professors of Obstetrics & Gynecology: Canada). Carl Nimrod Educator Award, 2007. APGO (Association of Professors of Gynecology and Obstetrics: North America – US & Canada) Excellence in Teaching Award, 2008. Bernard Lapointe Canadian Hospice Palliative Care Association, Award of Excellence, 2007 Carmen Loiselle Loiselle, C.G., & McVey, L. Technology and intensive care units: Health information and support are just as present. 2nd place prize at the Regional Order of Nurses Competition for Clinical Innovation/3M. Montreal, Quebec, (May 26, 2008). Photo submitted was one of 33 chosen to become part of the FRSQ Image Bank. Le fonds de la recherche en santé du Québec (FRSQ) Scientific Photo Competition, November 2007. Neil MacDonald Statesman Award - American Society of Clinical Oncology. May 2007 Ervin Podgorsak Fellowship (2007): The American College of Medical Physics (ACMP). Gold Medal, Canadian Organization of Medical Physicists (COMP), June 27, 2008. I-1
  • 147. Dept. of Oncology Appendix I: Honours, Awards and Prizes June 1, 2007-May 31, 2008 Shafaat Rabbani Outstanding Achievement Award, Society of American Asian Scientists in Cancer Research 2008 Janusz Rak Honorary Professorship at Masaryk University, Czech Republic- in progress 2008 Khalil Sultanem Voted as outstanding teacher by the McGill University Radiation Oncology Residency Program Marc Tischkowitz Fanconi Anemia Research Fund Discovery Award, October 2007 FRSQ Chercheur-bousier clinicien Junior 1 (commenced July 2007) Anna Towers Ethel Lilian Creller Award, MUHC Research Institute, Oct 2007 Te Vuong CIHR Investigator Salary Award The Hebert S.Lang Oncology Surgery award October 2007 I-2
  • 148. Dept. of Oncology Appendix II: Publications January-December 2007 Appendix II: Publications Articles in Peer Reviewed Journals B. Nicolau, W. M. Thomson, J.G. Steele & Allison P.J. (2007): Life-course epidemiology: concepts and theoretical models and its relevance to oral chronic conditions. Community Dentistry & Oral Epidemiology. 35(4):241-249 D. Locker, A. Jokovic & P. Allison (2007): Direction of wording and responses to items in oral health-related quality of life questionnaires for children and their parents. Community Dentistry & Oral Epidemiology. 35(4):255-262 Saub R*, Locker D, Allison PJ, Disman M (2007): Cross-cultural adaptation of the Oral Health Impact Profile (OHIP) for the Malaysian adult population. Community Dental Health 24(3):166-75 Khambata-Ford S, Garrett CR, Meropol NJ,, Basik M, Harbison CT, Wu S, Wong TW, Huang X, Takimoto CH, Godwin AK, Tan BR, Krishnamurthi SS, Burris HA, Poplin EA, Hidalgo M, Baselga J, Baselga J, Clark EA, Mauro DJ. Expression of epiregulin and amphiregulin and K-RAS mutation status are associated with disease control in metastatic colorectal cancer patients treated with cetuximab. Journal of Clin Oncol, 2007 Aug 1;25(22):3230-7. Al-Qahtani K, Brousseau VJ, Paczesny, Domanowski G, Hamid Q, Hier MP, Black MJ, Franco E, Kost KM. Koilocytosis in Oral Squamous Cell Carcinoma: What Does It Mean? J Otolaryngol. 2007 Feb 36(1):26-31. Aslani M, Sultanem K, Voung T, Hier M, Niazi T, Shenouda G. Metastatic Carcinoma To The Cervical Nodes From An Unknown Head And Neck Primary Site : Is There A Need For Neck Dissection ? Head & Neck/. 2007 June 29(6):585-590. Mlynarek Alex M., Balys Richard L., Su Jie. Hier Michael P, Black Martin J., Alaoui- Jamali Moulay A. A Cell Proteomic Approach for the Detection of Secretable Biomarkers of Invasiveness in Oral Squamous Cell Carcinoma. Arch Otolaryngology Head and Neck Surgery. 2007;133:910-918. Noordzij JP, Lee SL, Bernet VJ, Payne RJ, Cohen SM, McLeod IK, Hier MP, Black MJ, Kerr PD, Richards ML, Lo CY, Raffaelli M, Bellantone R, Lombardi CP, Cohen JI, Dietrich MS. Early prediction of hypocalcemia after thyroidectomy using parathyroid hormone: an analysis of pooled individual patient data from nine observational studies. Journal of the American College of Surgeons 2007; 205(6):748:754. Côté V, Kost K, Payne R.J., Hier M.P. Sentinel Lymph Node Biopsy in Squamous Cell Carcinoma of the Head and Neck : Where We Stand Now, and Where We Are Going. Journal of Otolaryngology, Vol. 36, No. 6 (Dec) 2007: 344-349. II-1  
  • 149. Dept. of Oncology Appendix II: Publications January-December 2007 Côté V, Sands N, Hier MP, Black MJ, Tamilia M, MacNamara E, Zhang X, Payne RJ. The Value of Postoperative 1-hr Parathyroid Hormone Level as a Predictor of Post- thyroidectomy Hypocalcemia. Otolaryngology – Head and Neck Surgery 2008; 138(2):204-208. Pintos J, Black MJ, Sadeghi N, Ghadirian P, Zeitouni AG, Viscidi RP, Herrero R, Coutlee F, Franco EL. Human papillomavirus infection and oral cancer: A case-control study in Montreal, Canada. Oral Oncol. 2007 Apr 26 Cheng, C. Y., P. Blanchette, and P.E. Branton. 2007. The Adenovirus E4orf6 E3 Ubiquitin Ligase Complex Assembles in A Novel Fashion. Virology 364, 36-44. Mount BM, Boston P, Cohen SR. Healing connections: on moving from suffering to a sense of well-being. Journal of Pain and Symptom Management, 2007; 33(4) 372-388. Crooks VA, Williams A, Stajduhar KI, Allan DE, Cohen SR. The information transfer and knowledge acquisition geographies of family caregivers: An analysis of Canada’s Compassionate Care Benefit. Canadian Journal of Nursing Research, 2007; 39(3) 36-54. S. Faria, R. Lisbona, J. Stern, S. Devic, L. Souhami, C.R. Freeman, O Uso de FDG- PET/TC scan no planejamento da radiotherapia em câncer do pulmão não de pequenas células (Use of FDG-PET/TC scan in the planning of radiation therapy for non-small cell lung cancer), Radiol. Bras. 40, 345-348 (2007). William D Foulkes, Parviz Ghadirian, Mohammed Reza Akbari, Nancy Hamel, Sylvie Giroux, Andrew Darnel, Robert Royer, Aletta Poll, Eve Farfad, André Robidoux, Ginette Martin, Tarek A. Bismar, Marc Tischkowitz, Francois Rousseau and Steven A Narod. Identification of a novel truncating PALB2 mutation and analysis of its contribution to early-onset breast cancer in French Canadian women. Breast Cancer Research, 2007 9(6) McLaughlin JR, Risch HA, Lubinski J, Moller P, Ghadirian P, Lynch H, Karlan B, Fishman D, Rosen B, Neuhausen SL, Offit K, Kauff N, Domchek S, Tung N, Friedman E, Foulkes W, Sun P, Narod SA; Hereditary Ovarian Cancer Clinical Study Group. Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study. Lancet Oncol, 8 (1): 26-34, 2007. Kotsopoulos J, Lubinski J, Lynch H.T, Klijn J, Ghadirian P, Neuhausen SL, Kim-Sing C, Foulkes WD, Moller P, Isaacs C, Domchek S, Randall S, Offit K, Tung N, Ainsworth P, Gershoni-Baruch R, Eisen A, Daly M, Karlan B, Saal HM, Couch F, Pasini B, Wagner T, Friedman E, Rennert G, Eng C, Weitzel J, Sun P, Narod SA, Hereditary Breast Cancer Clinical Study Group. Age at first birth and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res., 105(2):221-8, 2007. II-2  
  • 150. Dept. of Oncology Appendix II: Publications January-December 2007 Refae MA, Wong N, Patenaude F, Bégin LR, Foulkes WD. Hereditary leiomyomatosis and renal cell cancer: an unusual and aggressive form of hereditary renal carcinoma. Nature Clinical Practice Oncology, 4(4): 256-61, 2007. Hamel N, Wong N, Alpert L, Galvez M, Foulkes WD. Mixed ovarian germ cell tumor in a BRCA2 mutation carrier. Int J Gybecol Pathol, 26 (2): 160-4, 2007. Mesurolle B, Kadoch L, El-Khoury M, Lisbona A, Dendukuri N, Foulkes WD. Sonographic Features of Breast Carcinoma Presenting as Masses in BRCA Gene Mutation Carriers. Ultrasound Med, 26(6):817-24, 2007. Camp NJ, Cannon-Albright LA, Farnham JM, Baffoe-Bonnie AB, George A, Powell I, Bailey-Wilson JE, Carpten JD, Giles GG, Hopper JL, Severi G, English DR, Foulkes WD, Maehle L, Moller P, Eeles R, Easton D, Badzioch MD, Whittemore AS, Oakley- Girvan I, Hsieh CL, Dimitrov L, Xu J, Stanford JL, Johanneson B, Deutsch K, McIntosh L, Ostrander EA, Wiley KE, Isaacs SD, Walsh PC, Thibodeau SN, McDonnell SK, Hebbring S, Schaid DJ, Lange EM, Cooney KA, Tammela TL, Schleutker J, Paiss T, Maier C, Grönberg H, Wiklund F, Emanuelsson M, Isaacs WB. Compelling evidence for a prostate cancer gene at 22q12.3 by the International Consortium for Prostate Cancer Genetics. Hum Mol Genet, 1;16(11):1271-8, 2007. Apicella C, Dowty J, Dite G, Jenkins M, Senie R, Daly M, Andrulis I, John E, Buys S, Li F, Glendon G, Chung W, Ozcelik H, Miron A, Kotar K, Southey M, Foulkes WD, Hopper J. Validation study of the lambda model for predicting the BRCA1 or BRCA2 mutation carrier status of North American Ashkenazi Jewish women. Clin Genet. 72(2):87-97, 2007. Yasmeen A, Bismar TA, Kandouz M, Foulkes WD, Desprez PY, Al Moustafa AE. E6/E7 of HPV type 16 promotes cell invasion and metastasis of human breast cancer cells. Cell Cycle. 6(16):2038-42, 2007. Foulkes WD. Clinically relevant biology of hereditary breast cancer. Semin Oncol. 34(5):379-83, 2007. Gagnon S, Hankins C, Money D, Pourreaux K, Canadian Women's HIV Study Group, Franco EL, Coutlée F. Polymorphism of the L1 capsid gene and persistence of human papillomavirus type 52 infection in women at high-risk or infected by HIV. Journal of Acquired Immunodeficiency Syndrome 44: 61-65, 2007. Kohli M, Ferko N, Martin A, Franco EL, Jenkins D, Gallivan, S, Sherlaw-Johnson C, Drummond M. Estimating the long-term impact of a prophylactic human papillomavirus (HPV) 16/18 vaccine on the burden of cervical cancer in the UK. British Journal of Cancer 96: 143-150, 2007. II-3  
  • 151. Dept. of Oncology Appendix II: Publications January-December 2007 Sichero L, Ferreira S, Trottier H, Duarte-Franco E, Ferenczy A, Franco EL, Villa LL. High grade cervical lesions are caused preferentially by non-European variants of HPVs 16 and 18. International Journal of Cancer 120: 1763-1768, 2007. Al-Qahtani K, Brousseau V, Paczesny D, Domanowski G, Hamid Q, Hier M, Black M, Franco E, Kost K. Koilocytosis in oral squamous cell carcinoma: what does it mean? Journal of Otolaryngology 36: 26-31, 2007. Schaffer A, Koushik A, Trottier H, Duarte-Franco E, Mansour N, Arseneau J, Provencher D, Gilbert L, Gotlieb W, Ferenczy A, Coutlée F, Pollak M, Franco EL(*). Insulin-like growth factor-I and risk of high-grade cervical intraepithelial neoplasia. Cancer Epidemiology, Biomarkers and Prevention 16: 716-722, 2007. Petignat P, Faltin DL, Bruchim I, Tramèr MR, Franco EL, Coutlée F. Are self-collected samples comparable to physician-collected cervical specimens for human papillomavirus DNA testing? A systematic review and meta-analysis. Gynecologic Oncology 105: 530- 535, 2007. Mahmud S, Robinson K, Richardson H, Tellier PP, Ferenczy A, Roger M, Coutlée F, Franco EL. HLA polymorphisms and cervical human papillomavirus infection in a cohort of Montreal university students. Journal of Infectious Diseases 196: 82–90, 2007. Franco EL, Ferenczy A. Cervical cancer screening following the implementation of prophylactic human papillomavirus vaccination. Future Oncology 3: 319-327, 2007. Brogly SB, Watts DH, Ylitalo N, Franco EL, Seage III GR, Oleske J, Eagle M, Van Dyke R. Reproductive health of adolescent girls perinatally infected with HIV. American Journal of Public Health 97: 1047-1052, 2007. Kim JJ, Kuntz KM, Stout NK, Mahmud S, Villa LL, Franco EL, Goldie SJ. Multi- Parameter Calibration of a Natural History Model of Cervical Cancer. American Journal of Epidemiology 166:137-150, 2007. Ferenczy A, Franco EL. Prophylactic human papillomavirus vaccines: Potential for sea change. Expert Reviews on Vaccines 6: 511-525, 2007. Goldie SJ, Kim JJ, Kobus K, Goldhaber-Fiebert JD, Salomon J, O’Shea MKH, Bosch FX, Sanjosé S, Franco EL. Cost-effectiveness of HPV 16,18 Vaccination in Brazil. Vaccine 25: 6257-6270, 2007. Dang-Tan T, Franco EL. Diagnosis delays in childhood cancer: A review. Cancer 110: 703-713, 2007. Spence A, Goggin P, Franco EL. Process of care failures in invasive cervical cancer: Systematic review and meta-analysis. Preventive Medicine 45:93-106, 2007. II-4  
  • 152. Dept. of Oncology Appendix II: Publications January-December 2007 Mahmud SM(§), Koushik A, Duarte-Franco E, Costa J, Fontes G, Bicho M, Coutlée F, Franco EL. Haptoglobin phenotype and risk of cervical neoplasia: a case-control study. Clinica Chimica Acta 385: 67-72, 2007. Khouadri S, Villa LL, Gagnon S, Koushik A, Richardson H, Matlashewski G, Roger M, Ferenczy AS, Franco EL, Coutlée F(*). Viral load of episomal and integrated forms of human papillomavirus type 33 in high-grade squamous intraepithelial lesions of the uterine cervix. International Journal of Cancer 121: 2674–2681, 2007. Mayrand MH, Duarte-Franco E, Rodrigues I, Walter SD, Hanley J, Ferenczy A, Ratnam S, Coutlée F, Franco EL, for the CCCaST Study Group. Human Papillomavirus DNA versus Papanicolaou Screening Tests for Cervical Cancer. New England Journal of Medicine 357: 1579-1588, 2007. Coutlée F, Rouleau D, Ghattas G, Hankins C, Vézina S, Coté P, Macleod J, Pokomandy A, Money D, Walmsley S, Voyer H, Brassard P, Franco E. Confirmatory real-time PCR assay for human papillomavirus (HPV) type 52 infection in anogenital specimens screened for HPV infection with the linear array HPV genotyping test. Journal of Clinical Microbiology 45: 3821-3823, 2007. Franco EL. Expected Impact of HPV Vaccination on Cervical Cancer Screening Practices: Time to Rethink Preventive Strategies. African Organisation for Research and Training In Cancer (AORTIC) Newsletter 9: 15-16, 2007. Sichero L, Trottier H, Ferreira S, Duarte-Franco E, Franco EL, Villa LL. Re: Human papillomavirus type 16 and 18 variants: race-related distribution and persistence. Journal of the National Cancer Institute 99: 653-654, 2007. Petignat P, Franco EL, Coutlée F. Letter: Response to Pretorius and Belinson. Gynecologic Oncology 107: 596-597, 2007. Kim JJ, Franco EL, Stout NK, Goldie SJ. Letter: The authors reply re: Multi-Parameter Calibration of a Natural History Model of Cervical Cancer. American Journal of Epidemiology 166: 983-984, 2007. Franco EL, de Pokomandy A, Spence AR, Burchell AN, Trottier H, Mayrand MH, Lau S. Letter: Vaccination against human papillomavirus. Canadian Medical Association Journal 177: 1524-1525, 2007. Brogly SB, Franco EL, Watts DH, Van Dyke R. Letter: Reproductive health of adolescent girls perinatally infected with HIV. American Journal of Public Health 97: 1930, 2007. II-5  
  • 153. Dept. of Oncology Appendix II: Publications January-December 2007 W. Parker, E. Filion, D. Roberge, C.R. Freeman; Intensity modulated radiotherapy for craniospinal irradiation: Target volume considerations, dose constraints, and competing risks, Int J Radiat Oncol Biol Phys. 69, 251-257, (2007). Korones DN, Fisher PG, Kretschmar C, Zhou T, Chen Z, Kepner J, Freeman C. Treatment of children with diffuse intrinsic brain stem glioma with radiotherapy, vincristine and oral VP-16: a children’s oncology group phase II study. Pediatric Blood & Cancer 2007 50:227-230. Denschlag D, Masoud I, Stanimir G, Gilbert L. Prognostic factors and outcome in women with uterine sarcoma: A comparison between endometrial stromal sarcoma, leiomyosarcoma and mixed mullerian tumors. European Journal of Surgical Oncology, Feb 2007; 33(1):91-5. Sagr Er, Denschlag D, Kerim-Dikeni A. Stanimir G, Gilbert L. Prognostic Factors and Treatment-related Outcome in Patients with Uterine Papillary Serous Carcinoma. Anticancer Research, Mar-Apr 2007; 27(2):1213-7. Denschlag D, Tan L, Patel S, Kerim-Dikeni A, Souhami L, Gilbert L. Stage III endometrial cancer: preoperative predictability, prognostic factors, and treatment outcome. Am J Obstet Gynecol. 196:546-547, 2007. Huang Jy, Buckett W, Gilbert L, Stanimir G, Tan SL, Chian RC. Retrieval of immature oocytes followed by in-vitro maturation and vitrification of oocytes: A new possibility for fertility preservation in women with borderline ovarian malignancy. Gynecologic Oncology, May 2007; 105(2):542-4. Denschlag D, Tan L, Patel S, Kerim-Dikeni A., Souhami L, Portelance L, Duclos M, Arseneau J, Stanimir G, Gilbert L. Stage III endometrial cancer: preoperative predictors of survival. Am J Obstet Gynecol, June 2007; 196(6):546.e1-7. Chian RC, Gilbert L, Huang JYJ, Demirtas E, Holzer H, Benjamin A, Buckett Wm, Tulandi T, Tan Sl. Live birth after vitrification of in vitro matured human Oocytes. Fertility and Sterility, 2007; doi 10.1016/j.fertnstert.2007.11.088 Kolb S*, Radon K, Goldberg MS. The short-term influence of weather on daily mortality in congestive heart failure. Arch Environ and Occup Health 2007;62(4):169-76. JY Kim, RT Burnett, L Neas, GD Thurston, J Schwartz, PE Tolbert, B Brunekreef, MS Goldberg, I Romieu. Panel Discussion Review: Session Two – Interpretation of Observed Associations between Multiple Ambient Air pollutants and Health Effects in Epidemiologic Analyses. Journal of Exposure Science and Environmental Epidemiology 2007;17:S83-S89. II-6  
  • 154. Dept. of Oncology Appendix II: Publications January-December 2007 Goldberg MS. On the interpretation of epidemiological studies of ambient air pollution. Journal of Exposure Science and Environmental Epidemiology. Journal of Exposure Science and Environmental Epidemiology 2007;17:S66-S70. Jeffrey R. Brook, Richard T. Burnett, Tom F. Dann, Sabit Cakmak, Mark S. Goldberg, Xinghua Fan. Further Interpretation of the Acute Effect of Nitrogen Dioxide Observed in Canadian Time Series Studies. Journal of Exposure Science and Environmental Epidemiology. Journal of Exposure Science and Environmental Epidemiology 2007;17:S36–S44. Nicolas L. Gilbert, Mark S. Goldberg, Jeffrey R. Brook, Michael Jerrett. The influence of highway traffic on ambient nitrogen dioxide concentrations beyond the immediate vicinity of highways. Atmospheric Environment. Atmospheric Environment, 2007;41:2670–2673. Bruchim I, Gotlieb WH, Mahmud S, Tunitsky E, Grzywacz K, Ferenczy A. HPV related vulvar intraepithelial neoplasia: outcome of different management modalities. Intl J Gynecol Obstet. 2007 Fung-Kee-Fung M, Provencher D, Rosen B, Hoskins P, Rambout L, Oliver T, Gotlieb WH, Covens A. Intraperitoneal chemotherapy for patients with advanced ovarian cancer: A review of the evidence and standards for the delivery of care. Gynecol Oncol. 2007 Yinon Y, Beiner ME, Gotlieb WH, Korach Y, Perri T, Ben-Baruch G. Clinical outcome of cystectomy compared with unilateral salpingo-oophorectomy as fertility-sparing treatment of borderline ovarian tumors. Fertil Steril (2007) 88:479–84 Ferenczy A, Gotlieb W, Lau S. Benign glandular inclusions in pelvic sentinel lymph nodes may cause false-positive histological diagnosis. Gynecol Oncol (2007) 107:156-7 Petignat P, Gotlieb W Advancing women’s cancer care. Gynakol Geburtshilfliche Rundsch (2007) 47 : 240-242 Hirsh V, Soulieres D, Duclos M, Faria S, Del Vecchio P, Ofiara L, Ayoub JP, Charpentier D, Gruber J, Portelance L, Souhami L. Phase II multicenter trial with carboplatin and gemcitabine induction chemotherapy followed by radiotherapy concomitantly with low-dose paclitaxel and gemcitabine for stage IIIA and IIIB non- small cell lung cancer. J Thor Oncol 2:927-932, 2007. Pietila TE, Veckman V,Lehtonen A, Lin R, Hiscott J, Julkunen I. Multiple NF-κB and interferon regulatory factors regulate CCL19 gene expression in human monocyte- derived dendritic cells. J. Immunol. 178: 253-261 (2007). II-7  
  • 155. Dept. of Oncology Appendix II: Publications January-December 2007 Solis M, Romieu-Mourez R, Goubau D, Grandvaux N, Mesplede T, Julkunen I, Nardin A, Salcedo M, Hiscott J. Involvement of TBK1 and IKKε in LPS-induced activation of the interferon response in primary human macrophages. Eur. J. Immunol. 37 : 528-539 (2007). Sharif-Askari E, Nakhaei P, Oliere S, Tumilasci V, Hernandez E, Wilkinson P, Lin R, Bell J, Hiscott J. Bax-dependent mitochondrial depolarization promotes IRF3-mediated innate immune responses during VSV oncolysis. Virology 365 : 20-33 (2007). Zhao TJ, Yang L, Sun Q, Arguello M, Ballard DW, Hiscott J, Lin R. The NEMO/IKK adapter bridges NF-κB and IRF signaling pathways. Nature Immunology, 8: 592-600 (2007). Holm GH, Zurney J, Tumilasci V, Leveille S, Danthi P, Hiscott J, Sherry B, and Dermody TS.. RIG-I and IPS-1 augment proapoptotic responses following mammalian reovirus infection via IRF-3. J. Biol. Chem. 282: 21953-61 (2007). Solis M, Goubau D, Hiscott J. RIG-I has guts: identification of a role for RIG-I in colitis development. Cell Res. 17:974-975 (2007). Lezin A, Gillet N, Olindo S, Signate A, Grandvaux N, Verlaeten O, Belrose G, Bittencourt M, Hiscott J, Burny A, Cesaire R, Willems L. Histone deacetylase mediated transcriptional activation reduces proviral loads in HAM/TSP patients. Blood 110: 3722- 3728 (2007). Caposio P, Gugliesi F, Zannetti C, Sponza S, Mondini M, Medico E, Hiscott J, Young HA, Gribaudo G, Gariglio M, Landolfo S. A novel role of the interferon-inducible protein IFI16 as inducer of proinflammatory molecules in endothelial cells. J. Biol. Chem. 282: 33515-33529 (2007). Arguello M and Hiscott J. UB surprised: Viral OTU-domain proteases remove ubiquitin and ISG15 conjugates. Cell Host and Microbe 2:367-369 (2007). Hiscott J. Triggering the innate antiviral response through IRF-3 activation. J. Biol. Chem. 282: 15325-29 (2007). (Innate immunity series – S. Akira, T. Fujita, J. Hiscott). Hiscott J. Convergence of the NF-κB and IRF pathways in the regulation of antiviral defense. Special Issue on the Milstein Awards, Cyto. Growth Factor Rev. 18: 483-490 (2007). Lemay G, Tumilasci V, Hiscott J. Uncoating Reo: uncovering the critical steps for oncolysis. Mol. Therapy 15: 1406-7 (2007). II-8  
  • 156. Dept. of Oncology Appendix II: Publications January-December 2007 Hagen NA, Fisher KM, Lapointe B, du Souich P, Chary S, Moulin D, Sellers E, Ngoc AH,; on behalf of the Canadian Tetrodotoxin Study Group. An Open-Label, Multi-Dose Efficacy and Safety Study of Intramuscular Tetrodotoxin in Patients with Severe Cancer- Related Pain. J Pain Symptom Manage. 2007;34: 171-182 Liben S, Papadatou D, Wolfe J. Paediatric palliative care; challenges and emerging ideas. The Lancet August 16, DOI:10.1016/S0140-6736(07)61203-3, 2007 Mongeau S, Champagne M, Liben S. Participatory Research in Pediatric Palliative Care: Benefits and Challenges. J of Pall. Care 23:15-13, 2007 Loiselle, C. G. (2007). Training the next generation of researchers in psychosocial oncology: An innovative transdisciplinary multimethod approach. Brazilian Journal of Cognitive Therapies, 3(2), 17-24. Lambert, S., & Loiselle, C. G. (2007). Health information-seeking behaviour. Qualitative Health Research, 17(8), 1006-1019. Philibert, M., Pampalon, R., Hamel, D., Thouez, J-P., & Loiselle, C. G. (2007). Material and social deprivation and health and social services utilisation in Québec: A local-scale evaluation system. Social Science & Medicine, 64(8), 1651-1664. Macdonald, ME, Carnevale, FA, Razack, S. Understanding What Residents Want and What Residents Need: The Challenge of Cultural Training in Pediatrics. Medical Teacher 2007, 29(5): 464–471 MacDonald N. Cancer Cachexia and Targeting Chronic Inflammation: a unified approach to cancer treatment and palliative/supportive care. Journal of Supportive Oncology 2007;5(4):157-162. Discussion 164-166, 183. MacDonald N. Cancer symptom control trials: how may we advance this field? Current Oncology 2007;14(3):86-88. De Lima L, Krakauer E, Lorenz K, Praill D, MacDonald N, Doyle D. Ensuring Palliative Medicine Availability: the development of the IAHPC List of Essential Medicines for Palliative Care. Journal of Pain and Symptom Management 2007; 33(5):521-526. MacDonald N. Cancer Cachexia and Targeting Chronic Inflammation: a unified approach to cancer treatment and palliative/supportive care. Journal of Supportive Oncology 2007;5(4):157-162. Schricker T., Meterissian S., Donatelli F., Carvalho G., Mazza L., Eberhart L., Wykes L. and Carli F. 2007 Parenteral nutrition and protein sparing after surgery: do we need glucose? Metabolism , 56:1044-1050 II-9  
  • 157. Dept. of Oncology Appendix II: Publications January-December 2007 Schricker T., Wykes L., Carvalho G., Mazza L., Eberhart L., Carli F. and Meterissian S. 2007 Perioperative amino acid supplementation of hypocaloric glucose does not impair glucose metabolism after surgery Metabolism 56(11):1508-13. Neumayer L., Meterissian S., McMasters K., Members of the Evidence-Based Reviews in Surgery Group 2007 Canadian Association of General Surgeons and American College of Surgeons Evidence-Based Reviews in Surgery. 23. ASCO recommended guidelines for sentinel lymph node biopsy for early-stage breast cancer Can. J. Surg. 50:482-4 Meterissian S., Liberman M. and McLeod P 2007 Games as Teaching Tools in a Surgical Residency Med Teach. 29:e258-60 Assaraf M, Diaz Z, Liberman A, Miller WH Jr, Arvanitakis Z, Li Y, Bennett D, Schipper HM. Brain Erythropoietin Receptor Expression in Alzheimer Disease and Mild Cognitive Impairment. J Neuropath and Exp Neurology, 66:389-398, 2007. Diaz Z, Laurenzana A, Mann K, Schipper H, and Miller WH Jr. Trolox enhances the anti-lymphoma effects of As2O3, while protecting against liver toxicity. Leukemia, 21:2117-2127, 2007. Goss P, Bondarenko I, Manikhas G, Pendergrass K, Miller WH Jr, Langecker P, Blanchett D. Atamestane plus Toremifene versus Letrozole in Postmenopausal Women with Advanced Receptor Positive Breast Cancer: Phase III Double Blind Controlled Trial. Journal of Clinical Oncology, 25:4961-4966, 2007. Goulet, B., L. Sansregret, L. Leduy, M. Bogyo, E. Weber, S. Chauhan and A. Nepveu. Increased Expression and Activity of Nuclear Cathepsin L in Cancer Cells Suggests a Novel Mechanism of Cell Transformation. Molecular Cancer Research, 5:899-907. 2007. Truscott, M., J.-B. Denault, B. Goulet, L. Leduy, G. Salvesen and A. Nepveu. Carboxy- terminal proteolytic processing of CUX1 by a caspase enables transcriptional activation in proliferating cells. Journal of Biological Chemistry, 282:30216–30226. 2007. Niazi TM, Elliott E, Olivotto I, Ackerman I, Chua B, Bowen J, Sussman J, Truong P, Parulekar, W, Whelan TJ. An Analysis of the Real Time Radiotherapy Review Process in an International Phase III Study: MA.20 Int J Radiat Oncol Biol Phys. V (69) S183; Oct 2007. Niazi TM, Parulekar W, Brundage M, Cakir B, Whelan TJ , Parliament MB. What Is Adequate Radiotherapy Quality Assurance in Phase III Clinical Trials Involving Radiation Therapy. Radiot Oncol. CARO supplement, Oct 2007. II-10  
  • 158. Dept. of Oncology Appendix II: Publications January-December 2007 Niazi TM, Burcu Cakir, Michael Brundage, Wendy Parulekar, and Matthew B. Parliament. A review of Quality Assurance (QA) including Real Time Review (RTR) in the trials involving Radiotherapy (RT). Journal of Clinical Trials. ACT Supplement, 2007. Watts JK, Choubdar N, Sadalapure K, Robert F, Wahba AS, Pelletier J, Mario Pinto B, Damha MJ. (2007) 2'-Fluoro-4'-thioarabino-modified oligonucleotides: conformational switches linked to siRNA activity. Nucleic Acids Res. 35, 1441-1451 Akimitsu, N., Tanaka, J., and Pelletier, J. (2007). Translation of nonSTOP mRNA is repressed post-initiation in mammalian cells. EMBO J. 26, 2327-2338 Cencic. R., Yan, Y., and Pelletier, J. (2007). Homogenous time resolved fluorescence assay to identify modulators of cap-dependent translation initiation. Combinatorial Chemistry & High Throughput Screening. 10, 181-188. Costa-Mattioli, M., Gobert, D., Stern, E., Gamache, K., Colina, R., Cuello, C., Sossin, W., Kaufman, R., Pelletier, J., Rosenblum, K., Krnjevic, K., Lacaille, J.-C. Nader, K., and Sonenberg, N. (2007) eIF2a phosphorylation bidirectionally regulates the switch from short- to long-term synaptic plasticity and memory. Cell 129, 195-206. Kazemi, S., Mounir, Z., Baltzis, D., Raven, J.F., Wnag, S., Krishnamoorthy, J.L., Pluquet, O., Pelletier, J., and Koromilas, A.E. (2007). A novel function of eIF2a kinases as inducers of the phosphoinositide-3-kinase signaling pathway. Mol. Biol. Cell. 18:3635-3644. Gerard, B., Cencic, R., Pelletier, J., and Porco, J.A., Jr. (2007). Enantioselective synthesis of the complex rocaglate (-)-silvestrol. Angew. Chem. Int. Ed. Engl. 46:7831- 7834. Wendel, H.G., Silva, R.L., Malina, A., Mills, J.R., Zhu, H., Ueda, T., Watanabe- Kukunaga, R., Fukunaga, R., Teruya-Feldstein, J., Pelletier, J., and Lowe, S. (2007) Genes Dev. 21: 3232-3237. Cencic, R., Robert, F., and Pelletier, J. (2007). Identifying small molecule inhibitors of eukaryotic translation initiation. Methods in Enzymology. 431: 269-302. A. Sarfehnia†, K. Jabbari, J.P. Seuntjens, E. B. Podgorsak, Experimental verification of beam quality in high-contrast imaging with orthogonal bremsstrahlung photon beams, Med. Phys. 34, 2896-2906 (2007). S. Devic, T. Vuong, B. Moftah, M.D.C. Evans, E.B. Podgorsak, Image-guided high dose rate endorectal brachytherapy, Med. Phys 34, 4451-4458 (2007). II-11  
  • 159. Dept. of Oncology Appendix II: Publications January-December 2007 S. Devic, N. Tomic, Z. Pang, J.P. Seuntjens, E.B. Podgorsak, C.G. Soares, Absorption spectroscopy of EBT model GAFCHROMICTM film, Med. Phys. 34, 112-118 (2007). S. Devic, N. Tomic, S. Faria, G. Dean, R. Lisbona, W. Parker, C. Kaufmann, E.B. Podgorsak, Impact of 18FDGPET/CT on biological target volume (BTV) definition for treatment planning for non-small cell lung cancer patients, Nuclear Instruments and Methods in Physics Research 571, 89-92 (2007). M.D.C. Evans, S. Devic, E.B. Podgorsak, High dose-rate brachytherapy source position quality assurance using radiochromic film, Med. Dosim. 32, 13-15 (2007). M.E.R. Poli, W. Parker, H.J. Patrocinio, L. Souhami, G. Shenouda, L. L. Campos, E.B. Podgorsak, An assessment of PTV margin definitions for patients undergoing conformal 3D external beam radiation therapy for prostate cancer based on an analysis of 10,327 pretreatment daily ultrasound localizations, Int. J. Rad. Oncology Biol. Phys. 67, 1430- 1437 (2007). N. Tomic, M. Gosselin, J.F. Wan, U. Saragovi, E.B. Podgorsak, M.D.C. Evans, S. Devic, Verification of cell irradiation dose deposition using a radiochromic film, Phys. Med. Biol 52, 3121-3131 (2007). W. Parker, M.E.R. Poli, H.J. Patrocinio, L. Souhami, G. Shenouda, E.B. Podgorsak, In reply to Dr. Scarborough et al., Int J Radiat Oncol Biol Phys. 68, 1579-80 (2007). Schwartz M, Vuong T, Ballivy O, Parker W, Patrocinio H, Podgorsak E. Accelerated radiotherapy using simultaneous integrated boost fractionation scheme and intensity modulated radiotherapy (SIB-IMRT) for advanced head and neck cancer. Otolaryngology-Head and Neck Surgery. 2007 Apr; 136(4): 549-55. Liu B, Lee KW, Anzo M, Zhang B, Zi X, Tao Y, Shiry L, Pollak M, Lin S, Cohen P. Insulin-like growth factor-binding protein-3 inhibition of prostate cancer growth involves suppression of angiogenesis. Oncogene. 26: 1811-9, 2007. Okereke O, Kang JH, Ma J, Hankinson SE, Pollak MN, Grodstein F. Plasma IGF-I levels and cognitive performance in older women. Neurobiol Aging. 28: 135-42, 2007. Eliassen AH, Tworoger SS, Mantzoros CS, Pollak MN, Hankinson SE. Circulating insulin and c-peptide levels and risk of breast cancer among predominately premenopausal women. Cancer Epidemiol Biomarkers Prev. 16: 161-4, 2007. Pollak M. Insulin-like growth factor-related signaling and cancer development. Recent Results Cancer Res. 174: 49-53, 2007. II-12  
  • 160. Dept. of Oncology Appendix II: Publications January-December 2007 Tamimi RM, Cox DG, Kraft P, Pollak MN, Haiman CA, Cheng I, Freedman ML, Hankinson SE, Hunter DJ, Colditz GA. Common genetic variation in IGF1, IGFBP-1, and IGFBP-3 in relation to mammographic density: a cross-sectional study. Breast Cancer Res. 9: R18, 2007. Kaplan RC, McGinn AP, Pollak MN, Kuller LH, Strickler HD, Rohan TE, Cappola AR, Xue X, Psaty BM. Association of total IGF-I, IGFBP-1 and IGFBP-3 levels with incident coronary events and ischemic stroke. J Clin Endocrinol Metab. 92: 1319-25, 2007. Schaffer A, Koushik A, Trottier H, Duarte-Franco E, Mansour N, Arseneau J, Provencher D, Gilbert L, Gotlieb W, Ferenczy A, Coutlee F, Pollak MN, Franco EL; Biomarkers of Cervical Cancer Risk Study Team. Insulin-like growth factor-I and risk of high-grade cervical intraepithelial neoplasia. Cancer Epidemiol Biomarkers Prev. 16: 716-22, 2007. Lonn S, Inskip PD, Pollak MN, Weinstein SJ, Virtamo J, Albanes D. Glioma risk in relation to serum levels of insulin-like growth factors. Cancer Epidemiol Biomarkers Prev. 16: 844-6, 2007. McSorley MA, Alberg AJ, Allen DS, Allen NE, Brinton LA, Dorgan JF, Pollak M, Tao Y, Helzlsouer KJ. C-reactive protein concentrations and subsequent ovarian cancer risk. Obstet Gynecol. 109: 933-41, 2007. Brisson J, Berube S, Diorio C, Sinotte M, Pollak M, Masse B. Synchronized seasonal variations of mammographic breast density and plasma 25-hydroxyvitamin d. Cancer Epidemiol Biomarkers Prev. 16: 929-33, 2007. Levitt RJ, Zhao Y, Blouin MJ, Pollak M. The hedgehog pathway inhibitor cyclopamine increase levels of p27, and decreases both expression of IGF-II and activation of Akt in PC-3 prostate cancer cells. Cancer Lett. 255: 300-6, 2007. de Bono JS, Attard G, Adjei A, Pollak MN, Fong PC, Haluska P, Roberts L, Melvin C, Repollet M, Chianese D, Connely M, Terstappen LW, Gualberto A. Potential applications for circulating tumor cells expressing the insulin-like growth factor-I receptor. Clin Cancer Res. 13: 3611-6, 2007. Pollak MN. Insulin, insulin-like growth factors, insulin resistance, and neoplasia. Am J Clin Nutr. 86: S820-1, 2007. Tworoger SS, Lee IM, Buring JE, Pollak MN, Hankinson SE. Insulin-like growth factors and ovarian risk: a nested case-control study in three cohorts. Cancer Epidemiol Biomarkers Prev. 16: 1691-5, 2007. Li H, Bubley GJ, Balk SP, Gaziano JM, Pollak M, Stampfer MJ, Ma J. Hypoxia- inducible factor-1 alpha gene polymorphisms, circulating insulin-like growth factor binding protein-3 levels and prostate cancer. Prostate 67: 1354-61, 2007. II-13  
  • 161. Dept. of Oncology Appendix II: Publications January-December 2007 Wolpin BM, Michaud DS, Giovannucci EL, Schernhammer ES, Stampfer MJ, Manson JE, Cochrane BB, Rohan TE, Ma J, Pollak MN, Fuchs CS. Circulating insulin-like growth factor binding protein-1 and the risk of pancreatic cancer. Cancer Res. 67: 7923- 8, 2007. Michaud DS, Wolpin B, Giovannucci E, Liu S, Cochrane B, Manson JE, Pollak MN, Ma J, Fuchs CS. Prediagnostic plasma C-Peptide and pancreatic cancer risk in men and women. Cancer Epidemiol Biomarkers Prev. 16: 2101-9, 2007. Wolpin BM, Michaud DS, Giovannucci EL, Schernhammer ES, Stampfer MJ, Manson JE, Cochrane BB, Rohan TE, Ma J, Pollak MN, Fuchs CS. Circulating insulin-like growth factor axis and the risk of pancreatic cancer in four prospective cohorts. Br J Cancer. 97: 98-104, 2007. Schernhammer ES, Tworoger SS, Eliassen AH, Missmer SA, Holly JM, Pollak MN, Hankinson SE. Body shape throughout life and correlations with IGFs and GH. Endocr Relat Cancer. 14: 721-32, 2007. Rich-Edwars JW, Ganmaa D, Pollak MN, Nakamoto EK, Kleinman K, Tserendolgor U, Willett WC, Frazier AL. Milk consumption and the prepubertal somatotropic axis. Nutr J. 6: 28, 2007. Borugian MJ, Spinelli JJ, Sun Z, Kolonel LN, Oakley-Girvan I, Pollak M, Whittemore AS, Wu AH, Gallagher RP. Prediagnostic C-peptide and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev. 16: 2164-5, 2007. Dowling RJ, Zakikhani M, Fantus IG, Pollak M, Sonenberg N. Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Res. 67: 10804-12, 2007. Raina K, Blouin MJ, Singh RP, Majeed N, Deep G, Varghese L, Glode LM, Greenberg NM, Hwang D, Cohen P, Pollak MN, Agarwal R. Dietary feeding of silibinin inhibits prostate tumor growth and progression in transgenic adenocarcinoma of the mouse prostate model. Cancer Res. 67: 11083-91, 2007. Singh RP, Deep G, Blouin MJ, Pollak MN, Agarwal R. Silibinin suppresses in vivo growth of human prostate carcinoma PC-3 tumor xenograft. Carcinogenesis. 28: 2567- 74, 2007. Venkateswaran V, Haddad AQ, Fleshner NE, Fan R, Sugar LM, Nam R, Klotz LH, Pollak M. Association of diet-induced hyperinsulinemia with accelerated growth of prostate cancer (LNCaP) xenografts. J Natl Cancer Inst. 99: 1793-800, 2007. Patone H, Souhami L, Parker W, Evans M, Duclos M, Portelance L. A dosimetric comparison of two high-dose-rate brachytherapy planning systems in cervix cancer: II-14  
  • 162. Dept. of Oncology Appendix II: Publications January-December 2007 Standardized template planning vs. computerized treatment planning.  Brachytherapy. 2008 Jul-Sep;7(3):254-9. Epub 2008 Jun 24. Small W Jr, Mell LK, Anderson P, Creutzberg C, De Los Santos J, Gaffney D, Jhingran A, Portelance L, Schefter T, Iyer R, Varia M, Winter K, Mundt AJ.  Consensus guidelines for delineation of clinical target volume for intensity-modulated pelvic radiotherapy in postoperative treatment of endometrial and cervical cancer.  Int J Radiat Oncol Biol Phys. 2008 Jun 1;71(2):428-34. Epub 2007 Nov 26. Gaffney DK, Du Bois A, Narayan K, Reed N, Toita T, Pignata S, Blake P, Portelance L, Sadoyze A, Pötter R, Colombo A, Randall M, Mirza MR, Trimble EL. Practice patterns of radiotherapy in cervical cancer among member groups of the Gynecologic Cancer Intergroup (GCIG). Int J Radiat Oncol Biol Phys. 2007 Jun 1;68(2):485-90. Epub 2007 Mar 2. Devy L, Rabbani SA, Stochl M, Ruskowski M, Mackie I, Naa L, Toews M, van Gool R, Chen J, Ley A, Ladner RC, Dransfield DT, Henderikx P. PEGylated DX-1000: pharmacokinetics and antineoplastic activity of a specific plasmin inhibitor. Neoplasia. 2007 Nov;9(11):927-37. Chen L, Maures TJ, Jin H, Huo JS, Rabbani SA, Schwartz J, Carter-Su C. SH2B1beta (SH2-Bbeta) enhances expression of a subset of nerve growth factor-regulated genes important for neuronal differentiation including genes encoding urokinase plasminogen activator receptor and matrix metalloproteinase 3/10. Mol Endocrinol. 2008 Feb;22(2):454-76. Epub 2007 Oct 18. Garde SV, Forté AJ, Ge M, Lepekhin EA, Panchal CJ, Rabbani SA, Wu JJ. Binding and internalization of NGR-peptide-targeted liposomal doxorubicin (TVT-DOX) in CD13- expressing cells and its antitumor effects. Anticancer Drugs. 2007 Nov;18(10):1189-200. Rabbani SA, Mazar AP. Evaluating distant metastases in breast cancer: from biology to outcomes. Cancer Metastasis Rev. 2007 Dec;26(3-4):663-74. Casimiro M, Rodriguez O, Pootrakul L, Aventian M, Lushina N, Cromelin C, Ferzli G, Johnson K, Fricke S, Diba F, Kallakury B, Ohanyerenwa C, Chen M, Ostrowski M, Hung MC, Rabbani SA, Datar R, Cote R, Pestell R, Albanese C. ErbB-2 induces the cyclin D1 gene in prostate epithelial cells in vitro and in vivo. Cancer Res. 2007 May 1;67(9):4364-72. Jallal H, Valentino ML, Chen G, Boschelli F, Ali S, Rabbani SA. A Src/Abl kinase inhibitor, SKI-606, blocks breast cancer invasion, growth, and metastasis in vitro and in vivo. Cancer Res. 2007 Feb 15;67(4):1580-8. II-15  
  • 163. Dept. of Oncology Appendix II: Publications January-December 2007 C. Milsom, G. M. Anderson, J. I. Weitz & J. Rak (corresponding author): Elevated tissue factor procoagulant activity in CD 133-positive cancer cells. Journal of Thrombosis and Haemostasis, 2007, 5, 12:2550-2552 H. Klement, B. St. Croix, C. Milsom, L. May, J. L. Yu, P. Klement & J. Rak Atherosclerosis and vascular aging as modifiers of tumor progression, angiogenesis and responsiveness to therapy. American Journal of Pathology 2007, 171, 4: 1342-1351 M. Derouet, L. May, X. Wu, T. Sasazuki, S. Shirasawa, J. Rak and K. V. Rosen. Oncogenic mutations of ras but not loss of p53 are required for anoikis resistance of colorectal cancer cells. Neoplasia 2007, 7:536-545 C. Milsom, J. Yu, L. May, B. Meehan, Nathalie Magnus, K. Al-Nedawi, J. Luyendyk, J. Weitz, P. Klement, G. Broze, N. Mackman & J. Rak (corresponding author): The role of tumor- and host-related tissue factor pools in oncogene-driven tumor progression. Thrombosis Research, 2007, 120, Supp. 2:S82-S91 D. Roberge, T. Muanza, G. Blake, C. Shustik, T. Vuong, C.R. Freeman. Does adjuvant alpha-interferon improve outcome when combined with total skin irradiation for mycosis fungoides? . Br.J. Dermatolol. 2007(1) 56:57-61. Ivanisevic L, Zheng W, Woo SB, Neet KE, Saragovi HU. TrkA receptor "hot spots" for binding of NT-3 as a heterologous ligand. J Biol Chem. 2007 Jun 8;282(23):16754-63. Moffett, Serge., Melançon, Dominic., Decrescenzo, Gregory., St-Pierre, Caroline., Deschênes, François., Saragovi, H. Uri., Gold, P., and Cuello, A. Claudio. Preparation and Characterization of New Anti-PSMA Monoclonal Antibodies with Potential Clinical Use. Hybridoma, v. 26, Number 6, 2007 Shi Z, Birman E, Saragovi HU. Neurotrophic rationale in glaucoma: a TrkA agonist, but not NGF or a p75 antagonist, protects retinal ganglion cells in vivo. Dev Neurobiol. 2007 Jun;67(7):884-94. Erratum in: Dev Neurobiol. 2007 Sep 15;67(11):1547-8. Lowenthal JW, Malek TR, Saragovi H. Measurement of lymphokine receptors. Curr Protoc Immunol. 2001 May;Chapter 6:Unit 6.1. Moffett S, Mélançon D, DeCrescenzo G, St-Pierre C, Deschénes F, Saragovi HU, Gold P, Cuello AC. Preparation and characterization of new anti-PSMA monoclonal antibodies with potential clinical use. Hybridoma (Larchmt). 2007 Dec;26(6):363-72. Angell Y, Chen D, Brahimi F, Saragovi HU, Burgess K. A combinatorial method for solution-phase synthesis of labeled bivalent beta-turn mimics. J Am Chem Soc. 2008 Jan 16;130(2):556-65. II-16  
  • 164. Dept. of Oncology Appendix II: Publications January-December 2007 K. Al-Yahya, F. Verhaegen, J.P. Seuntjens, Design and dosimetry of a few leaf electron collimator for energy modulated electron therapy, Med. Phys. 34, 4782-91 (2007). K. Jabbari, A. Sarfenia†, E.B. Podgorsak, J.P. Seuntjens, Monte Carlo feasibility study of orthogonal bremsstrahlung beams for improved radiation therapy imaging, Phys. Med. Biol. 52, 1171-1184 (2007). A. Alexander, F. DeBlois, G. Stroian, K Al-Yahya†, E. Heath†, J.P. Seuntjens, MMCTP: A radiotherapy research environment for Monte Carlo and patient-specific treatment planning, Phys. Med. Biol. 52, N1-N12, (2007). Sarfehnia A, Stewart K, Seuntjens J. An absorbed dose to water standard for HDR 192Ir brachytherapy sources based on water calorimetry: numerical and experimental proof-of- principle. Med Phys. 2007 Dec;34(12):4957-61. Chetty IJ, Curran B, Cygler JE, DeMarco JJ, Ezzell G, Faddegon BA, Kawrakow I, Keall PJ, Liu H, Ma CM, Rogers DW, Seuntjens J, Sheikh-Bagheri D, Siebers JV. Report of the AAPM Task Group No. 105: issues associated with clinical implementation of Monte Carlo-based photon and electron external beam treatment planning. Med Phys. 2007 Dec;34(12):4818-53. Heath E, Collins DL, Keall PJ, Dong L, Seuntjens J. Quantification of accuracy of the automated nonlinear image matching and anatomical labeling (ANIMAL) nonlinear registration algorithm for 4D CT images of lung. Med Phys. 2007 Nov;34(11):4409-21. Stewart KJ, Elliott A, Seuntjens JP. Development of a guarded liquid ionization chamber for clinical dosimetry. Phys Med Biol. 2007 Jun 7;52(11):3089-104. Epub 2007 May 10. M.Aslani, K.Sultanem, T.Vuong, M.Hier, T. M. Niazi, G.Shenouda. Metastatic carcinoma to the cervical nodes from an unknown head and neck primary site: Is there a need for neck dissection? Head and Neck.2007, Jun, 29 (6): 585-90. Machtay M. Pajak TF. Suntharalingam M. Shenouda G. Hershock D. Stripp DC. Cmelak AJ. Schulsinger A. Fu KK. Radiation Therapy Oncology Group. Radiotherapy with or without erythropoietin for anemic patients with head and neck cancer: a randomized trial of the Radiation Therapy Oncology Group (RTOG 99-03). International Journal of Radiation Oncology, Biology, Physics. 69(4):1008-17, 2007 Nov 15 Patel S, Portelance L, Gilbert L, Tan L, Stanimir G, Duclos M, Souhami L. Analysis of prognostic factors and patterns of recurrence in patients with pathologic Stage III endometrial cancer. Int J Radiat Oncol Biol Phys. 68:1438-1445, 2007. II-17  
  • 165. Dept. of Oncology Appendix II: Publications January-December 2007 Poon I, Xia P, Weinberg V, Sultanem K, Akazawa C, Akazawa P, Verhey L, Quivey JM, Lee N.A treatment planning analysis of inverse-planned and forward-planned intensity-modulated radiation therapy in nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 2007 Dec 1;69(5):1625-33. Abou Youssif T., Kassouf W., Steinberg J., Aprikain A.G., Laplante M., Tanguay S. Active surveillance for selected patients with renal masses: Updated results and long term follow up. Cancer, 110: 1010, 2007. Al-Otaibi M., Tanguay S. Management of locally advanced Renal Cell Carcinoma. Can Urol Ass J., 1: S55, 2007. Savoie S., Tanguay S., Centomo H., Beauchamp G., Anidjar M., Prince F. Postural control during laparoscopic tasks. Am J Surg., 193 : 498, 2007. Forget MA., Turcotte S., Beauseigle D., Godin-Ethier J., Pelletier S., Martin J., Tanguay S., Lapointe R. Wnt pathway regulator DKK1 is preferentially expressed in hormone- resistant breast tumours and in some common cancer types. Br J Cancer, 96: 646, 2007 Marc Tischkowitz, Jean-Sébastien Brunet, Louis R Bégin, David G. Huntsman, Maggie CU Cheang, Lars Akslen, Torsten O. Nielsen and William D Foulkes. The influence of additional basal markers on the prognosis of “triple negative” (ER, PR-, HER2-) breast cancer – a two centre study. BMC Cancer 2007;7(1):134 Kaurah P, Macmillan A, Boyd N, Senz J, De Luca A, Chun N, Suriano G, Zaor S, Van Manen L, Gilpin C, Nikkel S, Connolly-Wilson M, Weissman S, Rubinstein WS, Sebold C, Greenstein R, Stroop J, Yim D, Panzini B, McKinnon W, Greenblatt M, Wirtzfeld D, Fontaine D, Coit D, Yoon S, Chung D, Lauwers G, Pizzuti A, Vaccaro C, Redal MA, Oliveira C, Tischkowitz M, Olschwang S, Gallinger S, Lynch H, Green J, Ford J, Pharoah P, Fernandez B, Huntsman D. Founder and Recurrent CDH1 Mutations in Families with Hereditary Diffuse Gastric Cancer. JAMA. 2007;297(21):2360-72. Georgitsi M, Raitila A, Karhu A, van der Luijt RB, Aalfs CM, Sane T, Vierimaa O, Makinen MJ, Tuppurainen K, Paschke R, Gimm O, Koch CA, Gundogdu S, Lucassen A, Tischkowitz M, Izatt L, Aylwin S, Bano G, Hodgson S, De Menis E, Launonen V, Vahteristo P, Aaltonen LA. Germline CDKN1B/p27Kip1 mutation in multiple endocrine neoplasia. J Clin Endocrinol Metab. 2007;92(8):3321-5 Tischkowitz, M., Xia, B., Sabbaghian, N., Reis-Filho, J. S., Hamel, N., Li, G., Van Beers, E. H., Li, L., Khalil, T., Quenneville, L., Omeroglu, A., Poll, A., Wong, N., Nederlof, P. M., Ashworth, A., Tonin, P. N., Narod, S., Livingston, D. M. and Foulkes, W. Analysis of PALB2/FANCN–associated breast cancer families. Proc Natl Acad Sci U S A 2007; 104 (16): 6788-6793. II-18  
  • 166. Dept. of Oncology Appendix II: Publications January-December 2007 Reid, S., Schindler, D., Hanenberg, H., Barker, K., Hanks, S., Kalb, R., Neveling, K., Kelly, P., Seal, S., Freund, M., Wurm, M., Batish, S. D., Lach, F. P., Yetgin, S., Neitzel, H., Ariffin, H., Tischkowitz, M., Mathew, C. G., Auerbach, A. D. & Rahman, N. Biallelic mutations in PALB2, which encodes a BRCA2 interacting protein, cause Fanconi anemia subtype FA-N and predispose to childhood cancer 2007; Nat Genet 39: 162-4. Benoît M-H, Hudson TJ, Maire G, Squire JA, Provencher D, Mes-Masson A-M, Tonin PN. 2007. Global analysis of chromosome X gene expression in primary cultures of normal surface epithelial cells of the ovary and epithelial ovarian cancer cell lines. Int J Oncol. 30(1):5-17. Zietarska M, Maugard CM, Filali-Mouhim A, Alam-Fahmy M, Tonin PN, Provencher DM, Mes-Masson A-M. 2007. Molecular description of a 3D in vitro model for the study of epithelial ovarian cancer (EOC). Mol Carcinog 46(10):872-85. Ouellet V, Le Page C, Madore J, Guyot MC, Barrès V, Lussier C, Tonin PN, Provencher DM, Mes-Masson AM. 2007. An apoptotic molecular network identified by microarray: On the TRAIL to new insights in epithelial ovarian cancer. Cancer. 110(2):297-308. Tonin PN, Maugard CM, Perret C, Mes-Masson A-M, Provencher DM. 2007. A review of histopathological subtypes of ovarian cancer in BRCA-related French Canadian cancer families. Fam Cancer 6(4):491-7. Puiffe M-L, Le Page C, Filali-Mouhim A, Ziertarska M, Ouellet V, Tonin PN, Chevrette M , Provencher DM, Mes-Masson M-M. 2007. Characterization of ovarian cancer ascites on cell invasion, proliferation, spheroid formation and gene expression in an in vitro model of epithelial ovarian cancer. Neoplasia 9(10): 820-829. Wojnarowicz PM, Breznan A, Arcand SL, Filali-Mouhim A, Provencher DM, Mes- Masson A-M, Tonin PN. 2007. Construction of a chromosome 17 transcriptome in serous ovarian cancer identifies differentially expressed genes. Int J Gynecol Cancer 2007 Nov 19. [Epub ahead of print] J.F. Carrier, M. D’Amours, F. Verhaegen, B. Reniers, A.G. Martin, E. Vigneault, L. Beaulieu, Postimplant dosimetry using a monte carlo dose calculation engine: A new clinical standard, Int. J. Radiat. Oncol. Biol. Phys. 68, 1190-1198 (2007). S. Devic, T. Vuong, B. Moftah, M. Evans, E. B. Podgorsak, E. Poon, and F. Verhaegen. Image Guided High Dose Rate Endorectal Brachytherapy. Medical Physics 2007, 34: (11). 4451-58. Liu D, Poon E, Bazalova M, Reniers B, Evans M, Rusch T, Verhaegen F. Spectroscopic characterization of a novel electronic brachytherapy system. II-19  
  • 167. Dept. of Oncology Appendix II: Publications January-December 2007 T. Vuong, S. Devic, E. Podgorsak, High dose rate endorectal brachytherapy as a neoadjuvant treatment for patients with resectable rectal cancer, Clinical Oncology 19, 701-705 (2007). T. Vuong, N. Kopek, T. Ducruet, L. Portelance, B. Bahoric, S. Faria, S. Devic, Conformal therapy improves the therapeutic index of patients with anal canal cancer treated with combined chemotherapy and external beam radiotherapy, Int. J. Rad. Oncology Biol. Phys. 67, 1394-1400 (2007). M. Schwartz, T. Vuong, O. Ballivy, W. Parker, H.J. Patrocinio, Accelerated radiotherapy with simultaneous integrated boost fractionation and intensity-modulated radiotherapy for advanced head and neck cancer, Otolaryngology-Head and Neck Surgery 136, 549-555 (2007). I. Zlobec, T. Vuong, S.Hayashi, D.Haegert, L.Tornillo, L.Tornillo, A. Lugli, J. Jass. A simple and reproducible scoring system for EGFR in colorectal cancer: application to prognosis and prediction of response to brachytherapy. British Journal of Cancer, Feb. 2007.12,96(5). 793-800. Rafei, M.; Wu, J.H.; Lejeune, L.; François, M. and Galipeau, J. A GMCSF & IL15 fusokine leads to paradoxical immunosuppression in vivo via asymmetrical JAK/STAT signalling through the IL15 receptor complex. Blood, 2007, 109:2234-2242. Hamilton, D.; Wu, J.H. and *Batist, G. Structure-based identification of novel human γ- glutamylcysteine synthetase inhibitors. Mol. Pharmacol., 2007, 71:1140-1147. Yahyaoui, W., Callejo. M., Price, G.B. and Zannis-Hadjopoulos, M. (2007). Deletion of the cruciform binding domain in CBP/14-3-3 displays reduced origin binding and initiation of DNA replication in budding yeast. BMC Molecular Biology 8:27 (12 April 2007). Zannis-Hadjopoulos, M. (December 2007). DNA replication. In: Encyclopedia Of Life Sciences, John Willey & Sons, Ltd.; Chichester, UK http://www.els.net/ (Review - Peer- reviewed, [10.1002/9780470015902.a0005282.pub2]) Books and Book Chapters Branton, P.E., R.C. Marcellus, and E. Querido. 2007. Adenoviruses, In "Fundamentals of Molecular Virology". Ed. N. Acheson. John Wiley and Sons, New York, NY, Chapter 12: Adenoviruses. Franco EL, Mahmud S, Dean AG. Epidemiological Methods: A View from the Americas. In: Holland W, Olsen J, Florey C (eds.) The Development of Modern Epidemiology. Oxford University Press, 2007, pp. 275-287, ISBN 978-0-19-856954-1. II-20  
  • 168. Dept. of Oncology Appendix II: Publications January-December 2007 Mayrand MH, Franco EL. Chapter 8: Prevention of uterine cancers. In: Meisels A, Morin C (eds.) Modern Uterine Cytopathology. American Society of Clinical Pathologists, ASCP Press, Chicago, 2007, pp. 136-154. Spence A, Franco EL. Chapter 9: Epidemiology of uterine cancers. In: Meisels A, Morin C (eds.) Modern Uterine Cytopathology. American Society of Clinical Pathologists, ASCP Press, Chicago, 2007, pp. 155-168. Freeman, C.R., Farmer, J-P. Brain Stem Tumours. In: Clinics in Developmental Medicine. MacKeith Press, London. Eds: E.J. Estlin and S. Lowis. Chapter 12, pp 234-244, 2005. S. Lehnert, Biomolecular Action of Ionizing Radiation (530 pages), Taylor & Francis: London, England, 2007 (ISBN: 0750308249). Liben S. Pediatric Palliative Care In: Palliative Care: Core Skills & Clinical Competencies. LL Emanuel & SL Librach (eds). (2007). Saunders Elsevier Press. T.L. Phillips, E.E. Bloom, D.R. Clarke, L.W. Connell, R.P. Gardner, C.R. Liu, M. Lowenthal, R. McBurney, E.B. Podgorsak, T. Raubenheimer, S. Wagner, D.L. Weiner, “Radiation Source Use and Replacement” (10 chapters, 232 pages) The National Academies Press, Washington, D.C. (ISBN-10: 0-309-11014-9). Roberge D., Shenouda G., Souhami L. Pituitary In Perez and Brady's Principles and Practice of Radiation Oncology 5th Edition, Ed E C Halperin, C A Perez, L W Brady, and D E Wazer, Lippincott 2007. Shenouda G. Perez and Brady’s Principles and Practice of radiation Oncology: Chapter 33, page 751. Lippincott Williams and Wilkins 2008. Towers A. Lymphoedema, Chapter 92, in Walsh D. ed. Palliative Medicine Elsevier Philadelphia, 2008. Accepted Conference Proceedings F Ottery, M Chasen, M Munch Nielsen. Preliminary Look at Survey of Clinician Attitudes on Rehabilitation and Survivorship (SCARS): A Pilot Study. Supportive Care in Cancer. Vol 15:6, June 2007 p776 (#P-200), St. Gallen, Switzerland, June 2007 Margaret Eades, Martin Chasen, Pasqualina Di Dio, Virginia Lee. A Prospective Descriptive Comparison of the Cancer Symptom Experience of Two Groups of Patients Participating in an 8-Week Ambulatory Cancer Nutrition Rehabilitation (CNR) Service. Supportive Care in Cancer. Vol 15:6, June 2007, p779 (#P-205), St. Gallen, Switzerland, June 2007 II-21  
  • 169. Dept. of Oncology Appendix II: Publications January-December 2007 Pasqualina Di Dio, Martin Chasen, Margaret Eades, Siobhan Carney, Shafia Amdouni, Marta Jelowicki, Josee Lemoignan, Rajesh Sharma. Use of the Distress Thermometer in patients enrolled in a Cancer Nutrition and Rehabilitation Program. Supportive Care in Cancer. Vol 15:6, June 2007, p777 (#P-201), St. Gallen, Switzerland, June 2007 Virginia Lee, Robin Cohen, Martin Chasen. The Meaning-Making Intervention: A concrete approach to the search for meaning. Supportive Care in Cancer. Vol 15:6, June 2007, p671 (# S-39), St. Gallen, Switzerland, June 2007 M. Chasen, M. Eades, P. Di Dio. Cancer Nutrition and Rehabilitation – A program that works. Supportive Care in Cancer. Vol 15:6, June 2007, p 769 (#P-185), St.Gallen, Switzerland Chasen, M., Eades, M., Di Dio, P., et al. Cancer Nutrition and Rehabilitation: a Program that Works. (CLN-WS365) Journal of Palliative Care. Vol 23 (3), Autumn 2007, p 201, Toronto, Canada J Bosede, L Souhami, S Jeyaganth, S Faria, G Shenouda, M David, F Cury, M Duclos Does Testosterone recovery from prolonged androgen ablation impact on outcome of patients with localized prostate cancer treated by radiotherapy? Radiotherapy & Oncology 2007 Oct (suppl 2); 84:pS71, abstr 249 SL Faria, S Menard, S Devic, R Lisbona, C Sirois, V Hirsh, L Souhami, CR Freman. Radiotherapy volume delineation with PET in lung cancer may be less useful than foreseen. Journal of Thoracic Oncology 2007 Aug 2 (8) (suppl), abstract B5-03, p S347-8 S Faria, R Lisbona, J Stern, W El Sheshtawy, L Souhami, S Devic, CR Freeman. Is PET scan useful in differentiating active tumour from fibrosis after curative radiotherapy alone for lung cancer? Radiotherapy & Oncology 2007 Oct (suppl 2); 84:pS58, abstr 201 Loiselle, C. G., Degner, L. F., Butler, L., & Bottorff, J. (2007). A Canadian exemplar of high quality, cutting-edge transdisciplinary research training in psychosocial oncology. Making Connections: A Canadian Cancer Research Conference. Celebrating NCIC’s 60th Anniversary. Book of Abstracts, p. 154, Abstract #S-69. Lambert, S. D., & Loiselle, C. G. (2007). An in-depth analysis of cancer-related information-seeking behaviors among individuals diagnosed with prostate, breast or colorectal cancer. Poster presented at the 8th Annual Advances in Qualitative Methods Conference. Banff, Alberta, Canada, September 21, 2007. Loiselle, C. G., & Edgar, L. (2007). The impact of an IT informational intervention on psychosocial adjustment to cancer and health care service use: Are women and men with cancer reacting differently? Invited Speaker at the 5th annual Cancer Patient Education Network (CPEN) Canada Conference: Reasons to Hope, Knowledge to Cope - Innovations in Cancer Patient Education. Montreal, Quebec, May 31 – June 2, 2007. II-22  
  • 170. Dept. of Oncology Appendix II: Publications January-December 2007 Lambert, S., Dubois, S., & Loiselle, C. G. (2007). Complementary data collection strategies to enhance data richness: The case of information-seeking behaviour in cancer. Oral presentation given at the 22nd Annual Conference of the Canadian Association of Psychosocial Oncology (CAPO): Communication, Collaboration and Creativity. Winnipeg, Manitoba, May 9-11, 2007. Dubois, S., & Loiselle, C. G. (2007). Informational support and health care service use: A qualitative study among individuals newly diagnosed with cancer. Oral presentation given at the 22nd Annual Conference of the Canadian Association of Psychosocial Oncology (CAPO): Communication, Collaboration and Creativity. Winnipeg, Manitoba, May 9-11, 2007. Saint-Arnaud, J., Côté, J., Chapados, C., Bourdeau, M., Loiselle, C. G., Bouchard, L., Verrier, P., Audet, M., Gagnon, J., & Dupuis, C. (2007). Les critères de sélection des candidats à la dialyse au Québec: Aspects éthiques. Oral presentation given at the Congrès annuel de la Société québécoise de nephrology. Quebec City, Quebec, April 26- 28, 2007. A Al Hamad, T Hijal, K Sultanem, S Faria, T Muanza. Hypofractionated radiotherapy and adjuvant chemotherapy do not increase radiation induced dermatitis in breast cancer patients. Radiotherapy & Oncology 2007 Oct (suppl 2); 84:pS28, abstr 95 L Souhami, G Stroian, C Martens, R Lisbona, V Hirsh, S Faria, J Seuntjens. Dose- effect correlation for radiotherapy induced fibrosis using Monte Carlo dose calculations and a novel fibrosis image segmentatiion technique. Journal of Thoracic Oncology 2007 Aug 2 (8) (suppl), abstract B5-02, p S347 F Cury, M Duclos, A Aprikian, G Shenouda, S Faria, M David, H Patrocinio, M Evans, L Souhami. Improving the results of intermediate risk prostate cancer treated with high dose rate (HDR) brachytehrapy and hypofractionated external beam radiation therapy. Radiotherapy & Oncology 2007 Oct (suppl 2); 84:pS15, abstr 50 Monographs Loiselle, C. G., Profetto-McGrath, J., Polit, D. F., & Beck, C.T. (2007). Canadian essentials of nursing research. Second Edition. New York: Lippincott. Loiselle, C. G., Profetto-McGrath, J., Polit, D. F., & Beck, C.T. (2007). Méthodes de recherche en sciences infirmières: approches quantitatives et qualitatives. ERPI (Editions du renouveau pédagogique Inc.): Montreal, Quebec, Canada. II-23